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1.  Introduzione 
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Metabolomics in systems biology 
“There is an epoch in the growth of a science during which facts accumulate faster than 
theories can accommodate them.”1 
“But one thing is clear: to understand the whole one must study the whole.”2 
With the onset of full-scale DNA sequencing projects, scientists began to look at organisms in 
an entirely and globally new way. In contrast to last century’s paradigm, genes are not the 
only target of investigations, and sequencing is just the first step in order to understand 
organisms at a molecular level. To really understand the function of genes, biological systems 
have to be analyzed at multiple levels of control both following external parameters 
(environment, developmental stage, molecular signals, etc.) and internal parameters 
(transcription and mRNA degradation, post-trascriptional modification, protein dynamics, 
metabolite concentrations, etc.)3. Therefore the decoding of human and other mammalian 
genomes caused a strong evolution in the field of molecular biology and new “omics” 
sciences born. The first born of these new sciences were transcriptomics and proteomics, 
which studies respectively gene expression and protein expression in different disease state, 
subjects, organ, tissues or cell line4,5. In this context both metabolomics and metabonomics 
are defined (see Figure 1).  
The distinction between metabolomics and metabonomics is mainly philosophical, rather than 
technical6. The term metabonomics is defined as “the quantitative measurement of the 
dynamic multiparametric metabolic response of living systems to pathophysiological stimuli 
or genetic modification”7: the goal is understanding systemic change through time in complex 
multi cellular systems6. The term metabolomics was introduced later as the “comprehensive 
and quantitative analysis of all metabolites” in a system8: the aim is to characterize and 
quantify all the small molecules in a sample. In practice, the terms are often used 
interchangeably, and the analytical and statistical procedures are almost the same6.  
There were two, largely independent, starting points of metabolomics. In 1960s the idea was 
born of quantifying metabolite concentrations, and different methods were proposed in order 
to do that: gas chromatography (GC) and GC coupled to mass spectrometry (MS)6 are the 
most important examples. The second starting point can be identified in the development of 
nuclear magnetic resonance (NMR) spectroscopy. Instead, by the mid-1980s, 1H NMR was 
sensitive enough to identify metabolites in unmodified biological fluids9.  
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Metabonomics beautifully agrees with the spirit of systems biology, because it provides a 
global overview of biochemistry in complex organisms, that is the final product of the cascade 
of interactions that take place initially between genes, therefore between proteins, and finally 
between metabolites in individual cell types. A problem of this approach is that each level of 
this cascade (gene expression, protein expression and metabolism) operates on a markedly 
different timescale from the others, making it difficult to find causal linkages. Moreover, 
environmental and lifestyle factors greatly influence metabolism, making it difficult to 
separate their effects from gene-related effects6.  
For a long time it was believed that the relationship between genes and environmental factors 
was essentially additive: genotypes explained a certain fixed amount of the population 
variance in disease prevalence and when environmental factors were added to genotype, the 
sum of heredity and environment gave the visible phenotype 
Vphenotype = Vgenotype + Venviroment 
The problem with this approach is that linear equations do not accurately reflect the 
complexity of nonlinear interactions at a molecular level. Most environmental factors cause 
epigenetic changes that affect multiple systems simultaneously10.  
Metabonomics solves these problems by monitoring the global outcome of all the influencing 
factors, without making assumptions about the effect of any single contribution to that 
outcome6. 
                              
Figure 1 The “omics” sciences 
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Most metabolomics studies involve common biofluids as urine and serum/plasma that are 
easily obtainable from mammalians, especially from humans. Moreover, these types of 
biofluids are obtained in a non- or poorly-invasive way and they are easy to find and collect 
because they are commonly used for many other biological analyses. Hence they can be used 
for disease diagnosis and in a clinical trials setting for monitoring drug therapy. However, all 
biological fluids are useful for metabolomics analysis, as cerebrospinal fluid, synovial fluid, 
exhaled breath condensate, saliva and so on11. There are some problems associated to the use 
of these peculiar fluids for which they are not normally analyzed: poor collectable quantity, 
highly-invasive extraction techniques, poor metabolites information carried on. In addition, 
some metabolomics studies use tissue samples and their aqueous or lipid extracts12 or in vitro 
cell systems13. The number of different metabolites in these human fluids is unknown; 
estimates range from a minimum of 2,000 to 3,000 to a maximum of around 30,000 
metabolites, compared with an estimated 20,000-25,00014 genes and about 40,000 proteins15. 
Small metabolites, that are low-molecular weight (usually less than 1 kDa16) compounds that 
serve as substrates and products in various metabolic pathways, are of particular interest for 
metabolomics researchers. These small molecules include compounds such as lipids, sugars, 
and amino acids, as well as bioactive products acting at very low concentrations in tissue 
signaling functions17. 
Analytical technologies in metabolomics 
The main analytical techniques employed in metabolomics are NMR spectroscopy and MS, 
but optical techniques, such as Raman spectroscopy and infrared spectroscopy, can also be 
employed37. Both MS and NMR methods provide information on a wide range of metabolites 
in a single measurement, without having to preselect analytes to detect. Furthermore, both can 
be used to identify the metabolites’ structures and to measure the relative and absolute 
concentrations of the molecules (although NMR is more reliable for determining 
concentrations)6. 
NMR spectroscopy is a non-destructive and high reproducible technique that is generally used 
to detect 1H nuclei in metabolites providing detailed information on molecular structure of 
both pure compounds and complex mixtures18. In a typical biological-fluid sample, all 
hydrogen-containing molecules in the sample will give an 1H NMR spectrum, as long as they 
are present in concentrations above the detection limit. The NMR spectrum of a biological 
fluid is therefore the superposition of the spectra of thousands different small molecules (up to 
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2500 for urine, up to 200 for serum/plasma) present in sample at concentration >1 µM19 
(Figura 2). An advantage of NMR is that the biological fluid requires only a mild physical or 
chemical treatment prior to the analysis. A typical 1H NMR spectrum is obtained using water 
suppression techniques and adding TSP (sodium trimethylsilyl [2,2,3,3-2H4]propionate) as 
internal reference: it contains for urine predominantly sharp lines due to small molecules, 
while for serum and plasma both broad and sharp signals are present due respectively to 
macromolecules, as lipoproteins, and low molecular weight metabolites. The broad signal 
contribution from protein and other high molecular weight components can be removed by 
applying a Carr-Purcell-Meiboom-Gill (CPMG) filter to a standard 1D sequence20. 
Conversely, signals from small molecules can be removed by appropriate diffusion-based 
gradient filter editing experiments21. One of the principal disadvantages of the NMR approach 
is the difficult identification of all metabolites in the samples, a process that involves other 
techniques like two-dimensional NMR experiments (Figura 3). Indeed the 1H NMR of 
biological fluids is very complex and even though many resonances can be directly assigned 
on the base of their chemical shifts, multiplicity and by addition test, various two-dimensional 
NMR experiments are necessary to increase, but not to complete, the identification of 
biomarkers in biofluids. These 2D experiments include: i) 1H-1H J-resolved (J-res), to 
attenuate macromolecules signals and to give more information about multiplicity and 
coupling patterns ii) 1H-1H correlation spectroscopy (COSY) and 1H-1H total correlation 
spectroscopy (TOCSY), to provide 1H-1H spin-spin coupling connectivities iii) various 
heteronuclear experiments that use information coming from other types of nuclei as 13C, 15N 
and, if it is present, 31P, as for example 13C-1H HSQC, to obtain information on the direct 
coupling 13C-1H.  
 
Figure 2 1D 1H NMR NOESY1Dpresat spectrum of urine acquired at 600 MHz 
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Figure 3 Example of a 2D HMBC spectrum acquired at 900 MHz. The zoomed zone 
represents the aromatic region. It possible to distinguish some aromatics peaks of Hippurate 
(1), PAG (2), Histidine (3) and mHPPA (4). 
MS is a destructive technique that requires a very low quantity of sample. Over the last few 
years its application to mammalian study increased, especially for its great sensitivity, higher 
than NMR, and because it is a major technique for molecular identification, through the use of 
tandem methods for fragmentation studies or of Fourier transform MS for a very accurate 
mass determination3. As opposite to NMR, MS usually require that the metabolites are 
separated from the biological fluid before detection, typically by using GC or Liquid 
Cromatography (LC) (Figura 4). 
 
Figura 4 Gas chromatogram of a plasma sample (A) and mass spectrum of alanine 
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GC-MS is a robust technique for the analysis of volatile and semi-volatile compounds suitable 
for chemical derivatization to increase their volatility22. Derivation methods based on oxime 
and silylation reactions to replace reactive functional group such as carbonyl, hydroxyl, amino 
and sulfydryl located in carboxylic acid, amino acid, amine, sugar and steroid metabolites23,24 
have been predominantly employed. Electron Ionization (EI) in GC-MS is quite 
reproducible22. In contrast to GC-MS, LC-MS is especially suitable for the analysis of non-
volatile and/or thermally unstable metabolites. The process of ionization in LC-MS, for 
biofluids as urine, is usually obtained by the electron spray (ESI) method, and then both 
positive and negative chromatograms are measured. A three-dimensional chromatogram 
(retention time, mass, intensity) is generated by applying the LC (or GC)-MS approach. The 
great advantage is the possibility to cut off any mass peak from interfering substance (as for 
example drug metabolites or contaminant) without altering the dataset3. 
Biological samples contains hundreds of thousands of metabolites which cannot be 
adequately separated using a single LC or GC experiment to resolve and detect all the 
metabolites. The separation of the largest number of compounds in a complex mixture can be 
accomplished using orthogonal multidimensional separation approaches, mostly 2D-
cromatography. In 2-D methodology two different mechanism of separation are employed 
either by selecting two different column chemistries or two different mobile phases25. 
The introduction of UPLC (Ultra Performance Liquid Chromatography) and capillary LC 
enabled better peak resolution and further increase in sensitivity and speed analysis and it is 
still successfully applied to metabolomics studies26. Another characteristic of capillary LC is 
lower sample consumption. 
Because NMR does not damage analytes, it is particularly useful for studying metabolite 
levels in intact tissues, such as biopsy samples, which can then be used in further experiments. 
The non-destructive nature of NMR also enables the dynamics and sequestration of 
metabolites in tissue samples to be observed; such information is lost in MS experiments, 
because this technique disrupts the structures and interactions of molecular complexes6. 
The sensitivity problems of NMR are partially solved by using cryogenic probes, where the 
detector coil and the pre-amplifier are cooled around 20 K, increasing the signal-noise ratio27; 
moreover, the recent development of a technique called high resolution 1H magic angle 
spinning (MAS) made feasible the acquisition of data on little pieces of tissue without any 
treatment; indeed, with the rapid spinning of the sample at an angle of 54.7° relative to the 
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applied magnetic field, the line broadening effects and the associated loss of information28,29,30 
are reduced.  
HR-MAS, in combination with multivariate analysis, clearly discriminates the metabolic 
profiles of cancer tissue and normal and/or adjacent tissue in different cancer types such as 
breast31, colorectal32, prostate33, and cervical cancer34. 
The integration of multiple metabolic profiling techniques will provide complementary 
information. Indeed, some “hyphenated” approaches like HPLC-NMR-MS35, in which each 
eluting HPLC peak is split to enable a parallel analysis by NMR and MS, are still used for a 
complete metabolic identification. 
Metabolomics and disease 
Metabolites serve critical roles in biology due to their involvement in cellular and 
physiological energetics, structure, and signaling. Fatty acids contribute, for instance, to all 
three of these central processes through fatty acid metabolism, cellular membrane formation, 
and nuclear receptor activation, respectively. Similar functions can be delineated for different 
types of metabolites, such as amino acids, sugars, and many other metabolite classes36. The 
idea that various disease states can be reflected by changes in metabolite concentrations is 
fundamental to metabolomics, and some has dated the principle back to the ancient Greeks6. 
Analyzing metabolic differences between unperturbed and perturbed systems, such as healthy 
volunteers and patients with a disease or exposed to a specific treatment, can lead to insights 
into the underlying pathology37.  
Within disease diagnosis metabolomics and metabolic profiling can be utilized in a number of 
ways. However, two extremes can be single out. On one side it is possible to base a diagnosis 
method purely on metabolic fingerprinting by applying pattern recognition techniques to 
determine if a suspected patient has the disease. This does not necessarily require much 
knowledge about the underlying metabolic perturbations leading to the diagnosis. If a method 
is developed that is sufficiently specific this strategy can potentially be useful in fast 
screening of larger patient populations. The other extreme case consists of using 
metabolomics strategies to find a single biomarker that is sufficiently specific to confidently 
detects the investigated disease. In reality, the successful approach will be dictated by the 
specific project aims and will often lie in between the two extremes. In the majority of 
metabolomics studies, more than a single metabolite was necessary in order to provide 
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acceptable specificity. This means that the diagnosis have to be based either on the whole 
metabolomics dataset or on a selection of biomarkers (biomarker profile), which can be 
quantified in a reliable way37. 
The use of sensitivity and specificity38 for reporting results provides an easy way of 
comparing results between alternative methods, as well as makes it possible to assess the 
results even if one is not familiar with the methods used in producing the results. Results from 
metabolomics studies should always be seen in the light of the methods presently available: 
Some diseases are very difficult to diagnose, and here even methods with moderate 
classification success can be of interest. On the other hand a metabolomics method that 
diagnoses for example high blood pressure with 100% sensitivity might not in itself be very 
interesting to the clinical community, since this condition can be diagnosed much easier and 
by less expensively way. 
One of the major diseases classes targeted by metabolomic researches is cancer. 
Metabolomics can be used for diagnosing cancer states directly in body fluids, with the aim of 
facilitating fast screening, or it can be applied to histological samples in order to classify 
different tumors using techniques such as magic angle spinning (MAS)-NMR39or metabolite 
extraction followed by MS analysis. However, one of the main goals within cancer 
metabolomics is to develop fast and reliable methods for non-invasive diagnosis by means of 
urine and blood derivates. The use of metabolomics within cancer research has been discussed 
in several reviews40,15,41,42,43,44,45. The existence of studies applying metabolomics to liver 
46,47,48
, bladder49, prostate50,51, oral52,53,54, stomach55, renal56,57,58, brain59,60,61 and colorectal 
cancer62,63,64,65, as well as a selection of women's cancer66,67,68,69,70 demonstrates the wide 
application potential of these methods in oncology. 
Another cornerstone is the uses of metabolomics in diabetes diagnosis, treatment and 
research71,72 Two different types of diabetes exist. Type 1 diabetes is characterized by lack of 
insulin, due to an autoimmune destruction of the insulin producing beta-cells in the pancreas. 
Type 2 diabetes is, at least at early stages, characterized by insulin resistance and decreased 
excretion, and is now becoming one of the major health problems in developed countries due 
to lifestyle factors73 Early diagnosis is of big importance in both cases, since many of the 
complications can be avoided or decreased by early intervention: this make these diseases 
interesting from a metabolomics point of view. Indeed, because they are metabolic diseases, 
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metabolomics profiles are expected to be sensitive at very early stages. All these observation 
justify the several are the metabolomics studies on type 174,75,76,77 and type 2 diabetes78,79. 
Cardiovascular diseases comprise a group of disease states including a large number of more 
specific conditions, such as heart failure, coronary heart disease, atheroschlerosis and 
hypertension72. Collectively, diseases of the cardiovascular system are the leading causes of 
death in many industrialized countries80,81. Metabolomics collected a lot of results also in this 
field: coronary artery disease82,83,84, cardiac events in diabetic subjects85, myocardial 
ischemia86,87, hypertension88,89, preeclampsia90,91. 
The nervous system, including the brain, is the most complex biochemical system in 
humans92. Common neurological diseases include depression, schizophrenia, epilepsy, 
Parkinson's disease, Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis. 
Usually these diseases lack robust biomarkers; their diagnosis and prognosis are therefore 
often problematic. Metabolomic approaches have been reported in multiple studies on 
nervous system diseases:  amyotrophic lateral sclerosis93, mild cognitive impairment94, 
Parkinson's disease patients95, Huntington's disease patients96, schizophrenia97,98,99, 
Alzheimer's disease100, meningitis101. 
Other metabolobics studies concern respiratory diseases like asthma102 or chronic obstructive 
pulmonary disease103; gut diseases as celiac disease104, inflammatory bowel diseases105,106,107, 
appendicitis108; renal diseases like uremia109 or glomerulonephritis110; other inflammatory 
diseases like hepatitis B111 or HIV112. 
The application of metabolomics to all these pathologies showed the potential of 
metabolomics in identifying disease-related differences in one or more of the numerous 
endogenous metabolites found in clinical samples as biofluids and tissues. Moreover it is 
important highlight as global metabolomics analysis of accessible biofluids provides 
information on all tissues that deliver and obtain metabolites from those fluids113. Instead 
target- or metabolite-specific studies, unlike global metabolomics, searches for specific 
groups of metabolites (amino acids, lipids, peptides, fatty acids, steroids, sugar, extrogen, 
etc…) based on a priori knowledge of the biological system or metabolomic pathway114,115. 
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Future applications 
One of the long-term goals of metabolomics is clearly the understanding of the existing 
relationships between genetic polymorphisms of different individuals and their metabolic 
fingerprint, in order to completely understand the response of different organisms to external 
stimuli. Achieving this goal could be very important in the field of pharmacometabolomics, 
leading to personalized healthcare116. Thus, an individual’s drug treatment could be tailored 
so as to achieve maximal efficacy and avoid adverse drug reactions. In order to accomplish 
this purpose it is necessary to exactly determine the genetic and environmental influences on 
the basal metabolic fingerprint of an individual, since these factors will also influence the 
outcome of a chemical intervention. In this direction a great improvement is obtained with the 
demonstration of the existence of unique individual metabolic phenotypes, called 
metabotypes117,118 
Moreover, there is a wide range of current and emerging applications of metabolomics: i) 
investigation of invertebrates tissue extracts and biofluids to monitor environmental 
toxicity119,120; ii) investigation of plant biofluids121; iii) studying of relationship between 
specific changes in gene expression and alteration of biochemical process (functional 
genomics)122,123  
Chemometrics methods 
Once the spectra of each biofluid are collected, it is necessary to analyze these data. Both 
NMR spectroscopy and MS can be thought of as a multidimensional set of metabolic 
coordinates, whose values are the spectral intensity at each data point (ppm for NMR and 
retention time for mass) (Figura 5). Starting from these data, the principal aims of 
metabolomics can be summarized in four goals: i) visualization of overall differences, trends 
and relationships between samples and variables, ii) determination of whether there is a 
significant difference between groups, for instance between healthy subjects and sick subjects 
for a pathology, iii) highlighting all metabolites that are responsible for these differences and 
iv) construct a predictive model for new samples. Multivariate statistical analyses is the key to 
achieve these goals. 
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Figura 5 Workflow of metabolomics studies37 
Starting from NMR spectra, high dimensional data sets are obtained by “bucketing”. 
Bucketing is a procedure used to reduce the total number of variables. One bucket (or bin) is a 
little slice of the spectrum (Figura 6). The corresponding intensity of this slice is calculated in 
order to obtain our primary variables for each bucket. Obviously, the size of the buckets is 
one of the parameter to choose: 0.02 ppm is a good compromise between the necessity to 
reduce residual chemical shift drift and data complexity and the loss of the spectra resolution 
important for the following biomarker identification118. 
 
Figura 6 Result of the bucketing of a 1D 1H NMR NOESY1Dpresat spectrum 
Observations in a high-dimensional space are necessarily sparser and less representative than 
those in a low-dimensional space. Often, many of the dimensions in a data set (the measured 
features) are not useful in producing a model, being irrelevant or redundant. Regression and 
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classification algorithms may require large amounts of storage and computation time to 
process raw data, and even if the algorithms are successful the resulting models may contain 
an incomprehensible number of terms. Because of these challenges, multivariate statistical 
methods in metabolomics often begin with some type of dimension reduction, in which data 
are approximated by points in a lower-dimensional space. Dimension reduction often leads to 
simpler models and fewer measured variables, with consequent benefits when measurements 
are expensive and visualization is important. This is possible because metabolomics data are 
often highly collinear. One of the simplest data reduction techniques largely used in 
metabolomics is PCA (Principal Component Analysis) (Figura 7). PCA is a quantitatively 
rigorous method for achieving this simplification. The method generates a new set of 
variables, called principal components (PCs). Each PC is a linear combination of the original 
variables (buckets). All the PCs are orthogonal to each other, so there is no redundant 
information. There are an infinite number of ways to construct an orthogonal basis for several 
columns of a dataset: PCA is a linear technique that expresses the maximum of variance in a 
data set through a small number of PCs. The first PC (PC1) expresses the maximum 
percentage of variability, then the value of variance quickly decreases in such a way that the 
first PCs are the responsible for the great part of variability, while the last PCs are 
significantly less important and express noise variability. The trasformation of data matrix 
into PCs gives two new matrices: score matrix and loading matrix. The score matrix contains 
the coordinates of the original data in the new coordinate system defined by the PCs and it is 
the same size as the input data matrix. The loading matrix contains the coefficients of the 
linear combinations of the original variables that generate the PCs. Hence, in the loading plot, 
each point represents a different spectral intensity and the weight of the variables in the 
discriminate between samples, practically which buckets are responsible for the maximum 
variance124 Moreover PCA is used for giving an overview of data, which will reveals outliers, 
groups and trend of data125. 
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Figure 7 Plot of the first two components after the PCA analysis 
After the initial overview of the data the aim is usually to build a model that is useful for 
classifying new samples, and at the same time allows identification of biomarkers for the 
studied diseases. Classification can be done using linear methods such Partial Least Square 
(PLS), OPLS (Orthogonal Projection to Latent Structures method), Linear Discriminant 
Analysis (LDA) or non linear method such as Self-Organising Maps (SOMs), Artificial 
Neural Networks (ANNs), Support Vector Machine (SVM) and k-Nearest-Neighbour (k-NN) 
rule. Linear methods have the advantage that biomarkers are readily identified from the model 
using the loading values. For non-linear methods it is often impossible to interpret the model 
biologically, since statistical significance of the coefficients and their direction may not be 
directly related to the importance of the corresponding variables for the model building126. 
PLS127 is a technique used with data that contain correlated predictor variables regression 
such as information about the nature of the samples (healthy or sick in case of studies of 
pathologies). This technique is between multiple linear regression, that allow to find a 
combination of the predictors that best fit a response, and PCA, that permit to single out 
combinations of the predictors with large variance without use response values. PLS finds 
combinations of the predictors that have a large covariance with the response values by 
combining information about the variances of both the predictors and the responses, also 
considering the correlations among them. One recent modification of the PLS method is 
constituted by the OPLS128, that is used to remove irrelevant and confusing parameters. The 
basic idea of OPLS is to separate the systematic variation in data matrix in two parts, one 
linearly related to predictor variables matrix, and the other unrelated (orthogonal) to it. This 
partition facilitates model interpretation and model execution on a new set of samples. 
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LDA129 is based on finding linear combination of n-dimensional predictor variable values, 
with large ratios of between group to within group sums of square. LDA analysis constructs, 
for a two-classes problem, a separating hyperplane between the two datasets. PCA, OPLS and 
PLS can be used combined with LDA to establish the optimum of discrimination between 
samples130. 
The analysis of variance (ANOVA) technique takes a set of grouped data and determine 
whether the mean of a variable differs significantly among groups. Often there are multiple 
response variables, and the interest is determine whether the entire set of means is different 
from one group to the next. There is a multivariate version of analysis of variance that can 
address the problem: MANOVA technique. MANOVA function in Matlab 7.9.0 allows also 
to perform the Canonical Analysis (CA) that give the canonical component that allow the 
LDA analysis. PCA looks for the combination of the original variables that has the largest 
possible variation. MANOVA instead looks for the linear combination of the original 
variables that has the largest separation between groups. Having found that combination, the 
base idea is next look for the combination with the second highest separation, and so on124. 
SOMs is an unsupervised method of classification that reduces the dimensionality of the data 
through the creation of an array of nodes, each one described by a “codebook” vector. During 
the training, each sample is presented to the map and the node with the closest reference 
vector is selected as the final node for the sample (also called “winning node”). Clearly the 
number of chosen nodes is a fundamental variable; with few nodes, for instance, the map does 
not represent faithfully the data distribution, while with a large number of nodes phenomena 
as overfitting and noise susceptibility influence the analysis. Moreover, another disadvantage 
is associated to the final position of similar clusters, that may end up in distant parts of the 
SOM despite their similarity.  
ANNs is one of the most popular supervised method for pattern recognition in biomedical 
area. It consists of a network of nodes. Each of these nodes performs an operation to give a 
single output. Theoretically the nodes can be divided into three layers: i) input nodes ii) 
hidden nodes and iii) output nodes. Generally in metabolomic studies each input node is 
formed by each single spectrum, while each output node represents each class of samples 
(even if it is better to have one more output node corresponding to an unknown class). Each 
hidden node receives some information from various input nodes and re-combines this 
information using a non-linear activation function to give a signal to the output nodes. For 
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their great versatility the ANNs are still applied to some metabolomic studies131,132,133,134. 
However, it is often difficult to clearly understand the connection weights to completely 
single the parameters (buckets in our case) responsible for identification. 
In the case of SVM, a data point is viewed as a p-dimensional vector (a list of p numbers) and 
we can separate such points with a (p-1)-dimensional hyperplane: this is called a linear 
classifier. There are many hyperplanes that might classify the data: the best hyperplane is the 
one that represents the largest separation, or margin, between two or more classes in a way 
that distance from it to the nearest data point on each side is maximized. If such a hyperplane 
exists, it is known as the maximum-margin hyperplane and the linear classifier it defines is 
known as a maximum margin classifier135. 
kNN rule is the simplest of all supervised classification approaches. Every sample is classified 
to the class most frequently expressed among the k nearest neighbour. Therefore the k is the 
fundamental parameter to set. Small values of k can lead to the construction of a model 
subject to significant statistical fluctuations, while large values of k reduce statistical errors 
but can smooth out many details of the class distribution. As k-means, this method gives a 
classification of the sample without associated visualization and interpretation of data and, 
therefore, it is not applied only in metabolomics124,136. 
Cluster consists in portioning a set of elements into subsets according to the differences 
between them. In other words, it is the process of grouping similar elements together. The 
main difference from the supervised classification is that, in clustering, we have no 
information about how many classes there are. Cluster analysis, also called data segmentation, 
has a variety of goals all related to grouping or segmenting a collection of objects into subsets 
or “cluster” in a such way that objects within each cluster are closely related to one other then 
objects assigned to different clusters. Sometime the goal is to arrange the cluster into a natural 
hierarchy: this involves successively grouping the clusters themselves so that, at each level of 
the hierarchy, cluster within the same group are more similar to each other than those in 
different groups. Central to all goals of cluster analysis is the notion of the degree of 
similarity (or dissimilarity) between the individual objects clusterized130. 
Hierarchical Cluster Analysis (HCA) is widely used in all areas of science and it has been 
recently applied to a metabolomic studies137. These methods groups data over a variety of 
scales by creating a cluster tree diagram or dendrogram, in which the relationships between 
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samples are expressed (Figura 8). The algorithm starts analyzing the similarity or 
dissimilarity between every pair of objects in the data set and calculating the distance between 
all pairs of data points. Then, it proceeds to group the objects into a binary, hierarchical 
cluster tree: in this step, this method links pairs of objects using the distance information 
generated in the previous step to determine the proximity of objects to each other. As objects 
are paired into binary clusters, the newly formed clusters are grouped into larger clusters 
(initially each cluster consists of a single data point) until a hierarchical tree is formed. The 
described algorithm is the agglomerative algorithm, but there is also a divisive algorithm that 
operates by successively splitting the groups, beginning with a single group and continuing 
until there are N groups, each of a single individual: generally, divisive algorithm are 
computationally inefficient130. The final step of the algorithm is determine where to cut the 
hierarchical tree into clusters: these clusters can be created by detecting natural groupings in 
the hierarchical tree or by cutting off the hierarchical tree at an arbitrary point. The tree is not 
a single set of clusters, but rather a multilevel hierarchy, where clusters at one level are joined 
as clusters at the next level. The main problem in the application of these methods to 
metabolomic studies is that the reproducibility is not good; the inclusion of new data, for 
instance, requires a complete re-computation of the dendrogram that can lead to a new 
structure not necessarily similar to that generated from the previous training set. Moreover, 
HCA does not generate diagnostic information about what features are responsible for the 
classification in sub-clusters. 
 
Figura 8 Example of HCA 
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K-means clustering is an unsupervised algorithm. It is a partitioning method: it partitions data 
into k mutually exclusive clusters, and returns the index of the cluster to which it has assigned 
each observation. It starts to work selecting the desired number of clusters and randomly 
assigning their center. For each iteration a data point is classified through the assignment to 
one of the clusters, basing on the closest cluster center. After this addition the new cluster 
centers are recomputed. Unlike HCA, k-means clustering operates on actual observations 
(rather than the larger set of dissimilarity measures), and creates a single level of clusters. The 
distinctions mean that k-means clustering is often more suitable than HCA for large amounts 
of data. However despite its popularity, k-means is not often applied to metabolomics. The 
main reasons are the absence of diagnostic tools and associated visualization. In order to 
avoid these disadvantages this technique can be applied in combination with other statistical 
procedures, as in a metabolomic study of plant and marine invertebrate extracts, with HCA124. 
Regardless of the chosen method, both statistical and biological validations are critical.  
When using metabolomics in diagnosis disease the end result will often be a prediction of 
class belonging, using a multivariate algorithm. It is important that this prediction is carried 
out in a relevant way. A model that seems valid can in some cases perform badly when 
predicting new samples, so it is important that the model is validated. A cross-validation 
scheme should been employed, to make sure the model is not over fitted. In cross-validation 
parallel models are build with a part of the data excluded; by subsequently predicting the 
excluded values it is possible to get a measure of the predictive ability of the model138. Cross-
validation is a good and widely used tool for optimizing multivariate models, however, it is 
prone to over fitting of the models-especially when using Leave-One-Out (LOO) cross-
validation139.  
In the LOO method, the statistical model is built on the entire dataset except one sample and 
the sample leave out is after predicted by means of some kind of classification method. The 
method is repeated for each sample. 
A better strategy for validation is therefore to use an external dataset for validation. Preferably 
a separate follow-up study analyzed separately should be used, since this will reduce the risk 
of undetected biases during sample collection or analysis, but alternatively a part of the data 
set can be excluded for validation purposes. This is the idea of the training/evaluation splitting 
method. In the training/evaluation splitting method the dataset is splitted into two subsets, 
called “training set” and “validation set”. The training set is used to build the mathematical 
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model which is used to predict samples belonging to the validation set. Naturally many 
random and variable training sets and validation sets can be built to correctly and fully 
investigate the data through a robust model. 
Biological validation of models can include studies that independently confirm or reject the 
assumed hypothesis or provide new biological explanation for the observed initial results. 
In order to single out the significant variables for the classification in a multivariate statistical 
approach, we can use Wilcoxon test or the Kruskal Wallis test according to a p-value ≤ 0.05 
or ≤0.02. 
The Wilcoxon-Whitney test, is a nonparametric test that compares two paired groups. It is 
used to test the null hypothesis that two populations have identical distribution functions 
against the alternative hypothesis that the two distribution functions differ only with respect to 
location (median), if at all. The Wilcoxon Mann-Whitney test does not require the assumption 
that the differences between the two samples are normally distributed. In many applications, 
the Wilcoxon Mann-Whitney Test is used in place of the two sample t-test when the 
normality assumption is questionable. 
The Kruskal-Wallis test is a nonparametric test used to compare three or more samples. It is 
used to test the null hypothesis that all populations have identical distribution functions 
against the alternative hypothesis that at least two of the samples differ only with respect to 
location (median), if at all. It is the analogue to the F-test used in analysis of variance. While 
analysis of variance tests depends on the assumption that all populations under comparison 
are normally distributed, the Kruskal-Wallis test places no such restriction on the comparison. 
It is a logical extension of the Wilcoxon-Mann-Whitney Test. 
Aim of the research 
The general aim of this thesis is to explore the potential of metabolomics for disease 
prognosis, diagnosis and therapy toxicity assessment and to highlight its necessary and 
irreplaceable role as a tool for understanding the biochemical mechanisms at the basis of the 
pathologies. Indeed metabolomics more than other omics sciences can help medical research 
in this sense by taking an overall picture of the ensemble of the metabolites present in 
biological fluids in a certain moment and extracting a disease signature from the multivariate 
analysis of the metabolic profiles. 
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All the results that I am presenting here are obtained on urine and serum, biofluids that can be 
collected in a non- or poorly-invasively way and easy to find because commonly used for 
many other clinical analyses. Considering the invasivity and the consequent stress for 
patients, especially if suffering of chronic diseases, of several diagnostic tools, this feature is 
undoubtedly a good point assessed for metabolomics. 
A milestone of the whole work relies on the establishment of the existence individual 
metabolomics signature of healthy subjects found to be stable over the years (Chapter 3). The 
definition of this unique fingerprint is the starting point because it allows to unravel whether 
modifications occur in the metabolomic profile have a physiologic or a pathologic origin. 
Once defined the “solidity” of metabolomic approach in this sense, at least in urine, we 
defined the metabolomic signature of three large impact diseases: breast cancer (Chapter 4), 
celiac disease (Chapter 5) and cardiovascular risk (Chapter 6). These pathologies are 
investigated applying the “holistic” approach (the analysis of the fingerprinting), followed by 
the research of the metabolites responsible for the pathological signature with respect the 
“healthy” signature.  
Moreover the toxicity of ozone therapy in blood is explored and also the role of metabolomics 
in the evaluation of toxicity of therapies is highlighted (Chapter 7). 
Finally the reliability of the metabolomics approach requires that the chemical nature and the 
relative concentration of the metabolites present in the biofluids are neither affected by the 
preanalytical conditions nor by the analytical methodology. The importance of metabolomics 
is clarified also in the definition of operating procedures aimed at collecting and preserving 
biological samples according to protocols as standardized as possible also that may be shared 
in biobanking activities and in general for all those studies in which the impact of the results 
is linked to the large number of the collected samples (Chapter 8). 
The specific project aims and results will be extensively treated and discussed in the dedicated 
chapters. 
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Sample preparation 
Urine samples, once collected following the standard procedures for urine colture, were 
processed, aliquoted and frozen as soon as possible (usually within the 4 hours) to – 80°C in 
order to avoid metabolites degradation. The day of analysis samples were thawed at room 
temperature and shaken before use.  
Blood samples, once collected in the specific vacutainers for plasma and serum collection, 
were differently treated for the isolation of each of these blood derivates: vacutainers for 
plasma collection containing different kind of anticoagulant compounds (citrate, 
ethylenediaminetetraacetic acid or EDTA, heparine, fluoride/oxalate) were centrifugated as 
soon as possible at a speed around 820 RCF for 10’ at 4°C, while vacutainers for serum 
collection were centrifugated usually after an half hour at room temperature, as required for 
clotting, at a speed around 1500 RCF for 10’at 25°C. In both the cases surnatant was 
recovered and frozen as soon as possible (usually within the 4 hours) to – 80°C. The day of 
analysis samples were thawed at room temperature and shaken before use.  
Blood serum is blood plasma without fibrinogen and the other clotting factors.1 
Urine. According to a commonly used protocol2,3, urine samples were shaken before use and 
630 µL were centrifuged at 14000 RCF for 5 min. 540 µL of the supernatant were added to 
sixty microliters of potassium phosphate buffer (0.2 M Na2HPO4, 0,2 M NaH2PO4, 30mM 
sodium azide (NaN3) and 10 mM sodium trimethylsilyl [2,2,3,3-2H4] propionate, TMSP, in 
100% 2H2O, pH 7.0). 540 µL of the mixture were pipetted into 4.25 mm NMR tubes (Bruker 
BioSpin srl). 
Blood-derivative NMR samples. Both serum and plasma, were prepared adding 300 µl of 
phosphate sodium buffer (70 mM Na2HPO4, 38 mM NaN3 and 55 mM TMSP in 20% 2H2O, 
pH 7.4) to 300 µl of plasma or serum. A total of 450 µl of this mixture was transferred into a 
4.25 mm NMR tube (Bruker BioSpin srl).  
NMR experiments and data analysis 
The strategy analysis of the projects described in this thesis can be synthesized by four basic 
steps: 
• Acquisition, processing (FT, phase correction, baseline correction, spectra alignment) 
of 1H-NMR spectra; 
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• Bucketing; 
• Data mining by the PCA and unsupervised clustering; 
• Supervised clustering and modeling; 
• Validation of the models; 
• Identification of the biomarkers. 
 
Acquisition and processing 
All 1H-NMR spectra were acquired using a Bruker 600 MHz spectrometer operating at 600.13 
MHz proton Larmor frequency and equipped with a 5 mm CPTCI 1H-13C/31P-2H cryo-probe 
including a z-axis gradient coil, an automatic tuning-matching (ATM) unit and an automatic 
sample changer. A PT 100 thermocouple served for temperature stabilization at the level of 
approximately ±0.1 K at the sample. Before measurement, samples were kept for at least 3 
minutes inside the NMR probe head, for temperature equilibration i.e., 300.0 K for urine and 
serum/plasma samples with the exception of plasma samples of the project AVIS that were 
analysed at a temperature of 310.0 K. The latter temperature were recently resolved to allow a 
better detection of lipidic profiles. 
Urine For each urine sample, a one-dimensional (1D) NMR spectrum was acquired with 
water peak suppression using a standard pulse sequence (NOESYpresat; Bruker), using 64 
scans, 64 k data points, a spectral width of 12,019 Hz, an acquisition time of 2.7 s, a 
relaxation delay of 4 s, and a mixing time of 100 ms.  
Blood-derivates For each serum/plasma sample 1D NOESYpresat spectra were recorded; 1D 
spectra were acquired also with the Carr-Purcell-Meiboom-Gill (CPMG; Bruker) spin-echo 
sequence to suppress signals arising from high molecular weight molecules. In this case 
NOESYpresat spectra consisted of 64 scans, 98 k data points, a spectral width of 18,028  
Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a mixing time of 100 ms. CPMG  
spectra consisted of 64 scans, 74 k data points, a spectral width of 12,019 Hz, an acquisition 
time of 3.1 s, a relaxation delay of 4 s and a mixing time of 100 ms 
For the project AVIS we acquire also also1H-1H J-resolved (J-res) spectra in order to get more 
information about signal multiplicity and coupling pattern and diffusion edited sequence using 
a diffusion time of 120 ms. 
Free induction decays were multiplied by an exponential function equivalent to a 1.0 Hz line-
broadening factor before applying Fourier transform. Transformed spectra were automatically 
corrected for phase and baseline distortions and calibrated (TMSP peak at 0.00 ppm for urine 
samples, alanine peak at 1.5 ppm for blood) using TopSpin 2.1 (Bruker Biospin srl).  
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Bucketing 
Each 1D spectrum in the range between 0.02 and 10.00 ppm was segmented into 0.02-ppm 
chemical shift bins, and the corresponding spectral areas were integrated using AMIX 
software (Bruker BioSpin). Regions between 6.0 and 4.5 ppm containing residual water and 
urea signals were removed. To compensate for the high dynamic range in metabolite 
concentration, the normalized data are also scaled using the mean centering method so that 
changes in abundant metabolites do not dominate statistical models. 
All resonances of interest were assigned on template one-dimensional NMR profiles by using 
matching routines of AMIX 3.8.4 (Bruker BioSpin) in combination with the BBIOREFCODE 
(Version 2-0-0; Bruker BioSpin) reference database and published literature when available.  
Data mining by the PCA and unsupervised clustering 
Multivariate statistical analysis is a tool to examine relationships among a great number of 
statistical variables at the same time (multivariate data). Generally multivariate data are 
represented by a matrix (the X matrix). Each row of this matrix corresponds to an object, 
while each column is a peculiar observable of the objects, for instance a bucket or a bin in 
metabonomics.  
Matlab is a computational environment that provide a strong programming language for the 
analysis of data organized in matrix. R is an open source environment for data statistical 
analysis. All the statistical calculations described in this chapter were performed using scripts 
scripts written in R4 and in MATLAB (The MathWorks, Natick, MA) language. 
Many methods can be applied in order to perform a multivariate statistical analysis. 
Substantially the aim of these methods is to obtain a clusterization without giving data 
information to the systems (unsupervised methods). The principal and most used of these 
methods is PCA5. In practice, it searches for correlating variables that allow a division of the 
objects in two or more classes. This technique aims to extract more information as possible 
from a multivariate dataset and synthesizes it in few linear combinations of the same 
variables. From a geometric point of view, this is a rotation process of the original data 
carried out in a way that the first new axis (the first principal component) is oriented in the 
direction of maximum percentage of variability of the data, the second axis is perpendicular 
to the first and in the direction of the second maximum percentage of variability of the data 
and so on for all the new axis. The algorithm creates the new components in a way that the 
explained variance from the nth component is bigger than the variance explained from the 
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(nth+1) component. The number of these new axis (principal components or PCs) it is equal 
to the number of the original variables; the matrix given from these new linear combinations 
is called “scores matrix”, while the matrix of the coefficient of this linear combinations is the 
“loading matrix”. Usually only a small number of new components, sufficient to explain data 
aggregation, is selected. Moreover the component analysis allow really useful graphical 
representations for the starting exploration of the data. 
In a following step, by the mean of the “Pattern Recognition” methods, the similarity between 
the samples could be evaluated and the features specific of the similarity classes could be 
extracted. Clustering techniques, as HCA, are employed in order to reach this goal in Chapter 
36,7. 
As in the previous step, also for this step the analysis is carried out without information on the 
data structure “external” to these methods. This kind of analysis methods are the so called 
“unsupervised” methods.  
HCA groups data over a variety of scales by creating a cluster tree diagram or dendrogram, in 
which the relationships between samples are expressed. The algorithm starts analyzing the 
similarity or dissimilarity between every pair of objects in the data set and calculating the 
distance between all pairs of data points. Then, it proceeds to group the objects into a binary, 
hierarchical cluster tree. As objects are paired into binary clusters, the newly formed clusters 
are grouped into larger clusters (initially each cluster consists of a single data point) until a 
hierarchical tree is formed. The described algorithm is the agglomerative algorithm, but there 
is also a divisive algorithm that operates by successively splitting the groups, beginning with 
a single group and continuing until there are N groups, each of a single individual: generally, 
divisive algorithm are computationally inefficient8. The final step of the algorithm is 
determine where to cut the hierarchical tree into clusters: these clusters can be created by 
detecting natural groupings in the hierarchical tree or by cutting off the hierarchical tree at an 
arbitrary point. The tree is not a single set of clusters, but rather a multilevel hierarchy, where 
clusters at one level are joined as clusters at the next level. The main problem in the 
application of these methods to metabolomic studies is that the reproducibility is not good and 
the inclusion of new data requires a complete re-computation of the dendrogram that can lead 
to a new structure not necessarily similar to that generated from the previous training set. 
Moreover, HCA does not generate diagnostic information about what features are responsible 
for the classification in sub-clusters. 
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Supervised clustering and modeling 
After that the unsupervised analysis provided a beginning picture of the intrinsic structure of 
the data, the following step allows to develop models by supervised regression methods like 
PLS (Partial Least Squares) regression, OPLS (Orthogonal Projection to Latent Structures) 
method, K-OPLS (Kernel-based orthogonal projections to latent structures) method, PLS-DA 
(Partial Least Squares Discriminant Analysis) and supervised classification method like PCA-
DA (PCA followed by Discriminant Analysis), SVM (Supported Vector Machine) and k-
Nearest-Neighbour (k-NN)9. Supervised classification methods provide mathematical models 
able to predict the belonging class of a sample among that singled out on the basis of the data. 
In order to reach this goal functional relations between the variables and one or more Y 
functions with the information about data structure “external” to these methods are used.  
The hard core of these methods is the use of multivariate analysis techniques and of 
classification algorithm for single out, separate and define the common features of the classes 
in which data are separated and that explain the similarities and differences between the 
samples: these are defined clustering techniques. Clustering is defined as the study of 
algorithms and methods that allow to group objects with common features. 
PLS10 is a technique used with data that contain correlated predictor variables regression such 
as information about the nature of the samples. This technique is between multiple linear 
regression, that allow to find a combination of the predictors that best fit a response, and 
PCA, that permit to single out combinations of the predictors with large variance without use 
response values. PLS finds combinations of the predictors that have a large covariance with 
the response values by combining information about the variances of both the predictors and 
the responses, also considering the correlations among them. One recent modification of the 
PLS method is constituted by the OPLS11, that is used to remove irrelevant and confusing 
parameters. The basic idea of OPLS is to separate the systematic variation in data matrix in 
two parts, one linearly related to predictor variables matrix, and the other unrelated 
(orthogonal) to it. This partition facilitates model interpretation and model execution on a new 
set of samples. The K-OPLS is a further modification of the PLS method with the 
introduction of the kernel trick. 
The analysis of variance (ANOVA) technique takes a set of grouped data and determine 
whether the mean of a variable differs significantly among groups. Often there are multiple 
response variables, and the interest is determine whether the entire set of means is different 
from one group to the next. There is a multivariate version of analysis of variance that can 
address the problem: MANOVA technique. MANOVA function in Matlab 7.9.0 allows also to 
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perform the Canonical Analysis (CA). PCA looks for the combination of the original variables 
that has the largest possible variation. MANOVA instead looks for the linear combination of 
the original variables that has the largest separation between groups. Having found that 
combination, the base idea is next look for the combination with the second highest 
separation, and so on12. PCA and PLS can be used also combined with CA/DA to establish the 
optimum of discrimination. 
In the case of SVM, a data point is viewed as a p-dimensional vector (a list of p numbers) and 
we can separate such points with a (p-1)-dimensional hyperplane: this is called a linear 
classifier. There are many hyperplanes that might classify the data: the best hyperplane is the 
one that represents the largest separation, or margin, between two or more classes in a way 
that distance from it to the nearest data point on each side is maximized. If such a hyperplane 
exists, it is known as the maximum-margin hyperplane and the linear classifier it defines is 
known as a maximum margin classifier13. 
The kNN rule is the simplest of all supervised classification approaches. Every sample is 
classified to the class most frequently expressed among the k nearest neighbour. Therefore the 
k is the fundamental parameter to set. Small values of k can lead to the construction of a 
model subject to significant statistical fluctuations, while large values of k reduce statistical 
errors but can smooth out many details of the class distribution. As k-means, this method 
gives a classification of the sample without associated visualization and interpretation of data 
and, therefore, it is not applied only in metabolomics14,15. 
Validation of the models 
For a proper cross validation, the total data should be divided into a training set and a test set. 
Using the training set a model is developed and optimized. The test set is only used to test the 
model performance. By repeating the procedure in a way that each sample appear once and 
only once in the test set, the prediction error is representative for new samples. Accuracy, 
specificity and sensitivity were estimated using standard definitions16. 
Identification of the biomarkers 
Finally to asses which buckets are significantly different among various classes a one-way 
analysis of variance is used. Statistical significance of difference in average values calculated 
over the two groups is assessed using Kruskal-Wallis or Wilcoxon test by using the 
Bonferroni correction on a nominal value of 0.005.  
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Project Dataoverview Modelbuilding Classification Model 
validation 
Identification 
of biomarkers 
Metabolic 
phenotypes PCA\HCA PCA-CA kNN 
Cross-
validation with 
Monte Carlo 
approach 
Kruskal-Wallis 
test 
Breast cancer 
and 
metabolomics 
PCA OPLS SVM 
Cross-
validation with 
Monte Carlo 
approach 
Wilcoxon test 
Celiac disease 
and 
metabolomics 
PCA KOPLS SVM 
Cross-
validation with 
Monte Carlo 
approach 
Wilcoxon test 
Cardiovascular 
risk and 
metabolomics 
PCA PLS-CA SVM 
Cross-
validation with 
Monte Carlo 
approach 
Wilcoxon test 
Ozone therapy 
and 
metabolomics 
\ \ \ \ ANOVA 
SOPs definition 
by metabolomics PCA 
PLS-CA\PCA-
CA kNN 
Cross-
validation with 
Monte Carlo 
approach 
Kruskal-Wallis 
test 
Table 1 Statistical methods of the projects described in this thesis 
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Background 
Since its birth, metabonomics shows a great potential in various research areas like prognosis 
and diagnosis assessment of diseases1, toxicology2, pharmacology3 and nutraceutics4,5. In 
particular the relevance of metabonomics can be greatly enhanced by the determination of the 
existence of a metabolic phenotype, typical for each subject and stable over time. Differences 
in experimental metabolic profiles due to genetic strain differences in animal models have 
been observed, leading to the suggestion that each individual or group of individual may be 
characterised by a different metabotype, defined as “the multiparametric description of an 
organism in a given physiological state based on metabonomic data”6. The major problem is 
that the experimental metabolic profile is influenced not only by the genotype but also by age, 
lifestyle, environmental factors, nutritional status, assumption of drugs, and other metabolites 
from symbiotic organisms, as gut microflora7,8,9. Consequently, changes in the metabolic 
profile of biologically complex organisms (as humans) in response to pathological stimuli 
may be difficult to distinguish from normal physiological variations. Despite these factors the 
experimental evidence of the existence of a metabolic phenotype has been recently 
collected10, assessing the influence of possible perturbing factors on the metabolic profiles 
and minimizing them in order to eliminate noise due to random daily variation. Indeed the 
approach used for the determination of the metabotypes counts on the NMR analysis (in a 
projet named MetRef1) of multiple urine samples (40 for each individuals) taken in quite 
consecutive days (about 2-3 months) from 22 healthy subjects. Each one of these subjects 
avoided alcohol and drug intake the day before the collection, and, moreover, filled a 
complete dietary sheet in order to better determine changes due to food behavior. In these way 
it has been obtained for the first time a natural, stable, and invariant metabolic profile that was 
typical of a given subject, even if not necessarily unique.  
Aim of the work 
The discovery of the existence of a stable individual human phenotypes in a short time (about 
2-3 months) is clearly an important improvement for metabonomics. At the same time it was 
necessary to unravel the behavior of the metabotypes in a more extensive time period, in order 
to completely help researchers in all above mentioned fields and, especially, for medical 
application. To reach this goal, 11 subjects of the project called MetRef110 were recruited 
again after 2 years, entering in the MetRef2 project, and 4 of them were recruited once more 
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time 1 year later, entering in the MetRef3 project. Nine healthy individuals, non present in 
MetRef1, were recruited 2 years of MetRef1 after together with the others 11 subjects. In this 
way the project MetRef2 was constituted by 20 individuals (9 males, 11 females), in the age 
range 25-55, donating 40 urine samples (first in the morning, preprandial) collected over a 
period of about 3 months. While MetRef3 was constituted only by 40 samples donated by 4 
subjects recruited for the third time (see Figure 1) 
 
      Figure 1 Collection scheme of the three MetRef projects 
In the new collections some singularities were present. Even if not statistically relevant, they 
allowed to better understand environmental and genetic contributions to the definition of the 
individual metabolic phenotypes. Indeed, as it is noticeable in Figure 1, two new recruited 
subjects were homozygous twins (indicated with TA and TB codes), while other two subjects 
(BU and BV) were father and son. Moreover some subjects that were donating in more than 
one project quite drastically changed their lifestyle, as BC, that between the two collections 
moved from Italy (MetRef1) to Spain (MetRef2), varying the diet, and AR, that quitted to 
smoke. 
Results and discussion 
The data yet published about the first MetRef work10 clearly showed that all subjects present a 
typical metabotype. This finding was confirmed through a predictive analysis that allowed to 
find out an average accuracy value of 99.7% for MetRef1 collection. 
The same identical analysis (PCA-CA) was done on the 20 individuals of the MetRef2 
projects giving a similar results with an average accuracy of about 99.6%. These results 
confirmed the robustness of the method used on the first work. Moreover analogous results 
were obtained pooling together all 31 individuals of the MetRef1 and MetRef2 collection 
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(clearly for the subjects that were participating to both collection the analyzed spectra were 
about 80 per each one). This result clearly highlight not only the existence of the individual 
metabolic phenotypes, but above all show their stability even a period of two years. 
In order to definitively confirm the time stability of the metabotypes, spectra of the same 
individuals presents in different collection (11 for MetRef1 and MetRef2, 4 for MetRef3) 
were used in a single vote classification as both training and test set (see Table 1). 
 
Table 2 Single vote classification. Different collections are used as training and test sets 
As it is noticeable, the average values were high and substantially similar, even if, using 
MetRef3 as training set and MetRef2 as test set, the value was slightly lower. The high 
percentages reported in the previous table demonstrate that the metabotypes substantially 
remain stable in a time scale of about two-three years and this is a significant basis to the 
medical implication of the metabotypes. Indeed this justifies that drugs are differently 
metabolized by different subjects that may show different responses and/or different adverse 
effects on the basis of their own metabolism. Moreover these findings suggest the necessity to 
develop all medical therapies in a personal way according to the various existing 
metabotypes. Moreover the robustness of this “healthy” metabotype allows, together with the 
understanding of its peculiar features, to unravel whether modifications occur in the 
metabolomic profile have a physiologic or a pathologic origin. 
Some considerations about the environmental and genetic contributions to metabotypes can 
be done by examining the obtained accuracy values for each subject and their respectives 
distances in the PCA-CA subspace. In particular TA and TB (homozygous twins) presented 
yet the shortest distance in the PCA-CA subspace, followed by BU and BV that are father and 
son, indicating the presence of a genetic component. This finding was also confirmed by the 
use of single vote classification; indeed the few misdiagnosed samples for TA and TB were 
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assigned to one another, non casually assigned to others subjects as it happened for all 
individuals. 
Finally it is necessary to do a consideration on the variability of the spectra. Even if in this 
work it was clearly shown the time stability of the metabotypes, the detailed visual analysis of 
the spectra revealed some differences between various collections. These differences were 
classified as “spikes”, “waves” and “jumps” and they seemed principally due to diet effects. 
In particular, i) spikes are signals that appears in a single spectra having a markedly 
differences in intensity between preceding and following days, ii) waves are signals that have 
a variation in intensity more gradual but that persist for several days, iii) jumps are signals 
that markedly appear in a collection as spikes but they remain practically unchanged for all 
the collection and, sometimes, they are carried to next collection and are reversible. Spikes are 
principally due to particular food intake, for instance the peak of TMAO (TriMethylAmine-
N-Oxide)11 clearly appeared in spectra of urine collected the day after a fish diet intake, as 
well mannitol appeared after chewing gum intake. Nevertheless a particular diet is one of the 
causes of some jumps, in particular for individual AW it was observed a jump for 
xanthosine12 due to an excessive meat consumption during a period of more days. Great part 
of jumps and waves are really due to the modification of gut microflora. Indeed it was noted 
that the peaks involved in waves and jumps were principally due to metabolites as hippurate, 
meta-hydroxyphenylpropionate, formate and phenylacetylglycine that were usually products 
of the metabolism of intestinal bacteria13,14,15,16,17 and, therefore, linkable to activity variations 
of gut microflora. This last consideration lead us to consider the individual metabolic 
phenotypes as a metagenomic entity strongly affected by both host genotype, environmental 
factors and gut microbiome. This concept is even stronger under the light of the last findings 
that showed that humans have ten times more bacteria than human cells18,19 that encode 100-
fold more genes than human genome. Moreover the majority of microbes reside in the gut 
itself. It is showed their profound influence on human physiology and nutrition, and are 
crucial for human life20,21. Furthermore, the gut microbes contribute to energy harvest from 
food, and changes of gut microbiome may be associated with bowel diseases or 
obesity22,23,24,25,26. This concept it will be even more clear in Chapter 5 where the gut 
microbioma metabolism will be highlighted as one of the main component of the celiac 
fingerprint. 
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and 
metabolomics 
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Introduction and classification 
In the worldwide breast cancer it is the second most common type of cancer after the 
lung cancer, with an incidence of 10.4 % (calculated on both sexes) and the fifth most 
common cause of cancer death (about 519.000 deaths in the 2004, equal to 7% of all 
cancer deaths)1. Breast cancer is about 100 times more frequent in women than in men, 
even if the rates of survival are practically equivalent2. Women are at higher risk of 
breast cancer because they have much more breast tissue than men do and because 
estrogens promote its development. Breast cancer is the most common malignances in 
women: 32% of all female cancers3. 
Each breast has about 20 sections called lobes, which have many smaller sections called 
lobules. The lobes and lobules are connected by ducts (Figure1). The most common 
type of breast cancer is ductal cancer. Cancers are classified as non-invasive (in situ) 
and invasive (infiltrating). The term in situ refers to cancer that has not spread past the 
area where it initially developed. Invasive breast cancer has a tendency to spread 
(metastasize) to other tissues of the breast and/or other regions of the body. A less 
common type of breast cancer is the inflammatory breast cancer, characterized by 
general inflammation of breast.4 
 
Figure 1 The structure of the female breast 
Beyond of the type of pathology, other classifications exist for the breast cancer.  
Grade of tumor: It is determined by the pathologist using a microscopy and the Bloom-
Richardson-Elston staging system5,6. With the microscopy it is assigned a score ranging 
from 1 to 3 to the three followed features: i) percentage of tumor with normal ducts, ii) 
number of observable mitotic figures and iii) characteristic of cell nuclei. Therefore the 
final score will be included between 3 (well differentiated, best prognosis) and 9 (poorly 
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differentiated, worst prognosis). In details tumor with scores between 3 and 5 are grade 
1, between 6 and 7 are grade 2 and between 8 and 9 are grade 3.  
Genetic and Proteic Expression: These tests are usually done by immunohistochemistry 
on tissue from a biopsy. The breast cancer cells are tested for expression of some genes, 
as estrogen receptor (ER) and progesterone receptor (PR), and of some protein, as 
human epidermal grow factor (EGF) or receptor 2 (HER2).  
In both pre- and postmenopausal women, levels of steroid receptors ER and PR can 
predict which women are likely to benefit from hormone treatment. Most breast cancers 
in post-menopausal women are ER-positive, meaning that they require estrogen to 
grow. These ER-positive breast cancers are less aggressive than ER-negative breast 
cancers, which are found generally in pre-menopausal women. 
HER2 is overexpressed in breast cancers as a result of HER 2 proto-oncogene 
amplification. It is measured in the tissue from a biopsy either by immunological assays 
of the protein or PCR. The presence of HER-2 is generally associated with a more 
aggressive growth and poorer prognosis or breast and ovarian cancer7. It can also help 
to determine treatment options and for resistance to some conventional therapies.   
Stage of tumor: TNM classification is based on the clinical size and extent of invasion 
of the primary tumor (T), the clinical absence or presence of palpable axillary lymph 
nodes and evidence of their local invasion (N), together with the clinical and imaging 
evidence of distant metastases (M). This is then translated into TNM classification 
which has been subdivided into:  
- Stage 0, called carcinoma in situ.  
- Stage I, early stage breast cancer where the tumor is less than 2 cm across and has not 
spread beyond the breast.  
- Stage II – early stage breast cancer where the tumor is either less than 2 cm across and 
has spread to the lymph nodes under the arm; or the tumor is between 2 and 5 cm 
(with or without spread to the lymph nodes under the arm); or the tumor is greater 
than 5 cm and has not spread outside the breast.  
- Stage III – locally advanced breast cancer where the tumor is greater than 5 cm across 
and has spread to the lymph nodes under the arm; or the cancer is extensive in the 
underarm lymph nodes; or the cancer has spread to lymph nodes near the breast 
bone or to other tissues near the breast.  
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- Stage IV – metastatic breast cancer where the cancer has spread outside the breast to 
other organs in the body. 
Etiology 
Even if the first work on the epidemiology and etiology of breast cancer was published 
on 1926 by Janet E. Lane-Claypon for British Ministry of Health, it is still not possible 
to definitely establish epidemiological risk factors and etiology for every type of breast 
cancer. Every woman is at risk for developing breast cancer. Several relatively strong 
risk factors for breast cancer that affect large portions of the general population have 
been identified. However, the majority of breast cancer cases occur in women who have 
no identifiable risk factors other than their gender8.  
About 5% of new breast cancers are attributable to hereditary factors and family history 
of breast cancer, while the etiology of the other 95% is unknown9. The risk of breast 
cancer is higher among women who have a close blood relative with the disease, 
especially if the relative developed breast cancer before the age of 5010. However, most 
women who get breast cancer (approximately 80%) have no such family history11. 
Recently, it has been shown that germline mutations in the BRCA1 and BRCA2 genes 
account for a large portion of cases of hereditary breast cancer12. In addition to 
mutations in the BRCA1 and BRCA2 genes, there are unidentified genetic defects that 
predispose to breast cancer development13,14 and additional studies may help in 
identifying these genes in the future.  
The other “established” risk factors for breast cancer beyond female gender are 
advanced age2,15, previous breast cancer16, benign breast disease17, early age at 
menarche17, late age at menopause2, late age at first full-term pregnancy17, 
postmenopausal obesity18,19, low physical activity20,21, race/ethnicity (non-Hispanic 
white, Hawaiian, and black women ethnicity) 22 and high-dose exposure to ionizing 
radiation early in life23. For almost all these factors estrogens play a pivotal role. 
Clinical manifestations and signs of breast cancer 
It is considered that, in about 80% of cases1, the breast cancer is discovered by the own 
patients when they find a lump that feels different from the surrounding breast tissue. 
Sometimes the lumps are discovered through a mammography. Moreover the presence 
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of a lump in the armpits (lymph nodes) is also a possible symptom of breast cancer. 
Obviously many other signs may be included as changes in size or shape, skin dimpling, 
nipple inversion. Pain (called mastodynia) is another possible symptom but it is not 
characteristic. Indeed it is possible to have it in many other breast pathologies such as 
mastitis and fibroadenoma. When breast cancer cells invade the dermal lymphatics, that 
are small vessels in the skin of breast, its presentation can resemble skin inflammation 
and thus is known as inflammatory breast cancer as previously mentioned. Another 
reported symptom complex of breast cancer is Paget’s disease that cause eczematoid 
lesions of the nipple skin. Approximately half of women diagnosed with Paget's also 
have a lump in the breast24. Furthermore, when breast cancer is manifest in the 
metastatic form, a great number of new usually “non-specific” symptoms appear and 
their features depend on the location of metastasis. Metastasis of breast cancer are 
commonly located in bone, liver, lung and brain25. 
Diagnosis and therapeutics 
The most common used screening method for diagnosis of breast cancer is a 
combination of x-ray mammography and clinical breast exam. In particular regular 
mammography is recommended in several countries in women over a certain age as a 
screening tool. In women at higher than normal risk, such as those with a strong family 
history of cancer, additional tools may include also genetic tests or breast Magnetic 
Resonance Imaging.  
A further support in the diagnosis and follow up of breast cancer could be given also by 
the cancer antigen (CA) dosage, that is usually elevated in breast cancer. However this 
test lacks of the required sensitivity and specificity for routine detection of breast cancer 
and does not discriminate patients with early carcinoma from those with benign breast 
disease. 
The common diagnoses is elaborated after a "triple test" of clinical breast examination, 
lead by a trained specialist, mammography, and fine needle aspiration and cytology 
(FNAC). These three tools can be used to diagnose breast cancer with a good accuracy. 
Another useful option is biopsy, that consists in the removal of either part or entire 
lump. As other tumors, breast cancer is treated by surgery when it is localized and, 
following, an adjuvant hormonal therapy, chemotherapy and/or radiotherapy is chosen 
on the basis of the features of the tumor and of the patient. Indeed, depending on 
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clinical criteria (age, type of cancer, size, metastasis), patients are collocated into risk 
groups and different therapy strategies are consequently applied. Adjuvant!online is a 
free software that is very useful to predict the risk of relapses and mortality associated 
to a breast tumor in not-operated subjects, if they will be not treated. Moreover the 
software also values the reduction of the risk in case of specific therapies. Parameters 
used by software are related to form and type of tumor, as size, hormonal receptor (ER) 
status, lymph node involvement26, but also to some patient characteristics, as age, diet, 
used drugs. 
Aim of the work 
An obvious aim of any research on breast or other types of cancer is the improvement of 
the knowledge of both pathologies and available clinical therapies. Metabonomics, as a 
science that provides a dynamic portrait of the metabolic status, can be very helpful in 
these directions. Indeed in Chapther 6, we have already shown the potentiality of 
metabolomics in define the presence of an individual fingerprinting stable over the time. 
On the other hand, in the study of breast cancer as well of the other examined 
pathologies of this thesis (celiac and cardiovascular disease risk), the goal is that of 
identify the pathological modifications that may occur in the individual profile 
distinguishing them from the physiologicals. Moreover one of the main goals within 
cancer metabolomics, but also within celiac disease, is to develop a standardazeble and 
non-invasively methods for diagnosing the disease27. 
Particularly an improved predictivity of clinical outcomes provides a better approach to 
the treatment of breast cancer, permits individualized therapy and reduces the side 
effects associated to it. For these purposes the attention was focused on the possibility to 
discriminate i) pre-operative not-metastatic breast cancer subjects ii) post-operative not-
metastatic breast cancer subjects and iii) post-operative metastatic breast cancer subjects 
on the basis of the analysis metabonomic analysis of their serum blood samples. 
Moreover, another important goal was to check the capability of metabonomics to 
single out the presence of micrometastasis in the organism. Indeed, in the treatment of 
early breast cancer, a critical issue is the identification of which individuals can really 
benefit from adjuvant intervention. As mentioned above, the patients are divided in risk 
groups and their therapy is decided starting from this classification. However it is 
common to under- or over-estimate the risk and, therefore, use to apply therapies that 
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are not completely correct and appropriate. One, and probably the most, important cause 
of this mis-assignment is the existence of unpredicted micrometastasis. The detection of 
micrometastasis is not a trivial task. In this work the idea was to detect whether a 
metabonomic fingerprint of the micrometastasis exists and to evaluate how the 
“metabonomic risk” correlate with that derived from the use of Adjuvant!online28 
software, which predict the 10-years mortality.  
Results and discussion 
The study was based on the metabolomic analysis of serum. Collected serum samples 
were divided in three classes: i) 44 pre-operative early breast cancer ii) 98 post-
operative early breast cancer (44 of which were the same that gave also the pre-
operative samples, 45 new recruited) iii) 51 metastatic breast cancer. For the early 
breast cancer patients the mean time between pre-operative collection and surgery was 
16 days (range 2:40), while for post-operative was 33 days (range 16-55). 
A good clusterization between early pre-operative and metastatic subjects was obtained 
above all on NOESYpresat serum spectra using O-PLS (Figure 1): this clearly 
separation highlight the existence of a metabonomic fingerprint for the metastatic 
pathology and was confirmed also by the clusterization between post-operative and 
metastatic subjects 
 
Figure 1 O-PLS of pre-operative (N=44) and metastatic (N=51) patients showing near 
complete separation of patient groups (NOESYpresat spectra). 
Also the double cross validation scheme confirmed the goodness of this clusterization 
with an accuracy of 75% for CPMG and 77% for NOESYpresat. The clusterization 
shown in Figure 1 suggests that some pre-operative samples present very similar 
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characteristic to metastatic samples. In order to better understand the origin of this 
misclassification, a risk factor, called “Metabolomic risk” was assigned to every not-
metastatic sample. The value of each Metabolomic risk was assigned measuring the 
Euclidean distance of each dot from the centre of metastatic cluster. Obviously it was 
supposed that samples that have an higher distance from metastatic center had less 
metastatic characteristic and, therefore, they had a less value of risk. Practically the 
short is the distance, the higher is the risk, and vice versa. The comparison between 
Metabolomic risk and 10-year mortality by Adjuvant! (described above) showed a clear 
relationship between the two established risks with a percentage values of concordance 
of about 48%. However there was a significant discordance for three samples that were 
classified as having a very high metabolomic risk whilst they resulted to be not at risk 
for Adjuvant! To explain these data the best possible assumption is related to the 
presence of micrometastasis in some breast cancer hosts. Indeed, micrometastasis were 
not considered in calculation of risk by Adjuvant!. Therefore pre-operative patients that 
had a metabonomic fingerprint similar to metastatic subjects, and thus closer to the 
metastatic cluster, could have micrometastasis.  
Perspectives 
The only and better way to confirm our findings is to repeat the study in a class of 
subjects donating also follow up samples. In such way it may possible to understand if 
the discordance in the risk assessment between Adjuvant! and metabolomics is due to 
the presence of micrometastasis that can be the cause of relapse. In order to have this 
validation we are presently analyzing blood serum samples collected by the Memorial 
Sloan Kattering of New York within a follow-up study longer than 5 years. These 
samples belong to 95 metastatics subjects and to 109 post-operative patients (60 low 
risk for Adjuvant! and 49 high risk for Adjuvant!). 
Another important approach can be the analysis of tissues of breast cancer. Analyses of 
tissues is used in metabonomics and led to the significant results of suggesting 
sarcosin29 as a possible biomarker of prostate cancer progression. An identical approach 
could be used to better understand the metabolism of breast cancer and also to study in 
details both the role of phenylalanine in tumor progression and the importance of its 
pathways in the onset of breast cancer and, moreover, in its progression to metastasis. 
56 
 
Bibliography 
                                                           
1
 World Health Organization (web site www.who.int) (2006). Fact sheets N. 297, Cancer. 
2
 Wu S.C., Hotes J., Fulton J.P., Chen V.W., Howe H.L. et al. (2002). Cancer in North America, 1995-1999. 
Volume III: NAACCR Combined Cancer Incidence Rates. Springfield, IL: North American Association of 
Central Cancer Registries. 
3
 Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A. et al. (2002). SEER Cancer Statistics Review, 
1973-1999, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1973_1999/, 2002.  
4
 WHO. World Health Organization (1981). Histological Typing of Breast Tumors, 2nd edn. Geneva: WHO. 
5
 Bloom H.J., Richardson W.W. (1957). Histological grading and prognosis in breast cancer; a study of 1409 
cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377. 
6
 Genestie C., Zafrani B., Asselain B., Fourquet A., Rozan S. et al. (1998). Comparison of the prognostic value 
of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major 
importance of the mitotic count as a component of both grading systems. Anticancer Res 18: 571-576. 
7
 Tiwari R.K., Borgen P.I., Wong G.Y., Cordon-Cardo C., Osborne M.P. (1992). HER-2/neu amplification and 
overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12 (2): 419-
425. 
8
 Kelsey J.L., Gammon M.D. (1990). Epidemiology of breast cancer. Epidemiol Rev 1990, 12: 228-240. 
9
 Madigan M.P., Ziegler R.G., Benichou J., Byrne C., Hoover R.N. (1995). Proportion of breast cancer cases in 
the United States explained by well-established risk factors. J Natl Cancer Inst 87: 1681-1685. 
10
 Claus EB, Stowe M, Carter D.(2003). Family history of breast and ovarian cancer and the risk of breast 
carcinoma in situ. Breast Cancer Res Treat 78 (1): 7-15.  
11
 Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 
58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001, 358(9291): 1389-1399.  
12
 Ford D., Easton D.F. (1995). The genetics of breast and ovarian cancer. Br J Cancer 72 (4): 805-812.  
13
 Jass J.R.  (1997). Origins of … familial cancer: histopathological perspectives. J Clin Pathol 50 (11): 892-895 
14
 Venkitaraman A.R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2.  Cell 108: 171-
182. 
15
 Edwards B.K., Howe H.L., Ries L.A., Thun M.J., Rosenberg H.M. et al. (2002). Annual report to the nation on 
the status of cancer, 1973-1999, featuring implications of age and aging  on U.S. cancer burden. Cancer 94 (10): 
2766-2792. 
16
 Minami Y., Ohuchi N., Taeda Y., Takano A., Fukao A. et al. (1999). Risk of breast cancer in Japanese women 
with benign breast disease. Jpn J Cancer Res 90 (6): 600-606. 
17
 Helmrich S.P., Shapiro S., Rosenberg L., Kaufman D.W., Slone D. et al. (1983). Risk factors for breast cancer. 
Am J Epidemiol 117 (1): 35-45. 
18
 Brown P., Allen A.R. (2002). Obesity linked to some forms of cancer. W V Med J 98 (6): 271-272. 
19
 Hirose K., Tajima K., Hamajima N., Takezaki T., Inoue M. et al. (2001). Association of family history and 
other risk factors with breast cancer risk among Japanese premenopausal and postmenopausal women. Cancer 
Causes Control 12 (4): 349-358. 
20
 Bernstein L., Henderson B.E., Hanisch R., Sullivan-Halley J., Ross R.K.(1994). Physical exercise and reduced 
risk of breast cancer in young women. J Nat Cancer Inst 86:1403-1408. 
57 
 
                                                                                                                                                                                     
21
 Friedenreich C., Bryant H.E., Courneya K.S. (2001). Case-control study of lifetime physical activity and 
breast cancer risk. Am J Epidemiol 154: 336-347. 
22
 Racial/Ethnic Patterns of Cancer in the United States 1988-1992. National cancer Institute Surveillance, 
Epidemiology, and end results Program. 
23
 Preston D.L., Mattsson A., Holmberg E., Shore R., Hildreth N.G. (2002). Boice JD Jr. Radiation effects on 
breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 158 (2): 220-235.  
24
 Marcus E. (2004). The management of Paget’s disease of the breast. Curr Treat Options Oncol 5: 153-160. 
25
 Lacroix M. (2006). Significance, detection and markers of disseminated breast cancer cells Endocr Relat 
Cancer 13: 1033-1067. 
26
 Ravdin P.M., Siminoff L.A., Davis G.J., Mercer M.B., Hewlett J. et al. (2001). Computer program to assist in 
making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991. 
27
 Madsen R., Lundstedt T., Trygg J. (2010). Chemometrics in metabolomics—A review in human disease 
diagnosis. Anal Chim Acta 659(1-2): 23-33. 
28
 Goldstein L., Gray R., Badve S., Childs B.H., Yoshizawa C. et al. (2008). Prognostic utility of the 21-gene 
assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J 
Clin Oncol 26: 4063-4071.  
29
 Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q. et al. (2009). Metabolomics profile 
delineate potential role for sarcosine in prostate cancer progression. Nature 2009 457: 910-914. 
58 
 
 
 
 
 
5. Celiac disease 
and 
metabolomics 
59 
 
Definition and etiology 
Celiac disease (CD) is an autoimmune disorder of the small intestine caused by a lifelong 
intolerance to gluten that occurs in people of all ages. It is characterized by immune-mediated 
enteropathy causing maldigestion malabsorption1. Although no pharmaceutical treatment is 
actually available, a lifelong free-gluten diet allows to reverse the symptoms and permit to 
patients to spent a normal life2. 
The pathology is caused by an immune reaction to gliadin, a gluten protein normally present 
in wheat, barley and rye. Prolamines, gliadin and glutamine, are rich proline proteins. The 
high proline content is the cause of the resistance to complete proteolytic digestion of these 
proteins by the enzymes of the human intestine, that are physiological deficient in prolyl 
endopeptidase activity3,4. This can result in the accumulation of relatively large peptide 
fragments (as many as 50 amino acids in length) with a high proline and glutamine content in 
the small intestine4,5. Celiac subjects show an altered intestinal permeably that allows these 
peptides to pass through the gut mucosa6. After exposure to gliadin, the enzyme tissue 
transglutaminase (tTG) modifies these peptides, by the addition of crosslinkins between 
gluttammine and lysine residues, and the immune system cross-reacts with the small-bowel 
tissue, causing an inflammatory reaction7 that leads to the atrophy of the villi of the small 
intestine. Finally this interferes with the absorption of nutrients, because the intestinal villi are 
responsible for absorption8. CD is a multifactorial disorder in which both genetic and 
environmental factors play a crucial role in pathogenesis9. Genetically it is associated with 
specific alleles: HLA-DQ2 and HLA-DQ8. HLA-DQ2 is expressed in more than 90% of 
people with CD10,11 (Figure 1). However the expression of these two alleles is not sufficient 
to develop CD. Other studies highlight the role of the gap junctions between enterocytes and 
the possible role carried out by zonuline12. Moreover, results of studies in homozygotic twins 
suggest that genes are not the main cause of the disease development13. 
 
Figure 1 HLA Types in Coeliac Disease Patients 
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Clinical manifestation of celiac disease 
Children between six and twenty-four months affected by CD tend to present bowel 
symptoms, abdominal distension, vomiting, growth problems, irritability and asthenia. The 
described symptoms are typical of classic form of the CD that starts after few months since 
the introduction of glutin in the diet. This form, in really rare cases, can also give the so called 
celiac crisis characterized by acute diarrhea, strong dehydration, hypotension and edema. 
Further the typical or classical form, CD give an atypical form in adults characterized by 
anemia caused by folic acid or iron deficiency, apathy, constipation, obesity, headache, 
anxiety, depression, cramps, paresthesia, but also chronic fatigue, muscular pain, athralgia, 
recurrent mouth ulcer and alteration of tooth enamel.  
Moreover several other conditions are described associated to CD as various type of cancer 
(T-cell lymphoma14,15,16, small bowel carcinoma16), endocrine diseases (type 1 diabetes17, 
autoimmune thyroiditis18 and Addison’s disease19), dermatologic diseases (herpetiform 
dermatitis20, psoriasi21, chronic uticaria22, alopecia23), neurologic disease (epilepsy24, 
athaxia24, drug resistant headache24, multiple sclerosis25, Corea di Huntington24, peripheral 
neuropathy24), osteoarticular diseases (osteoporosis26,27, rheumatoid arthritis28, Sjögren 
syndrome29), psychiatric diseases (depression30), cardiovascular diseases and others diseases 
as Systemic Lupus Erythematosus (Lupus)31, Down syndrome32, Turner syndrome33, 
Williams syndrome34, autism35, infertility36, polyabortively36. 
Under the inclusive definition of celiac disease, or gluten-sensitive enteropathy, the concepts 
of silent, latent and potential CD have been introduced. While silent CD is marked by severe 
damage to the jejunal mucosa in the absence of clinical symptoms, both latent and potential 
CD are characterized by jejunal mucosa that would be reported as normal by most clinical 
pathologists in an individual on a gluten-containing diet. Latent subjects sometimes in their 
life have had a flat jejunal biopsy which recovered on a gluten-free diet. Latent celiac patients 
are often symptomatic; neither high titres of gliadin antibodies nor mucosal changes 
(including raised intraepithelial lymphocyte counts) are obligate features of latent CD, 
although the presence of elevated endomysial antibodies is probably the best predictor of 
progression towards villous atrophy37.  
The term potential CD has been proposed for those subjects who, as opposed to latent CD 
patients, do not have, and have never had, a jejunal biopsy consistent with clear CD, and yet 
have immunological abnormalities similar to those found in celiac patients. Good markers of 
potential CD include the presence of serum endomysial antibodies, a high count of 
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intraepithelial lymphocytes and subtle pathological alteration such as increased density of 
intraepithelial lymphocytes expressing gamma delta T cell receptor, signs of activated 
mucosal cell-mediated immunity, celiac-like intestinal antibody pattern, and positive rectal 
gluten challenge37. 
Prevalence and incidence 
Celiac disease is one of the most common chronic disorders in Europe and western countries 
of European origin. Historically for celiac disease the prevalence was considered of about 
0.02%38, but the introduction of new diagnostic practices caused an increase in this value. 
Now the prevalence is considered to be between 0.54% and 0.94% in Italy39,40, the 0.95% in 
USA41, 0.60% in Argentina 42, 1,01% in Finland43,1.30% in Sweden44, the 0.40% in 
Australia45 and even the 5.56%. in an Arabic population of Sahara46. Moreover, the 
prevalence is indicated to be between 0.33% and 1.06% in children (for Sahrawi people is 
5.66%) and between 0.18% and 1.20% in adults41,46. It has been also reported a ratio 
male/female equal to 1/341. 
Corrado G et al. reported in a study of 200147 that patients whit classical celiac symptoms 
show a double increased mortality during the first three years after diagnosis. The main causes 
of mortality are malignant diseases (as no-Hodgkin lymphoma), digestive diseases and 
respiratory diseases. The mortality data are confirmed also by Peters U et al. in 200348: they 
find as main causes of death Hodking lymphoma, cancer of small intestine, rheumatoid 
arthritis, inflammatory bowel diseases and liver cirrhosis.  
Diagnosis and therapeutics 
Several tests could be used to diagnose CD, including serological and endoscopic tests. The 
biopsy by fiber-optic endoscopy is the test which carries the higher value of sensitivity (about 
100%) and a lower frequencies of error, due to the possibility to have false positive 
(specificity is about 61%). The positivity of the biopsy is based on the identification of 
different degree of lesions (1-3C) on the basis of the Marsh Classification modified by 
Oberhuber49 (Figure 2). However endoscopy represents a very invasive test, it is used to 
definitively confirm the presence of the CD in patients with positive serology and/or high-risk 
symptoms, as weight loss, anemia (more than 120 g/l in females and 130 g/l in males) and 
diarrhoea50.  
62 
 
 
Figure 2 Marsh Classification modified by Oberhuber. IELs: intraepithelial linfocytes. 
Serological tests are the first approach used to determine CD. Most used tests are the indirect 
immunofluorescence measures of four antibodies: IgA-anti-reticulin (ARA), IgA-anti-gliadin 
(AGA) and, above all, IgA-anti-endomysium (EMA) and IgA-anti-transglutaminase (tTG)51. 
In parallel total levels of all IgA are checked to avoid the possibility to have false negative 
results associated to celiac patients with IgA deficiency: in this case IgG antibodies could be 
useful to diagnose CD (25). These tests have very high value of sensitivity (98%) and 
specificity (about 99%)52. Similar value of specificity and sensitivity are associated with anti-
tTG test, even if it is quicker and easier than anti-EMA test53. Although serology appears as 
the better first approach to diagnose CD it is interesting to note that some case of apparent 
seronegative CD occur, even if in presence of normal serum IgA54. 
It is also important remember as the described diagnostic methods have to be employed only 
on freed diet-subjects because the gluten-free diet cause a progressive normalization of both 
serologic and endoscopic tests. 
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Historically the only one therapeutical approach in CD is a complete e permanent gluten-free 
diet2. After a period of diet, from few weeks to some months, all the symptoms, included 
villous atrophy, are totally reversed except for the alteration of the tooth enamel. All other 
tried strategies, for example the use of bacterial prolyl endopeptidase as dietary supplement to 
degrade anti-gliadin peptides55, have failed in vivo. 
Background 
A previous work56, published in Journal of Proteome Research, fully shows the existence of a 
typical metabonomic signature for celiac disease. The work was based on 1H NMR spectra of 
urine and serum samples of 34 CD patients and 34 healthy subjects. A CD patients’ subgroup 
was also examined after a gluten-free diet. Using this metabolic fingerprint, it was possible to 
make predictions about the CD status with reasonably good accuracy (about 84%). 
Furthermore, Bertini et al. found that after a year on a GFD all but one of the CD patients 
classified with the healthy group, showing that the metabolic impact of the disease changes 
during treatment and can be followed using metabolomics. These results, although extremely 
encouraging, are not particularly helpful from a merely diagnostic point of view, since 
serology by blood test already achieves a sensitivity of about 98% and a specificity of over 
95%52. However, the clear discrimination between patients and healthy subjects and patients 
and follow-up cases, achieved by metabolic fingerprinting, undoubtedly demonstrates the 
existence of a metabolic signature for CD both in serum and urine. Bertini et al. found that the 
metabolomic fingerprinting of CD is based on three components: i) malabsorption, ii) 
alteration of energy metabolism and iii) alteration of gut microflora. In this way it also 
suggests new features to explore and investigate some unsolved aspects of CD as chronic 
fatigue, that could be linked to the alteration of the energy metabolism that in CD patients 
seems to prefer other source of energy respect to glycolysis.  
Aim of the work 
Bertini et al. undoubtedly demonstrated the existence of a metabolic signature for CD both in 
serum and urine Nevertheless it is necessary to extend them to distinguish CD from other 
causes of malabsorption (small intestinal bacteria overgrowth, Crohn disease, short bowel 
syndrome and so on) and to well understand the capability of metabonomic to clearly 
highlights the presence of CD, even if for peculiar forms of the pathology, as silent or 
potential CD. 
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To solve these purposes of investigation 61 both urine and serum sample of different CD 
patients (11 males, 50 females, mean age 40.2 ± 13.9 yrs), 51 both urine and serum sample of 
different healthy subjects (19 males, 32 females, mean age 35.2 ±  14.3 yrs) and 29 both urine 
and serum sample of different potential celiac subjects (5 males, 24 females, mean age 37.1 ± 
14.7 yrs) were collected and analyzed. 
Our interest in potential CD subjects stems from the fact that they have all the typical 
immunoclinical features of clear CD, in the absence of any apparent intestinal damage. The 
aim of this work was investigate whether (and to what extent) potential celiac subjects share 
the same metabolic fingerprint of overt CD patients, thereby addressing an as yet open 
question: are the metabolic alterations associated to CD due to malabsorption (and therefore 
to intestinal damage) or are they independent of mucosal injury and therefore intrinsic to the 
metabolism of this pathology? In order to reach this goal, potential CD subjects could be an 
ideal subject of study because do not have villous atrophy. Moreover the comparison of the 
fingerprint of potential CD subjects with overt CD subjects and healthy controls can 
contribute to the open debate about whether or not it is necessary to put these patients on a 
gluten-free diet. 
Moreover, in addition to metabolomic analysis, in order to better characterize the clinical 
phenotype of potential CD patients, citrulline levels of the three kind of study subjects were 
monitored and compared. Plasma citrulline level is an indirect measure of the enterocyte mass 
and it was proposed as a clinical biomarker for enterocyte dysfunctions in many 
diseases57,58,59,60. Although the idea of observing citrulline levels of celiac patients was not 
new61, this was the first time that such analysis is done in potential celiac patients. 
Results and discussion 
The best clusterization of controls and untreated celiac subjects was obtained by means of k-
OPLS on CPMG spectra (shown in Figure 3).  
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Figure 3 Clusterization of CD patients (red) and healthy controls (green) obtained with kopls for 
CPMG serum spectra. Potential celiac patients (cross) are projected on the kopls component, predicted 
by SVM and coloured accordingly to the results.  
The statistical models applied proved to be effective in discriminating between patients and 
control subjects with values of accuracy in line with the previous work56: 81.2 vs 83.4 for 
CPMG spectra. The obtained results undoubtedly confirm the existence of the metabolic 
signature of CD, both in serum and in urine. Moreover if the potential celiac subjects were 
treated as blind samples and were subjected to classification by the previous statistical model, 
24 out of 29 were classified as celiac using CPMG serum spectra(Figure 3). Those results 
strongly suggest that potential celiac subjects are more similar to overt celiac than to healthy 
controls. Moreover, when the statistical analysis was used to discriminate potential from overt 
celiac subjects, the accuracy was significantly lower (57.8%), confirming that potential CD 
subjects and CD patients share a similar metabotypes. 
From the assessment of the significative buckets in the clusterization of spectra of serum 
samples and urine samples of untreated celiac patients and controls, again was confirmed that 
the metabolomic fingerprinting of CD is based on the three components: i) malabsorption, ii) 
alteration of energy metabolism and iii) alteration of gut microflora56. Otherwise the 
metabolic differences between potential CD and healthy controls in serum were quite similar 
to those between overt CD and controls at least for the metabolites related to energy 
metabolism. Especially, the key differences were in the metabolites originating from the gut 
microflora (m-HPPA, IS and PAG), confirming a relationship between overt CD, villous 
atrophy and bacterial consortia of the host. Apart from these differences, the metabolic 
patterns of overt CD and potential CD were largely the same, allowing us to hypothesize that 
CD exists as such before an evident intestinal damage occurs. 
In line with previous findings, the comparison of citrulline levels clearly showed that 
citrulline levels in the CD patients were markedly lower than in the control group. But, more 
interestingly, also potential CD subjects, that from endoscopy did not show any manifest sign 
of villous atrophy, had lower levels of citrulline than controls. According to clinical 
experience, if a celiac subject has a positive antibody test but does not show macroscopic 
alterations of intestinal mucosa there can be only two possibilities 1) a (limited) intestinal 
damage is present but the endoscopy was not able to detect it (some errors in the sampling 
procedure are possible) or 2) the intestinal mucosa is really intact and the subject is a so-
called “potential CD subject”. The interpretation of our data (both from metabolomics and 
from citrulline essay) suggests a third option: potential CD subjects are, indeed, non potential 
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at all. They already experience some subtle alterations of the enterocytes, at least at the 
microscopic functional level, but not at the macroscopic level. This may justify our results, 
showing that potential CD subjects are metabolically similar to CD, but they do not show 
endoscopic evidence of intestinal damage. Finally the core result from our investigation 
would be that metabolomics can detect CD also when its clinical manifestation is not fully 
evident. On this basis, putting potential CD subjects on a gluten fie diet can be extremely 
justified, because they are experiencing exactly the same pathological alterations as overt CD 
patients.  
Conclusions 
These results show that metabolomics can clearly identify a metabolomic fingerprinting of 
CD. Respect to the study on breast cancer (shown in Chapter 4) this results undoubtedly 
appear more robust. This finding is not at all completely unexpected because, respect to breast 
cancer, CD is a real metabolic pathology and, as shown by the variability of its clinical 
manifestation, strongly affects the functionality of the entire organism. This means that, 
although in Chapter 4 is shown that cancer is an interestingly subject of study for 
metabolomics, the field of the metabolic pathologies as CD or cardiovascular diseases (as we 
are going to show in Chapter 6) is that in which metabolomics seems to be the “natural” 
investigation tool. 
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Definition 
Cardiovascular diseases (CVDs) comprise a group of disease states including a large number 
of more specific conditions, such as heart failure, coronary heart disease, atheroschlerosis and 
hypertension1. Collectively, diseases of the cardiovascular system are the leading causes of 
death in many industrialized countries2,3. “Each year, heart disease kills more Americans than 
cancer”4. These classes of diseases involve the heart or blood vessels (arteries and veins)5. 
While the term technically refers to any disease that affects the cardiovascular system, it is 
usually used to refer to those related to atherosclerosis.The morbidity, mortality, and 
socioeconomic importance of CVDs make timely accurate diagnosis and cost-effective 
management of the utmost importance. In most people, CVD stems from the combined effect 
of a number of causal risk factors. For this reason the scientific community coined the term 
“metabolomic syndrome” (for its definition see next section) to asses “a constellation of lipid-
related and unrelated cardiovascular risk factors of metabolic origin”6, tightly linked to a 
general disorder known as insulin resistance.  
A debate is open on the utility of the metabolic syndrome diagnosis for clinicians in planning 
management strategy. However, several definitions based on different clinical parameters has 
been proposed. During the years it has been assessed the centrality of insulin resistance, that 
in the long time give type 2 diabetes, as amplifier factor of cardiovascular risk when the 
metabolic syndrome condition is present7. 
Since it was first proposed in New Zealand in 1993, estimating cardiovascular risk has 
become an integral part of determining the eligibility for treatment with aspirin, 
antihypertensives or statins8. To date, the Framingham cardiovascular equation remains the 
most widely used method of assessing cardiovascular risk. This equation was derived from a 
large cohort study in the United States. It determines cumulative incidence (risk) of any 
vascular event in individuals free from cardiovascular disease, using a combination of 
predictors such as age, sex, systolic blood pressure, smoking status, total cholesterol level, 
high-density lipoprotein (HDL) cholesterol level and diabetic status9. Cardiovascular risk 
estimation is therefore a diagnostic test that has become a part of routine clinical practice. 
Risk factors 
The major and independent risk factors for CVD are cigarette smoking, elevated blood 
pressure, elevated serum total cholesterol and low-density lipoprotein cholesterol (LDL), low 
serum HDL cholesterol, diabetes mellitus, and advancing age. The major risk factors are 
additive in predictive power. Accordingly, the total risk of a person can be estimated by a 
weighted sum of the risk imparted by each of the major risk factors. Other factors are 
associated with increased risk for CVD. These are of two types: conditional risk factors and 
predisposing risk factors. The conditional risk factors (elevated serum triglycerides, elevated 
serum homocysteine, elevated serum lipoprotein, prothrombotic factors (as fibrinogen), 
inflammatory markers (as C-reactive protein)) are associated with increased risk for CVD 
although their causative, independent, and quantitative contributions to CVD have not been 
well documented. The predisposing risk factors (obesity, abdominal obesity, physical 
inactivity, family history of premature heart disease, ethnic characteristics and psychosocial 
factors) are those that aggravate the independent risk factors. The adverse effects of obesity 
are worsened when it is expressed as abdominal obesity, an indicator of insulin resistance10. 
Insulin resistance is a condition in which normal insulin concentrations fail to achieve a 
normal metabolic response: this means that higher than normal insulin concentrations are 
needed to achieve a normal metabolic response11. Abdominal obesity and insulin resistance 
(two significant predisposing factors) are a manifestation of the “metabolic syndrome” which 
in turn is a key in the evolution of cardiovascular disease. There is debate regarding whether 
obesity or insulin resistance is the cause of the metabolic syndrome or if they are 
consequences of a more far-reaching metabolic derangement.  
A number of markers of systemic inflammation, including C-reactive protein, are often 
increased: they are fibrinogen, interleukin 6 (IL–6), tumor necrosis factor-alpha (TNFα), and 
others. Some have pointed to a variety of causes including increased uric acid levels caused 
by dietary fructose10. 
Aim of the work 
A number of recent reviews have assessed results and future possibilities for metabolomics 
research in the field of CVDs12,13,1415,16 However until now, no exhaustive metabolomic 
investigation of cardiovascular risk factors or, somewhat ironically, of the metabolic 
syndrome as such, has been reported, despite the major risk factors are essentially altered 
blood metabolites. The only exception is given by blood pressure that has been already 
investigated by Nicholson at al.17. However, because all of these alterations are of metabolic 
nature, we hypothesized that metabolomics would be an effective tool for a deeper 
investigation of the molecular mechanism and biochemical pathways involved in the 
composition of cardiovascular risk. 
In this study, we examined the metabolic profile of 864 healthy volunteers (678 males, 186 
females, mean age 40.87 ± 11.0 years) with the aim of investigating the metabolic alterations 
characteristic of an increased cardiovascular risk. 
Results and discussion 
We performed several statistical analyses in order to understand whether metabolic fingerprint 
of the plasma samples contains predictive information about the global status of the 
individuals. At a first inspection we did a classification analysis by the mean of PLS-CA, 
followed by SVM on the CA scores., using as predictor the full NMR profile, with respect to 
the total cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides, and glycaemia. 
For classification purposes the groups were created by dividing samples in two classes 
represented by the highest and the lowest quintiles. 
Values of sensitivity, specificity and accuracy, obtained from the double cross-validation 
procedure18, were extremely encouraging: all the accuracy values were always higher than 
95% for all classifications and types of 1-D spectra, except for glycaemia, that showed an 
accuracy around 85%. Interestingly this result could be also due to the fact the glucose is one 
of the metabolites that we found to be seriously affected by the standard operating procedures 
for the collection of serum/plasma (see Chapter 8). Therefore these results suggest that the 
whole plasma spectrum profile contains meaningful information about the metabolic status of 
individuals.  
With these encouraging results, a more sophisticated regression analysis was also performed, 
with the aim of establishing a quantitative relationship between clinical data and NMR 
spectra. The average relative error is less than 10% and the R2 higher the 0.80 for LDL and 
HDL cholesterol. These striking results were not completely unexpected, because the NMR 
spectra contain several strong peaks directly related to the lipidic components of the plasma. 
To confirm that metabolomics is able to extract also more subtle metabolic information, we 
tested whether we could classify individuals with high and low values of TC or glycaemia 
even after removing spectral regions with peaks associated with lipid fractions (for TC 
analysis) and with glucose (for glycaemia analysis). Although the accuracy decreased to 
around 75% (both for TC and glycaemia), it was still highly significant, especially 
considering that we removed more than 100 spectral buckets (25% of the total) in order to be 
on the safe side: this result is a convincing indicator that changes in the blood composition are 
a global phenomena that involve several metabolic alterations and not only obvious patterns 
of lipids and lipoproteins peaks. 
As it is well known that low levels of HDL cholesterol and high levels of TC correlate to high 
risk of developing CVDs, we performed the same analyses also for the TC/HDL ratio. Again 
the results, both for classification and regression, were extremely good, with an accuracy for 
classification even higher than for the two risk factors taken separately and an R2 of 0.88 for 
regression.  
The Framingham score for each individual was also calculated, using the equation of Wilson 
et al.9 The classification gave high accuracy values also in this case (over 89%), but lowest 
than obtained in the previous analysis. This may due to the fact that the Framingham risk 
score considers also non-analytical variables, but it can derive also from the fact that 
metabolomics is able to extract a far richer and more complex metabolic pattern. 
Finally, in order to identify the metabolites that were most characteristic of the metabolic 
fingerprint of cardiovascular risk, the univariate Wilcoxon test was applied on the different 
groups, using a significance level of P<.001. These results allow us to explore the metabolite 
composition of plasma profiles, in order to characterize what is typical of an undoubtedly a 
“low risk” status (high HDL levels, low LDL levels, low triglycerides and low glycaemia) and 
what is typical of a “high risk” status (the reverse). From the point of view of this 
comprehensive metabolic analysis it seems that the “low risk” pattern is mostly constituted by 
high levels of 3-HB and low levels of threonine and creatinine. On the other hand the “high 
risk” pattern is more complex, and is characterized by low levels of several metabolites, in 
particular α-ketoglutarate, dimethylglycine and serine.  
Having in hand the results of metabolite profiling one might already attempt to elaborate new 
hypothesis about the origin of the metabolic syndrome and its connection with cardiovascular 
risk. In particular our findings seem to highlight the role of 3-HB, α-ketoglutarate, threonine 
and dimethylglycine as the key to define the fingerprint associated to high or low 
cardiovascular risk. Although a full clarification of a so complex machinery is far away, all 
our findings point to an imbalance in the mitochondrial redox potential (caused by oxidative 
stress), as the starting point that can lead to an alteration of the fatty acids beta-oxidation 
pathway with an increased secretion of LDL lipoproteins in the blood. (Figure 1). The 
involvement of mitochondrial dysfunction in the genesis of insulin resistance in adolescents 
with familiar history of type-2 diabetes has been reported also by Befroy19, that observe a 
decreased rates of mitochondrial substrate oxidation of the 30% in lean, insulin-resistant 
offspring compared with insulin-sensitive control subjects. This observation can be easily 
linked to our findings, moving the starting point of obesity, insulin resistance, and of the risk 
of developing cardiovascular injury to the mitochondrial activity. 
 Figure 1 Metabolic effect of the discussed metabolites in high risk subjects. 
Conclusions and perspectives 
A metabolomic signature of cardiovascular risk exists, and its analysis may provide novel 
insights into the associated biochemical pathways and the current prevention therapies. 
Moreover, the good agreement with the calculated values of Framingham score supports the 
idea that metabolomic analysis of plasma samples can be an effective tool for monitoring the 
individual healthy status, and, in particular the risk of developing metabolic syndrome and 
cardiovascular disease. As discussed in the previous chapter, this good result is not 
completely unexpected because also here we are evaluating metabolomics as a tool for 
monitor the “health” of individual global metabolism. The mismatches between our prediction 
and the true Framingham values can be due to our ability to unravel subtle metabolic changes, 
which are not included in the classical risk scores that probably do not allow to take an overall 
picture of the living organism as well as metabolomics do. Our observations strongly suggest 
that metabolomic analyses should be included in future year-long prospective studies and a 
new (and possibly more efficient) cardiovascular score, as well as for the metabolomic risk 
assessed for the project on breast cancer (Chapter 4), have to be formulated on the basis of the 
whole metabolic fingerprint and/or on the basis of the plasma concentration of the discussed 
metabolites. 
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Applications 
Several and of different nature are the research studies on reactive oxygen species (ROS), 
both free radicals and nonradicals species, among which ozone plays an important role (Table 
1)1  
Free radicals Non radicals 
Superoxide, O2·- (1x10-3, 1x10-6 in 
presence of SODa) 
Hydroxyl, HO· (1x10-9) 
Hydroperoxyl, HO2· 
Peroxyl, RO2· (0.1-7) 
Carbonate, CO3·- 
Carbon dioxide, CO2·- 
Nitric oxide, NO· (0.1-5) 
Hydrogen peroxide, H2O2 (fairly stable in H2O, 2.5 
in plasma, < 1 in blood) 
Hypobromous acid, HOBr 
Hypochlorous acid, HOCl (fairly stable) 
Ozone, O3 
Singlet oxygen, 1O2 (1x10-6) 
Organic peroxides, ROOH 
Peroxynitrite, ONOO- (1-4) 
Peroxynitrous acid, NOOH 
Table 1 Nomenclature of ROS (numbers into brackets represents half life values, in sec, at 
37°C. aSuperoxide dismutase 
On the basis of previous results2,3,4,5, ozone causes lipid peroxidation and can generate a 
variety of compounds.  
In the stratosphere, ozone constitutes the protective layer around the planet while, at the 
ground level, it is a pollutant mixed with nitrogen oxides and hydrocarbons generated by 
human activities. At the same time for its fungicidal, virucidal and bactericidal capacities, it is 
used to purify the drinking water in many municipalities. The use of ozone for therapeutic 
purposes was reported in 1885 by doctor Charles J. Kenworthy and since that time it has been 
used in a rather empirical basis by many practitioners in the world. There are specific 
applications of ozone therapy in a number of pathologies such as vascular diseases, ulcers, 
acute and chronic viral diseases. On the basis of some biochemical studies6,7,8,9 performed 
during the last fifteen years, a framework for understanding the basic mechanisms of action of 
ozone when it comes in contact with human blood at appropriate doses is now available. 
These data have been critically reviewed10,11 and the following biological responses can be 
summarized as: a) improvement of blood circulation and oxygen delivery to ischemic tissue, 
owing to the concerted effect of NO and CO and a variable increase of intra erythrocytic 2,3-
bisphosphoglycerate level1213; b) enhancement of the general metabolism 12; c) up-regulation 
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of the cellular antioxidant enzymes and induction of Heme oxygenase (HO)-1 and Heat Shock 
Protein (HSP)-7014,13; d) induction of a mild activation of the immune system6,7 and 
enhancement of the release of growth factors from platelets15; e) excellent disinfectant activity 
when topically used in water and oils16,17 while this is negligible in the circulation owing to 
the potent blood antioxidant capacity18. Moreover, adequate ozone treatments do not procure 
acute or late side effects and often patients report a feeling of wellness12  
Recently, the therapeutic ozone application in clinical dentistry by NMR has been studied19. 
Aim of the work 
Our poupose was to investigate the effect on the metabonomic profile of normal human blood 
of: i) ozonation within the therapeutical concentration (0.42÷1.68 µmol/mL); ii) ozonation at 
high concentrations (3.36÷16.8 µmol/mL); iii) ozonation at abnormal high concentration (126 
µmol/mL) associated with other stressors, as performed by Torre-Amione et al.20 (Torre-
Amione et al., 2008) in order to define specific alterations and toxicity regarding the amount 
of metabolites and to suggest specific markers of oxidative stress. 
Results and discussion 
The examination of CPMG and NOESY1Dpresat spectra of the control samples treated with 
pure oxygen did not yield particular differences with respect to basal samples, except a small 
increment of pyruvate peak at 2.35 ppm. On the other hand, samples treated with increasing 
amounts of ozone (from 0 to 16.8 µmol/mL) showed variations in the concentration of several 
metabolites. In particular, a strong increase of the peaks at 8.45 ppm (CH-formate), 5.40 ppm 
(CH-allantoin), 2.29 ppm (CH3-acetoacetate) and 1.93 ppm (CH3-acetate) were observed as 
well as a dramatic decrease of the 2.35 ppm peak (CH3-pyruvate) and all the variations of 
these metabolites were strongly correlated with the concentration of insufflated ozone with R2 
values major than 0.95 (except for CH3 -pyruvate) and a linear trend (except for CH-allantoni 
that showed an hyperbolic trend). 
The variations of pyruvate and acetate are chemically correlated: acetate is formed by a direct 
ozone oxidation of pyruvate. Formate is the last product of the oxidative process of 
carbohydrates and allantoin comes from oxidation of uric acid19,21 which behaves as a 
“sacrificial” molecule in the presence of a strong oxidant such as ozone22,23. Acetoacetate is 
often formed in plasma by oxidation of γ-hydroxybutyrate24,19. 
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Notably, the main part of the information on the oxidative stress was obtained from the 
CPMG spectra: this observation suggests that, although it is known that ozone causes lipid 
peroxidation, ozone treatment doesn’t cause visible alteration in lipid composition of blood in 
the range of the well-documented therapeutic concentrations of ozone23.  
Additional tests were performed in order to: i) confirm the trends of variations of each 
metabolites at higher concentrations of ozone, ii) confirm the specificity of the obtained 
results for the ozone treatment in comparison to other kinds of oxidative stress. 
The increase of the ozone concentration up to 16.8 µmol/mL gas per mL of blood confirmed 
our findings for all the previous metabolites leading to the disappearance of the pyruvate 
signal from the spectrum caused by the excessive oxidative process. Moreover, following the 
treatment with an ozone concentration of 800 µg/mL, changes in several peaks, both in 
NOESY1Dpresat and in CPMG spectra were observed, leading to the hypothesis of a damage 
of cell membranes caused by lipid oxidation with possible cytolysis. It is important highlight 
as the first changes in the lipidic component appear only with high ozone concentrations  not 
normally used for therapeutic purpose (5.04 µmol/mL upward).  
A further analysis of the spectra highlighted the presence of unidentified new peaks. These 
peaks resonate at 2.82 and 8.08 ppm and they were not present in untreated plasma. Thus 
these peaks were due to specific products directly linked to the ozone activity and indeed their 
amounts in the plasma were related to different ozone concentrations (Figures 1). 
 
Figure 1 Linear trends of appearance of 2 unidentified peaks in relation to ozone dosages: 
signal areas at 2.82 ppm (A) and at 8.08ppm (B)(n ¼ 3;CV%<2). The correlations between 
the areas of each peak and the concentration of insufflated ozone are really high. 
These data suggest that these peaks may represent markers of oxidative stress. In order to 
express an hypothesis about the origin of these two peaks other tests were performed.  
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It is well known that ozone causes lipid peroxidation yielding several aldehydes among which 
HNE is quantitatively relevant25. This aldehyde have a double bond in beta and it is not stable. 
It reacts easily with free thiol groups of cysteine, glutathione and other metabolites normally 
present in plasma, to form adducts easily eliminable from the organism with the urine26,25. 
Recent studies indicates an interaction of HNE with Cys34 present in albumin27. Starting from 
these data some samples obtained with the addition of scalar concentration of HNE (from 0.08 
µM up to 3.2 µM) to a solution of 4% human albumin in saline were analyzed. After the 
addition of HNE to albumin, the two peaks at 2.82 ppm and 8.08 normally present after blood 
ozonation were absent, as well as the aldehydic signals of HNE. On the other hand, direct 
ozonation of a 4% albumin solution in saline allowed the detection of these two peaks which 
increased in intensity in relation to the amount of ozone concentrations, indicating that these 
two signals were due to the direct oxidant activity of ozone on the albumin. Indeed, also 
albumin has been categorized as a “sacrificial” molecule, although it has not been clarified 
whether albumin undergoes dimerization28 or allows the formation of sulfenic acid29. 
Moreover, the experiments with albumin + uric acid (300 µM) and/or ascorbic acid (50 µM) 
showed an increase in the formation of allantoin. The peak at 4.5-4.6 (ascorbic acid) present 
in the control sample, disappeared as soon as ozone (0.42 µmol/mL) is added. These results 
suggest that uric acid is oxidized to allantoin and ascorbic acid is oxidized to 
dehydroascorbate. Additionally, the presence of formate as well as the appearance of both 
2.82 and 8.08 ppm peaks were evidenced. 
On the basis of the very harsh ozonation of blood (about 6 mg/mL of blood) plus UV 
radiation and heat (42.5 °C) recently reported20, it was of interest to evaluate the spectra after 
blood treatment with: i) O3;  ii) O3 + UV rays; iii) O3 + heat ; iv) O3 + UV rays + heat; v) UV 
rays; vi) heat; vii) UV rays + heat. No appreciable influence of heat and/or UV treatments on 
the metabolites present in the blood was detected, except than at 4.43 and 8.19 ppm in case of 
heat. These signals were not present in ozone-treated samples. The remaining other types of 
treatments (i-iv) showed the typical fingerprint alterations already seen in the previous tests 
(formate, acetoacetate, acetate, allantoin go up; pyruvate goes down; arising peaks at 2.82 
ppm and 8.08 ppm) to indicate that the principal stressor is due to ozone. 
To confirm metabonomic results of the effects of blood oxidative stress on the erythrocytic 
membrane and the possible cell damages with intraerythrocytic material release, 
physicochemical investigation based on hemolysis as well as viscosity were also performed. 
A statistically significant increase of hemolysis was observed at 16.8 µmol/mL, while 
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viscosity variations started from 160 µg/mL. The combination of ozone + UV (ii) as well as 
ozone + UV + heat (iv) yields the highest values of hemolysis, while the viscosity markedly 
increased only in the ozone + UV combination. 
Conclusions and perspectives 
The metabolic profile of blood samples treated with ozone is defined: i) the principal 
metabolic variation with the possible markers of oxidative stress due to ozone treatment were 
indicated; ii) blood alterations due to ozone were demonstrated to be strictly correlated to the 
concentration of insufflated ozone. However when ozone concentrations are within the 
therapeutic range (10 µg/mL blood, or 0.21 µmol/mL - 80 µg/mL blood, or 1.68 µmol/mL) 
only few alterations were detected and are not associated to significant damages. On the other 
hand several conditions, such as the association of ozone with heat and/or UV, appear 
deleterious, as showed by the physicochemical investigation based on hemolysis and viscosity 
that highlighted an extensive blood cell destruction. In other words, if ozonetherapy has to be 
safely used, it requires precise and well-calibrated ozone concentrations and the avoidance of 
ozone bubbling as well as additional stressor.  
The present work demonstrates that the metabonomic approach is a valid instrument in the 
detection of alterations in plasma profile due to oxidative stress induced by ozone and other 
stressors. Moreover, in addition to the role in the investigation of diseases showed in the 
previous chapters, metabolomics shows here another promising application in the evaluation 
of the toxicity associated to the use of therapies and in the definition of the therapeutic 
windows. 
Of course the further step in the investigation of ozone therapy will be the metabolomic 
evaluation of the effect of ozone therapeutical concentrations in vivo. Although we may 
expect that the results of the study in vivo will be less clear then those show in this chapter for 
the increased complexity of the system and for dilution effects, we are confident that also in 
the in vivo validation metabolomics will play a good role. 
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8. SOPs 
definition by 
metabolomics 
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Introduction 
The potential of metabolomics for disease diagnosis, prognosis and, in a clinical trial setting, 
for monitoring drug therapy relies on its ability to extract a disease signature from the 
multivariate analysis of the metabolic profiles of statistically relevant ensembles of samples 
derived from different donors1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19. The reliability of the approach 
requires that the chemical nature and the relative concentration of the metabolites present in 
the biofluids are neither affected by the preanalytical conditions nor by the analytical 
methodology. For the great importance that this concept has in metabolomics, metabolomics 
itself is assuming a growing importance in the definition of operating procedures aimed at 
collecting and preserving biological samples according to protocols as standardized as 
possible. The idea of using metabolomic technologies for sample quality studies has been first 
proposed by the UK Biobank Pilot Study20,21,22,23. The definition of Standard Operating 
Procedures (SOPs) is essential for all those projects (often multicenter and retrospective) that 
are based on great numbers of samples24. Biobanks, that are infrastructure devoted to the 
collection, cataloguing and storing of biological material samples in order to make them 
available for medical and clinical research, represent an irreplaceable support for all those 
studies in which the impact of the results is linked to the large number of the collected 
samples. At the same time, they have to guarantee top quality biological samples for any 
possible future studies, including metabolomics (Scheme 1). 
 
Scheme 1. 
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Among the different metabolomic tools, NMR represents a technique of choice25 for the 
definition of pre-analytical procedures as it is a high-throughput tool requiring only minimal 
sample handling before spectra acquisition and allowing the contemporary detection of a large 
number of metabolites with different physiochemical properties. The variety of detectable 
molecules allows the monitoring of residual enzymatic activities and/or chemical reactions 
that may alter the NMR profile of the analyzed sample, which becomes no more 
representative of the metabolome before collection. These alterations could seriously bias the 
results of studies based on samples with a different collection, treatment and storage history, 
and differences in relative concentrations of the most sensitive metabolites should be 
considered with care. 
Common biofluids in metabolomics 
Most metabolomics studies, as that showed in this thesis, involve common biofluids as urine 
and serum/plasma that are obtainable from mammalians, especially from humans in a non- or 
poorly-invasively way and they are easy to find and collect because they are commonly used 
for many other clinical analyses. 
Urine could seem a biospecimen with little scientific value, but it is assuming an increasingly 
importance as a bio-bankable sample thanks to metabolomics studies. Browsing PubMed (on 
08/10/2010) for metabolomics/metabonomics publications resulted in 250 publications based 
on urine, 147 publications for serum, 185 for plasma and 185 for tissues. Use of urine as a 
first choice object of study is justified by the fact that the collection method is the simplest 
and the least invasive one: these characteristics allow the easy multiple sampling that 
guarantees reliability of the statistical analysis. In this thesis I showed that NMR analysis of 
urine is able to reveal individual metabolic phenotypes26,27, but also to extract disease 
signatures (as seen for celiac disease in Chapter 5).  
Blood (serum and plasma) is the second biofluid in order of importance in metabolomics 
studies (in terms of number of publications). The disadvantage with respect to urine is that the 
collection of blood samples is a little bit more invasive and it is not so easy perform multiple 
collections from patients and even more from healthy volunteers. On the other hand, blood is 
less affected by daily variations and daily diet than urine27. 
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Aim of the work 
In this study we focused on the most commonly used biofluids: urine, serum and plasma. 
The starting point for this research are the Recommendations on Biobanking Procedures for 
urine processing and management recently published by the European Consensus Expert 
Group Report28. According to this document, biobanking procedures for urine should consider 
the following general consensus recommendations: i) cells and particulate matter should be 
removed (for example by centrifugation); ii) samples should be stored at -80 °C or below; iii) 
time limits for the processing should have been defined experimentally and should be 
appropriate to the analytes to be measured; iv) unless specified for a particular downstream 
analysis, urine samples should be stored without additives. Nevertheless, as the authors 
pointed out, advances in new downstream analytical platforms may impose specific 
requirements related to the nature of the targeted analytes, thus leading to specific 
revision/elaboration of the general procedures. Here we address the above critical issues in 
relation to the consequences for downstream metabolomics applications. Several methods of 
urine sample processing (centrifugation, filtration, addition of preservative as sodium azide) 
or combination of them as well as sample storage temperature (at -80°C or in liquid nitrogen) 
were tested and found to have significant effect on the metablome, as detected by 1H-NMR. 
Presence of host or bacterial cells in urine is identified as a potential major source of 
alteration of the metabolic profile. 
Moreover we analyzed here the quality of serum and plasma samples as a function of the time 
delay (0-4 h) and storage temperature (25°C and 4°C) before processing. Moreover changes in 
the NMR profiles of these two biofluids after serum and plasma preparation were monitored 
for a further 48 hours, to simulate the effect of the time between processing and freezing. A 
number of metabolites which are often used as disease biomarkers in metabolomics studies 
are heavily affected by the tested variation factors. 
Results and discussion 
Urine Fresh urine is characterized by the presence of human cells (erythrocytes, leucocytes, 
urothelial cells, epithelial cells), bacteria, fungi, sperm counts, non cellular components 
(mucus filaments, cylinders, cylindroids, pseudocylindres, crystals, urates). The protocol for 
the analysis of urinary sediment proposes a speed around 1600 RCF for the centrifugation29 in 
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order to avoid the breaking of the frailest elements like cylinders. On the other hand, to avoid 
the presence of any particulate components in the NMR samples that will affect the spectral 
quality, standard protocols30 for the immediate NMR analysis of urine require a centrifugation 
of the sample at 14000 RCF for 5 minutes at 4 °C. Such a high speed may induce cell 
breaking and release of cellular components into the biofluid. We thus analyzed the advantage 
of applying a mild centrifugation (pre-centrifugation) to fresh urine before the high-speed 
centrifugation needed by the preparation of NMR samples for immediate use (Figure 1A).  
 
 
Figure 1 Experimental design for: (A) the evaluation of the impact of pre-centrifugation 
speed on the NMR metabolomic fingerprint, (B) the evaluation of the effect of the use of pre-
centrifugation as a function of the temperature used for sample storage, C) the comparison of 
the efficiency of pre-centrifugation, filtration and addition of sodium azide in reducing 
bacterial content 
Our results show that there is an effect of the pre-centrifugation speed. Apparently, the 
proposed 5-minutes 14000 RCF-centrifugation of the NMR protocol is too harsh as well as 
speeds ≥ 11000 RCF at the pre-centrifugation level. If a mild pre-centrifugation (between 
1000-3000 RCF) is applied, the cellular components are spun down and the subsequent 14000 
RCF centrifugation of the supernatant is useful for the elimination of other suspended, mainly 
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inorganic, particles. The importance of the pre-centrifugation step of course depends upon the 
content in cellular components of the analyzed samples, and may therefore be very different 
from one individual to another. 
Upon inspection of the NMR spectra it appeared that the above discussed differences between 
precentrifuged at 2500 RCF or non-precentrifuged samples discussed above were due to 
chemical shift changes in signals that are extremely sensitive to pH variations. However, no 
resonances attributable to new metabolites or increase in intensity of existing signals were 
observed, suggesting that soluble components released by cells in fresh urine are below the 
detection limit.  
The presence of cellular components has an impact on the NMR profiles even if non-fresh 
urine samples are analyzed, and the importance of the observed change depends upon the 
storage temperature (Figure 1B). NMR metabolic profiles of non pre-centrifuged samples 
stored for a week at –80 °C did differ from those that have undergone a mild (600-2500 RCF) 
pre-centrifugation before freezing at the same temperature. The effect is less severe if urine 
samples are stored in liquid nitrogen. This result is not unexpected because rapid freezing in 
liquid nitrogen, below the critical ice crystal temperature (–130 °C) avoids crystal formation 
which may cause cell breaking.  
Finally, we evaluated the two most commonly used preservation methods24: filtration and 
addition of sodium azide. They were used as such or in combination with a pre-centrifugation 
step at 1000 RCF, as summarized in Figure 1C. Differently treated aliquots of the same 
sample were analyzed either fresh or after storage for a week at -80 °C, that is the temperature 
most commonly used in biobanking. Spectral variations were followed for 24 hours after 
urine processing or thawing after a week of storage at -80°C. Changes over time were 
observed for pH-sensitive metabolites that undergo chemical shift variations. Changes in the 
relative concentration of some molecules were also observed: succinate and acetate increase 
with time; urea, lactate and glutamate/glutamine decrease. The extent of their variations 
depends upon the preservation method, pre-centrifugation and storage, but, consistent with 
available literature data24, filtration is the method that makes the NMR spectra more stable 
over time. 
With the aim of evaluate the origin of the changes that affect the NMR spectra of samples 
over time, we tested three working hypothesis 
- The chemical hypothesis: reactions (e.g. oxidations) occur with time. 
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- The bacterial hypothesis: the bacteria present in urine grow over time with the 
consequent production of bacterial metabolites. 
- The enzymatic hypothesis: the enzymatic activities of urine cause the consumption of 
certain metabolites and the increase of others. 
The three working hypotheses suggested above helped us in understanding the observed 
variations of the NMR signals, but it is also important to highlight that all three mechanisms 
are present and their effects may partially overlap. Instead, our results show that, in order to 
quench bacterial/enzymatic activity in urine a mild precentrifugation combined with filtration 
results to be the safest way to avoid contamination of the metabolome with soluble molecules 
derived from cellular components. Urine did not result to be sensitive to the presence of 
oxygen, but a number of enzymatic reactions occur in this biofluid. Addition of inhibitors is 
able to quench/slow-down such activities but invariably alters the metabolomic profile as it 
introduces in the spectra signals of the added molecules, whose presence may also induce 
changes in pH, ionic strength, further altering the whole spectral properties. In this sense, 
keeping the sample at the lowest possible temperature from collection throughout the analysis 
is extremely important. 
With respect to the general recommendations in Yuille et al.28, our studies permitted the 
definition of the best practices for the removal of cells and particulate matter. Nevertheless, as 
complete removal of cells is never achieved, long-term storing temperatures below the critical 
ice crystal temperature would be advisable. Changes in metabolite concentrations at room 
temperatures are relatively fast; reduction of time between collection and processing and the 
temperature at which urine samples are kept during this time delay is critical for a reliable 
NMR metabolic fingerprint. Annotation of time delays and temperatures for the entire history 
of each sample will add statistical value. 
Blood According to the same recommendations document mentioned in the urine section28, in 
the plasma/serum processing and management one should consider the following aspects: i) 
use of EDTA or citrate as anticoagulant, not heparin; ii) sample storage at a temperature of -
80 °C, or below if e.g. critical ice crystal formation is problematic; iii) recording of the time 
from collection through processing; iv) experimental definition of time limits that are 
appropriate to the analytes to be measured. In that article the ‘‘gold standard’’ for all 
downstream applications was considered to be the extraction of DNA for genetic analysis. 
Here we validate the above procedures and evaluate whether additional procedures may be 
needed for the optimal maintainance of the original metabolome. 
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The time limits for processing whole blood were examined (Figure 2A) by evaluating the 
effect on the NMR metabolic profile of serum and plasma-EDTA samples.  
 
Figure 2 Experimental design for: (A) the evaluation of the effect of the time between blood 
collection and processing on serum and plasma NMR spectra; (B) the evaluation of the effect 
of the time between processing and freezing on the quality of NMR spectra of plasma and 
serum. 
The PLS-CA analysis of CPMG spectra showed that the spectral patterns of serum and 
plasma samples processed at different times carry meaningful differences. Degradation 
processes are time-dependent and temperature-dependent both for serum and plasma samples: 
in both cases incubation at 25 °C causes deeper changes in the NMR profile. In order to 
unravel the main mechanisms at the basis of the degradation processes occurring from 
collection through processing, we singled out the significant buckets (P≤0.05) by Kruskal-
Wallis test. They correspond to the resonances of glucose, lactate and pyruvate. The decrease 
in glucose concentration is more important in serum, most probably because EDTA in plasma 
tubes exerts an inhibitory effect on metalloenzymes and metal-dependent enzymes involved in 
glycolysis. An increase in lactate, the end product of the anaerobic glycolysis is observed, 
which is steeper than the decrease in glucose, roughly in agreement with the expected 
stechiometry of the reaction. Otherwise less clear is the behaviour of pyruvate that is an 
intermediate metabolite of glycolysis. 
In clinical analyses, the standard for the measurement of glycaemia is represented by 
fluoride/oxalate coated vacutainers. It has been reported that glucose concentrations in plasma 
from blood collected into EDTA coated vacutainers showed no significant differences with 
glucose concentrations in plasma from fluoride/oxalate coated vacutainers (which represent 
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the standard for the measurement of glycaemia) up to 36 h22,23. Comparison of the changes in 
concentration of glucose and its derivatives during the time from collection through 
processing of citrate, EDTA and fluoride/oxalate plasma in the present work did not show 
meaningful differences. Therefore, none of these three anticoagulants solves the problem of 
glucose degradation and we can just suggest that for a reliable evaluation of glucose, lactate 
and pyruvate whole blood should be processed within 2 h from collection, keeping it at 4 °C, 
although the latter may still not be the best procedure for pyruvate.  
Possible degradation processes occurring in blood derivatives after processing were analyzed 
using 5 plasma and 5 serum samples of different patients (Figure 2B). Each sample was split 
in multiple aliquots and NMR spectra of each aliquot were acquired in the time range 0-24 
hours keeping the samples at room temperature. 
The PLS-CA analysis of the CPMG spectra showed that NMR spectra gradually shift in the 
same direction during the 24 h of monitoring time, the effects are larger for serum. In order to 
single out the significant buckets (P≤0.05), and thus the corresponding metabolites, that are 
responsible of this time progression we performed the Kruskal-Wallis test. The results of the 
test for serum identified the following metabolites as markers of the time changes: 
triglycerides, proline, choline, citrate and histidine; albumin and LDL/VLDL (low-density-
lipoproteins/very-low-density lipoproteins) also contribute to the variations of the NMR 
profile. The Hε1 signal of His shifts with time, consistently with a pH variation increase of 
about 0.1 units. The signals of the other metabolites, but citrate, and those of albumin and 
LDL/VLDL decrease in intensity. The decrease for fatty acids and LDL/VLDL is attributable 
to oxidation reactions, as the effect is attenuated if samples are kept under inert atmosphere. 
The chemical shift variations observed for the signals of citrate are consistent with literature 
data about saliva31 where the observed behavior has been rationalized in terms of a 
competition between calcium(II) and magnesium(II) binding to this chelator. Consistently, no 
chemical shift changes are detected in the present work for citrate in plasma EDTA-samples. 
The decrease in concentration observed in serum of all these molecules, but proline and 
choline, parallels that observed in plasma: otherwise no meaningful decrease in proline 
concentration is visible in plasma EDTA and citrate samples, whereas proline decreases 
sizably in plasma fluoride/oxalate samples. In summary, plasma appears to be slightly more 
stable than serum when kept at room temperature. 
 
94 
 
Conclusions and perspectives 
Our findings help contribute to the definition of standard procedures for specimen collection 
that will be implemented at the local da Vinci European Biobank 
(https://www.davincieuropeanbiobank.org/) and represent a step forward with respect to the 
available recommendations for biobanking procedures28. 
On the basis of the results of our experiments, we propose the following procedures for the 
optimal processing and management of urine samples to maintain as much as possible their 
original metabolome (Scheme 2): i) removal of cells and particulate matters through the 
combined use of a mild pre-centrifugation 1000-3000 RCF (5’ at 4 °C) and filtration; ii) long-
term storage of samples in liquid nitrogen (or liquid nitrogen vapour) to avoid breaking of 
residual cells; iii) fast processing (within 2 hours for collection); iv) storage at 4 °C between 
collection and processing. Recommendations at points iii) and iv) aim at reducing the effects 
of any possible enzymatic/cellular activities. Addition of additives (like enzyme inhibitors) 
should be avoided  because the required concentrations will introduce signals in the NMR 
spectra covering the resonance of metabolites and may also induce changes in pH, ionic 
strength, etc. thus further affecting the original NMR profiles.  
 
Scheme 1: Suggested procedure for the optimal processing and management of urine to be 
used for metabolomic NMR studies. 
Based on the results collected on blood derivates, we propose the following procedures for the 
optimal processing and management of blood and its derivatives when they have to be used 
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for future metabolomic NMR studies (Scheme 3): i) either EDTA or citrate can be used as 
anticoagulant for plasma samples; ii) time between collection and processing should not 
exceed 2 h; iii) during this time delay samples should be kept at 4 °C; iv) any handling 
procedure of plasma and serum should be performed under inert atmosphere; v) samples 
should be frozen immediately after processing; vi) long term storage should be done at -80 °C 
(no need of lower temperature once erythrocytes have been removed). 
 
 
Scheme 3. 
Beyond the effective contribution that metabolomics could give to the definition of SOPs for 
biobanking and in general for collection of huge quantity of samples for epidemiological 
studies, clearly this work highlights the importance to define SOPs for the collection, 
treatment and storage that allow to guarantee the reproducibility of the metabolomics results 
themselves. Instead, most of the metabolomics studies, as well as that presented in this thesis, 
point to single out some significant metabolites that allow to better define the metabolomics 
signature of diseases. However, because several metabolites, as highlighted by this work, are 
really sensitive to the protocols adopted for the collection and treatment of the samples, it is 
necessary pay attention to the “history” of the analyzed samples in order to develop coherent 
discussions and conclusions on them. 
The next step it will be obviously that of define by SOPs also for the less common samples 
studied by metabolomics as tissue, breath exhaled, saliva, cerebrospinal liquid and so on. 
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Conclusions 
Any study aimed at the identification of relevant metabolites should be presented with 
reference to the normal or control population in order to be able to allow the identification of 
relevant metabolic changes. This it was considered as the starting point of this thesis work 
(Chapter 3). 
Besides the perspectives opened by each project, that are reported in the appropriate section of 
each proper chapter, it is here generally demonstrated the feasibility of metabolomics studies 
for the interpretation of three large impact pathologies (breast cancer in chapter 4, celiac 
disease in chapter 5 and cardiovascular risk in chapter 6). In all these researches is the role of 
metabolomics not only as diagnostic tool, but also as a tool for the understating of the 
underlying biochemical mechanism is demonstrated. 
In addition, as showed in this thesis, because NMR is able to provide predictive profile of 
different kind of diseases, its role in this field is unquestionable. But the its role is so 
exclusive that NMR is even presented in Chapter 8 as an election technique1 for the definition 
of pre-analytical procedures. Indeed, NMR is a high-throughput methodology requiring only 
minimal sample handling before spectra acquisition and allowing collection of the whole 
metabolic profile, that means the simultaneous detection of a large number of metabolites 
with different physiochemical properties (hydrophobicity/hydrophilicity, acidity/basicity, 
redox reactivity). 
The obtained results demonstrated that the NMR based metabolomic approach can be ideally 
extended to other pathologies. Indeed some other metabolomics projects have already started 
or are in a starting-phase. These new projects involve some widespread pathologies such as 
diabetes (type II), lung carcinoma, Obstructive and Chronic BroncoPathy, liver cirrhosis and 
carcinoma, Helicobacter Pylori infection or validation of health status indicators (geriatric 
assessment). The study of these new pathologies lead us to better define their characteristic, 
but also allow us to clearly understand what are the ideal targets and the limits of the 
metabolomic approach. 
Moreover the application of metabolomics in the evaluation of toxicity of therapeutical 
treatments is assessed in the project on the effects of ozone therapy on blood (Chapter 7) 
Furthermore it is showed the necessary to continuously improve the step of the 
standardization: part of the work was done for the definition of standard operative procedures 
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for sample handing/storage (Chapter 8). But a lot of a work aimed to asses all the possible 
causes of variability have to be done. This because metabolomics is a relatively new 
technique and because the analytical technique itself is still undergoing optimization. This is 
particularly true and necessary when we start to analyze new fluids, such as exhaled breath 
condensate, saliva or tissue extract for instance.  
The same considerations apply also to statistical and NMR methods. The development of new 
simple 1D NMR pulse sequences, namely the 1D diffusion filtered recently implemented, can 
be very useful to single out some information: it allows us to obtain information only about 
macromolecules present in serum, and in general in a biofluid. Moreover the development of 
new statistical analysis could further increase the obtainable data. 
Finally the role of metabolic in systems biology is confirmed (Figure 1). Systems biology is 
one of the strongest driving forces in modern biomedical research with increasing emphasis 
on the integration of various “omics” science to understand integrated system activity2. 
Metabonomics dovetails beautifully with the spirit of systems biology, because it provides a 
‘top-down’, integrated view of biochemistry in complex organisms, as opposed to the 
traditional ‘bottom-up’ approach that investigates the network of interactions between genes, 
proteins and metabolites in individual cell types1. Given the clear results obtained using 
metabolomics for the three large impact pathologies described in this thesis and, more in 
general, for other several pathologies that afflict human being, as shown by literature and 
extensively discussed in the INTRODUCTION, I would like to think about a future, hopefully 
closer as possible, in which metabolomics it will be the omic science that really will carry 
system biology to the bed of the patient. 
 
Figure 1 Metabolomics in system biology (adapted from Nicholson J.K. & Holmes E., 20063)  
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Individual contribution 
 
Project Chapter Publication Role 
Metabolic 
phenotypes 3 1 
Collection of NMR spectra, 
processing and biological 
interpretation 
Breast cancer 
and 
metabolomics 
4 2 
Collection of NMR spectra, 
processing and biological 
interpretation 
Celiac disease 
and 
metabolomics 
5 3 Collection of NMR spectra and processing  
Cardiovascular 
risk and 
metabolomics 
6 4 
Collection of NMR spectra, 
processing, part of the statistical 
analysis and biological 
interpretation 
Ozone therapy 
and 
metabolomics 
7 5 
Collection of NMR spectra, 
processing, part of the statistical 
analysis and biological 
interpretation 
SOPs definition 
by metabolomics 8 6 
Collection of NMR spectra, 
processing, part of the statistical 
analysis and biological 
interpretation 
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Differences between individual phenotypes are due both to differences in genotype and to exposure
to different environmental factors. A fundamental contribution to the definition of the individual
phenotype for clinical and therapeutic applications would come from a deeper understanding of the
metabolic phenotype. The existence of unique individual metabolic phenotypes has been hypothesized,
but the experimental evidence has been only recently collected. Analysis of individual phenotypes over
the timescale of years shows that the metabolic phenotypes are largely invariant. The present work
also supports the idea that the individual metabolic phenotype can also be considered a metagenomic
entity that is strongly affected by both gut microbiome and host metabolic phenotype, the latter defined
by both genetic and environmental contributions.
Keywords: Metabolomics • NMR spectroscopy • individual metabolic fingerprint • human metabolites
• gut microflora metabolites • principal component analysis
Introduction
Individual phenotypes differ because individuals are geneti-
cally different, but also because of environmental factors. It is
the phenotype, rather than the genotype alone, that matters
when dealing with the development of pathologies or with the
individual responses to drug treatments or external stimuli.
An important contribution to the definition of an individual
phenotype for medical purposes would come from the knowl-
edge of themetabolic phenotype. The metabolic phenotype (or
metabotype1) is defined as a “multiparametric description of
an organism in a given physiological state based on metabo-
lomic data”. Life, indeed, is maintained by numerous bio-
chemical cycles, molecular and cellular mechanisms, whose
maintenance in steady states defines homeostasis. Individual
metabolic phenotypes can be regarded as images of these
steady states: deviations from the optimal conditions can be
directly linked to a pathophysiological status.
The existence of individual metabolic phenotypes has been
repeatedly postulated,2-4 but experimental hints to its existence
have been only recently obtained.5,6 The elusiveness of meta-
bolic phenotypes stems from the fact that the individual
metabolic profiles, such as those obtained from NMR spectra
of urine samples, can vary daily, and the variation is sufficiently
large as to make profiles from different individuals heavily
overlap. The source of variation can arise from random factors
(e.g., diet) or from cyclical biochemical variations: for example,
observation of cyclical variations of potassium content in
human urine dates back to the 19th century. More recently,
with the development of chronobiology, the periodicity of many
biochemical cycles such as those linked to hormonal secretion
and their circadian periodicity7-10 has been assessed. Never-
theless, recently, the collection of multiple urine samples from
each individual over a period of a few weeks provided clear
evidence that beyond these numerous sources of variations
there is a “stable” part of the profile, which was then found to
be strongly individual-specific.5 It was concluded that the stable
part of the profile was maintained at least for the few weeks of
the collection period, but a more extended analysis to unravel
and characterize the intrinsic metabolic phenotype complexity
was not attempted. For an individual metabolic phenotype to
be of physiological relevance and medical usefulness, one should
now be able to show that it is relatively stable over time for a
period of at least a few years and, above all, what are the most
relevant causes of its variability, if any, and their relative weight
with respect to a possible invariant contribution of genetic
origin.
The present research addresses the above issues by a
thorough statistical analysis of sets of about 40 urine samples
from each of 31 different individuals, out of which 11 provided
two 40-samples sets separated by 2 years, and 4 of them
provided again 40-samples sets for a third time 1 year later,
for a total of 1849 samples. It is found that the individual
metabolic phenotype is largely stable over the examined period
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of 2-3 years, that no age-related drift is apparent, that modest
changes of the phenotype may occur on a variety of timescales,
and that they are mainly due to changes in lifestyle and gut
microflora. Analysis of individual phenotypes over the timescale
of years demonstrates that metabolic phenotypes are the results
of complex interaction between environmental factors and
genetics. The effects of the environment are observable in the
periodical and/or sporadic metabolic fluctuations, while a
combination of genetic and environmental contributions is
present in the stable, invariant part of the metabolic phenotype
that allows to recognize spectra as belonging to a unique
subject even over a period of some years.
Materials and Methods
Sample and Metadata Collection. About 40 urine samples
(first in the morning, preprandial) were collected from 20
healthy individuals (9 males, 11 females) in the age range 25-55
over a period of about 3 months, in late-spring-early-summer
2007. Eleven of them (6 males and 5 females) had taken part
in a previous study involving 22 subjects,5 with sample collec-
tion in late-spring-early-summer 2005, and 4 of them (males)
were again recruited for another sample collection in late-
spring-early-summer 2008. The collection scheme is sum-
marized in Figure 1.
In total, 944 samples were analyzed. Samples were collected
from each individual in sterile 15-mL propylene tubes, frozen
within 4 h of collection, and stored at -80 °C. All subjects were
Caucasian. Personal data were collected from every subject,
including gender, age, BMI, and general habits such as prac-
ticed physical activity and normal diet. A detailed diet sheet
relative to the day before each collection was also provide by
each donor. Some subjects presented peculiarities: one quit
smoking during the time between the first and the second
collection, another one moved from Italy (2005 collection) to
Spain (2007 collection). Moreover, two subjects are homozy-
gous twins and two other subjects are father and son.
Sample Preparation. Frozen samples were thawed at room
temperature and shaken before use. Aliquots of each urine
sample (630 µL) were added to 70 µL of sodium phosphate
buffer (0.2 M Na2HPO4 and 0.2 M NaH2PO4 in 100% 2H2O, pH
7.0) to minimize variations in metabolite NMR chemical shifts
arising from differences in urinary pH, also containing 10 mM
sodium trimethylsilyl [2,2,3,3-2H4]propionate (TSP) and 30 mM
sodium azide. Samples were centrifuged at 14 000g for 5 min
to remove any solid debris; 450 µL of the supernatant was
placed in 4.25-mm-outer-diameter NMR tube (for Bruker
MATCH holder). All chemicals were from Sigma Aldrich.
NMR Experiments. The urine samples were analyzed by 600
MHz 1D 1H NMR spectroscopy. The 1D 1H NMR spectrum of
each sample was acquired with water peak suppression using
a standard pulse sequence (noesypresat; Bruker). For 12
selected samples taken from the four donors that participated
in all three collections (one sample for each subject from each
collection), a set of 2D spectra was acquired to improve
metabolites identification using a 900 MHz spectrometer
(Bruker BioSpin). The set of 2D spectra is constituted by the
following experiments: JRES, COSY, 1H-13C-HMBC (see Figure
2), 1H-13C-HSQC, TOCSY. All experiments were performed
using Bruker library sequences. Further details are reported in
Supporting Information.
Data Reduction and Preprocessing of the 1H NMR
Spectra. The generation of input variables for statistical analysis
was done by bucketing. For this, 1H NMR spectra were
normalized to the NMR signal intensity of the CH3-group of
creatinine which was calculated via nonlinear fitting and
localized spectral deconvolution in order to take off contribu-
tions from the neighboring creatine signal (further information
given in the Supporting Information). After scaling spectra,
bucketing was applied to the data where the spectral regions
δ > 9.5, δ 6.0-4.5, and δ < 0.5 were discarded before dividing
the remainder of each spectrum into sequential segments
(“bins”) of 0.02 ppm width and obtaining an integral for each
segment. Finally, prior to predictive multivariate statistics,
buckets were log-transformed.
Statistical Analysis: descriptive level. Statistical data analysis
was performed in MATLAB (The MathWorks, Natick, MA) using
standard procedures provided in MATLAB itself and in the
MATLAB STATISTICS TOOLBOX and using in-house written
routines.
Principal Component Analysis (PCA) was used as dimension
reduction technique and as a preparation of the data table for
further multivariate statistical analyses. Data reduction was
carried out by means of projection into a PCA subspace
explaining 99.9% of the variance in the data.
Multivariate statistical analysis was performed using the
MANOVA implementation of the Statistical Toolbox in
MATLAB. The dimensionality of the relevant subspace was
defined by the dimensionality of the group means provided
by the MANOVA output (see comments on MANOVA in the
Supporting Information). Linear combinations (canonical
variables) of the original variables that reflect the largest
possible separation between groups were obtained through
Canonical Analysis (CA).
Hierarchical Cluster Analysis (HCA) was performed using the
HCA implementation of the Statistical Toolbox in MATLAB.
Euclidean distance was considered.
Pairwise Comparison of Data Sets. For each possible pair
of the 46 different data sets, a Kruskal-Wallis test was applied
to assess the mean differences in metabolites concentrations.
A conservative estimate of significative levels of 1.288 × 10-8
was derived by using the Bonferroni correction on a nominal
value of 0.005. Kruskal-Wallis test (nonparametric ANOVA test
analogue) was chosen to infer differences on the biological
asymptotic assumption that metabolite concentrations are not
normally distributed. All resonances of interest were then
manually checked and signals were assigned on template one-
Figure 1. Collection scheme: 22 healthy individuals were involved
in the previous study, with sample collection in late-spring-early-
summer 2005. Eleven of them (plus nine new individuals) were
recruited in late-spring-early-summer 2007 and 4 of them were
again recruited for another sample collection in late-spring-early-
summer 2008.
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dimensional NMR profiles by using matching routines of AMIX
(Bruker BioSpin GmbH Rheinstetten, Germany) in combination
with the BBIOREFCODE (Version 2-0-0; Bruker BioSpin) refer-
ence database and published literature when available.
The most representative spectrum for each individual was
chosen with the criterion of minimizing the total sum of square
deviations from the average spectrum. The corresponding
samples were used for analysis at 900 MHz NMR.
Statistical Analysis: Predictive Level. The key of the valida-
tion of the NMR predictivity on person identity relies on the
Test Set Validation (TSV) approach which requires that models
do not have any knowledge on the existence of any test set
data. Two principal validation situations needed to be ad-
dressed, that is, within-collection validation (e.g., model set and
test set both from METREF1) and cross-collection validation
(e.g., model set from METREF1, test set from METREF2).
Within-collection validation was performed via Monte Carlo
embedded leave-25%-out cross-validation MC/CV. Key of
cross-collection validation was straightforward test set valida-
tion performed multiple times always using new model sets
obtained fromMonte Carlo based selection of 75% subsets from
the complete model data (e.g., 75% of METREF1 to classify
METREF2 spectra). In each validation, 1000 Monte Carlo
iterations were applied.
In each test set validation step, model set data were mean
centered and unit variance scaled first. PCA was applied to the
model set and scores of the subspace explaining 99.9% of the
variance were further subjected to CA in order to define a
further reduced subspace with optimum group separation;
dimensionality was chosen according to the MANOVA output
of the dimensionality of the respective group means. Then, test
set data were mean centered and unit variance scaled using
model set mean and model set variance values. Then, they
were projected into the PCA/CA subspace defined by the model
set. Finally, k-NN classification was applied to each test set
object, evaluating the distance to the nearest model set objects.
“Majority” rule was applied to classify training-set donors via
a preselected number (7) of test set samples per test set donor.
From this, (cross-) collection and donor specific probabilities
of correct and false classification (confusion matrix) were
calculated. Detailed information on the overall procedure is
given in the Supporting Information.
Results and Discussion
Metabolic Space. A dendrogram representing the intersam-
pling distances in the discriminant space of the PCA/CA
components is shown in Figure 3b, with the clusterization of
the 20 individuals of the 2007 collection. Figure 3a shows for
comparison the analogous representation for the 22 individuals
of the 2005 collection.5 It is apparent that on the descriptive
level the separation of individuals is of the same quality in the
two cases. Figure 3c shows the same representation where all
31 different individuals are reported. Clearly, no worsening of
the separation is observed.
On the predictive level, the average recognition rate of
randomly chosen spectra in the 2007 collection using the single
vote classification was 99.5%, practically identical to the 99.7%
in the 2005 collection, while the MRC classification gave 100%
in both cases. Table 1 reports the individual single vote scores
for the two collections, where it is apparent that most individu-
als in both collections had scores higher than 99% and several
individuals scored 100% recognition even with single vote
classification. Again, pooling together the 31 different individu-
als did not spoil these exceptionally high percentages (99.6%
average recognition rate). These results suggest that the number
Figure 2. Example of a 2D HMBC spectrum acquired at 900 MHz. The zoomed zone represents the aromatic region. It possible to
distinguish some aromatics peaks of Hippurate (1), PAG (2), Histidine (3) and mHPPA (4).
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of significantly different metabotypes in humans is much
higher than a few tens, and yet to be determined. The larger
the number of human metabotypes, the more meaningful will
be their perspective use in biology and medicine.
Two- and 3-year Recognition. The spectra of the same
individuals in different collections (11 in the first and second
collection, 4 in the third) were then used as training and test
sets, respectively, and subjected to single vote classifications
as described above. The results are reported in Table 2. On
average, the percentage of recognition was slightly lowered (but
still higher than 97%) for the 11 individuals after 2 years with
respect to their scores within each collection, and for the four
individuals after 3 years, the lowest values being higher than
92.5%. The fact that all individuals could be almost equally well
reassigned to their own metabolic phenotype after 2 to 3 years
as they were within each collection period of 3 months
demonstrates that the metabolic phenotype is largely constant
over a time frame of a few years. This is a very relevant finding
in view of the physiological meaning and perspective medical
usefulness of metabolic phenotypes information.
Figure 4 shows the color-coded matrix of the distances in
the metabolic space among all the individuals involved in at
least two collections. The shortest off-diagonal distances are
always between samples of the same individuals in different
collections. In particular, individual AS shows the shortest
distance between collections; that is, it is the most constant
subject. This correlates with the slightly lower recognition
percentage reported for AS in Table 1d, due to the fact that
samples of AS belonging to different collections are occasionally
confused with one another.
To better illustrate the implications of these findings, the
statistical analysis described above was repeated on the
descriptive level by considering each set of about 40 spectra
as originating from a different individual (a pseudoindividual)
even if 15 (11 + 4) of these sets were actually repetitions of
collections from the same individuals. A total of 46 pseudoin-
dividuals were thus defined, and subjected to PCA/CA. The
results are illustrated in Figure 3d. It is striking to note that
pseudoindividuals corresponding to the same individual always
cluster together. It should be noted that by this procedure the
distance in metabolic space of each individual from itself is
even exaggerated, as the present PCA/CA method is built to
maximize the distances within any ensemble of predefined
groups. Therefore, the similarity of the data sets for the same
individual emerges whatever attempt is made to differentiate
them, and so confirming the high stability of the metabotypes
over a period of years.
Metabolic Jumps and Periodicities. The clear-cut demon-
stration of the strong persistence of metabolic phenotypes,
together with the availability of the present large collection of
data sets, hints to the possibility that the sporadic and modest
fluctuations of these phenotypes over time frames ranging from
days to years can be analyzed in more detail and possibly
qualitatively understood. By visual inspection of spectral data
sets for each individual, either represented by single, double
or triple collection, it is possible to identify various types of
changes that, for simplicity, can be described as “spikes”,
“waves” and “jumps”. Spikes are signals that are observed in
single spectra having markedly different intensity from the
preceding and following days: they are most often caused by
sporadic assumption of particular food components (like
mannitol, contained, for example, in chewing-gum, or TMAO,11
contained in fish) or unusually high alcohol intake (ethanol
signal) or meat (carnosine12,13 and xanthosine14). Other spikes
are due to extraordinary physical activity (lactate). Interestingly,
Figure 3. Dendrograms relative to cluster analysis. (a) On the 21-
dimensional PCA/CA subspace for the 22 individuals of MetRef1
(2005 collection). (b) On the 19-dimensional PCA/CA subspace
for the 20 individuals of MetRef2 (2007 collection). (c) On the 30-
dimensional PCA/CA subspace for the 31 different individuals of
both MetRef1 and MetRef2. (d) On the 45-dimensional PCA/CA
subspace for the 46 different pseudoindividuals of MetRef1,
MetRef2 and MetRef3; taking the two/three times donor as
different pseudoindividuals. For every figure, clustering accord-
ing to donor is obvious.
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“anti” spikes have been also observed, that is, the sporadic
disappearance of the signal of a metabolite usually present, as
in the case of citrate (individual BF), possibly due to metal
complexation.
Waves are signals whose variation in intensity is more
gradual and persists for a number of days. Waves are mainly
found in the aromatic region of the spectra, a region whose
overall profile has been demonstrated to be strongly dependent
on the activity of the gut microflora. In several individuals,
waves can be observed in the concentration of hippurate
(benzoyl glycine) andm-hydroxyphenylpropionic acid, the two
major gut microbial mammalian co-metabolites,15,16 together
with phenylacetylglycine and formate.17-19 These variations are
likely due to drifts of the endogenous gut microflora population,
whose constancy apparently contributes to establish a stable
urinary profile. N-Methylnicotinamide, a metabolite involved
in energy metabolism, also showed a wave (individual BF).
Finally, jumps are sudden and marked changes in signal
intensities that, once occurred, persist for the entire collection
period and, in some cases, are even carried over to the next
collection. Jumps have been observed in the hippurate aromatic
signals, thus, indicating a net and sudden (re)modulation in
the activity and/or composition of the gut microflora (indi-
vidual AU). A jump for individual AS is observed in a signal
around 8.79 ppm, again in the aromatic region of the urine
spectra, dominated by gut microflora-related metabolites.
Other jumps have been observed for individual AW at 4.40 ppm
(identified as xanthosine, and in line with a higher meat
consumption,14 as declared in the dietary sheet) and for
individual AR in the region around 5.52 ppm (possibly due to
Table 1. The Individual Single Vote Scores for (a) the First Collection, (b) the Second Collection, (c) the 31 Different Donors, and
(d) All 46 Pseudodonors
(a) 2005 (b) 2007 (c) 31-donors (d) 46-pseudodonors
AD 99.905% AI 100.000% AD 99.895% AD 99.990%
AF 100.000% AO 100.000% AF 100.000% AF 100.000%
AG 100.000% AR 99.995% AG 99.997% AG 100.000%
AH 99.922% AS 99.941% AH 99.919% AH 99.989%
AI 99.760% AU 100.000% AI 100.000% AI 99.775%
AO 97.500% AW 99.998% AO 100.000% AO 97.500%
AP 97.500% BC 99.705% AP 97.500% AP 97.500%
AR 100.000% BF 99.629% AR 100.000% AR 100.000%
AS 100.000% BG 100.000% AS 99.992% AS 99.792%
AT 99.995% BH 100.000% AT 100.000% AT 100.000%
AU 100.000% BI 98.462% AU 100.000% AU 99.379%
AW 100.000% BQ 99.998% AW 100.000% AW 100.000%
AX 100.000% BS 100.000% AX 100.000% AX 100.000%
AZ 100.000% BT 99.983% AZ 100.000% AZ 100.000%
BC 99.998% BU 96.647% BC 99.965% BC 98.630%
BD 100.000% BV 99.998% BD 100.000% BD 100.000%
BE 100.000% BX 99.998% BE 100.000% BE 100.000%
BF 100.000% BZ 100.000% BF 99.497% BF 100.000%
BG 99.933% TA 98.450% BG 100.000% BG 98.838%
BH 100.000% TB 98.235% BH 100.000% BH 98.845%
BI 100.000% MEAN ) 99.552% BI 97.846% BI 99.323%
BK 99.470% BK 99.193% BK 99.855%
MEAN ) 99.726% BQ 100.000% AI 99.845%
BS 100.000% AO 99.716%
BT 100.000% AR 97.649%
BU 95.750% AS 86.669%
BV 100.000% AU 99.998%
BX 100.000% AW 99.848%
BZ 100.000% BC 99.988%
TA 97.668% BF 97.411%
TB 99.688% BG 94.456%
MEAN ) 99.578% BH 99.378%
BI 99.049%
BQ 100.000%
BS 100.000%
BT 100.000%
BU 94.982%
BV 100.000%
BX 100.000%
BZ 100.000%
TA 97.648%
TB 99.900%
AR 99.233%
AS 70.103%
AU 99.525%
AW 91.617%
MEAN ) 98.183%
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a drug or to some unidentified food additive, although no
particular notes are present in the dietary sheet).
A typical jump is shown in Figure 5a for individual AU, where
the spectra of the 2005 collection and the first 23 NMR spectra
of the 2007 collection are clearly distinct from the first two-
thirds of the 2008 collection, while a wave is shown in Figure
5b and a spike in Figure 5c.
Interestingly, suboptimal recognition rates within the same
collection period cannot generally be ascribed to spikes, waves
or metabolic jumps.
Jumps and waves are hardly related to significant changes
in lifestyle (which would have appeared in the metadata
provided by each donor). Excluding assumption of medicines,
which was also accurately monitored, it is likely that these
jumps are due, directly or indirectly, to changes in the gut
microflora, which may occur even in the absence of major
changes in diet. It is also interesting to note that jumps can be
reversible, as it has been noticed in the case of individual AU
during the 2008 collection (Figure 5a).
Despite and beyond all these sources of intraindividuals
variations (i.e., sporadic food component intake, persistent or
temporary changes in life-style, remodulation of gut microflora
populations) interindividual discrimination is still possible and
very strong. What defines the individual metabolic phenotype
is an invariant part that is very likely to descend both from
systematic life and dietary habits and from genetics.
The presence of a non-negligible genomic component is
hinted by the results of the study of subjects with common
genetic traits to different extents, like father and son and
homozygous twins. The study subjects TA and TB are female
homozygous twins, and the examination of Figure 3b or 3c
shows that on the descriptive level TA and TB are actually very
close to one another, although still distinct. In the respective
PCA/CA subspaces, all interindividual distances in Figure 3 are
much larger than the intraindividual distances, but strikingly,
Figure 3b shows that TA and TB are by far the two individuals
with the shortest interindividual distance in metabolic space,
followed by father and son BU and BV.
The average recognition percentage for the twins sisters
shown in Table 1 (98.3%) is on the low side, and also deserves
a comment. In contrast to most other individuals, that when
wrongly assigned are assigned to a variety of different other
Table 2. Single Vote Classification Different Collections As
Training and Test Setsa
MetRef1 f MetRef2 MetRef1 f MetRef3 MetRef2 f MetRef3
AI 99.971% AR 99.522% AR 100.000%
AO 100.000% AS 94.439% AS 99.915%
AR 97.242% AU 99.944% AU 97.377%
AS 98.754% AW 98.746% AW 92.699%
AU 100.000% MEAN ) 98.163% MEAN ) 97.498%
AW 99.712%
BC 99.434%
BF 97.132%
BG 98.645%
BH 100.000%
BI 98.723%
MEAN ) 99.056%
a These results show how all individuals could be almost equally well
reassigned to their own metabolic phenotype after 2 to 3 years.
Figure 4. Distances in metabolic space for all the individuals that
participated in at least two collections. The pseudoindividuals
corresponding to the same individual show lower distances with
respect to the others (blue squares).
Figure 5. (a) Metabolic “jump” (between 7.90 and 7.55 ppm) for
individual AU. (b) Metabolic “wave” (between 9.00 and 8.90 ppm)
for individual AS. (c) Metabolic “spike” (at 3.94 ppm) for
individual AU.
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individuals, TA and TB, when wrongly assigned, are mostly
assigned to one another (Supplementary Figure S8). In other
words, TA and TB are the only case of some confusion between
two individual metabolic phenotypes. Undoubtedly, this confu-
sion is of genetic origin, confirming that the genotype has a
non-negligible influence on the metabotype. While it is not
possible to quantify the extent of such influence from a single
observation of this type, it is instructive to compare the
distances in the PCA/CA space among all 46 pseudoindividuals
by inspecting the complete dendrogram (Figure 3d). It appears
again that the distance between TA and TB is one of the
shortest, and even shorter than several of the distances between
pseudoindividuals corresponding to different collections of the
same individual. In other words, the present homozygous twins
are metabolically as alike as is an individual with him/herself
after 2 to 3 years. All in all, genetics contributes to the
interindividual separation but also contributes to the actual
(pseudo)individuals clustering, by forcing them to cluster
together when they are analyzed after 2 or 3 years. The
similarity of one individual with him/herself is maintained even
when a significant change in lifestyle, such as modification in
dietary habits, quality and kind of food intake due to moving
to a different country has occurred, as is the case for individual
BC.
It can be concluded that the uniqueness of the metabotype
of an individual rests on both environmental factors and the
genotype.
Relevant Metabolites. Individual data sets have been used
to assess which regions of the spectra are more variable within
and between different subjects. Each matrix data set was
collapsed into a vector whose components are the standard
deviation of each column, that is, the standard deviation of
each integrated bucket. This allowed us to highlight which
spectral regions are more intrinsically variable. From Figure 6,
it appears that the more variable regions within a single
individual are in the range 8.0-7.5 ppm and 4.0-2.5 ppm.
By means of a pairwise comparison among all the 46
different data sets, 52 metabolites have been found to have
different mean concentration values at statistically significant
level, and are reported in Supplementary Table 1. Although a
systematic analysis of patterns of significantly different me-
tabolites is beyond the scope of this work, it can be noted that
some of these metabolites are related to fundamental metabolic
pathways, like glycolysis (lactate, pyruvate, acetoacetate), ke-
tonic bodies catabolism (acetoacetate, 3-hydroxyisobutyrate),
urea cycle (citrulline, ornithine, arginine), and Krebs cycle
(citrate, alpha-ketoglutarate, trans-aconitate, succinate). Other
metabolites, such as essential amino acids (isoleucine, leucine,
valine, lysine, threonine), choline and caproate, are introduced
with the diet. Some other metabolites, like hippurate, meta-
[hydroxyphenyl]propionic acid (mHPPA),15,16 phenylacetylg-
lycine (PAG),17,18 formate,19 indoxyl-sulfate (IS)20-22 and val-
erate23 are strongly related to gut microflora.24
Conclusions
Evidence of the existence of individual metabolic phenotypes
had been obtained by means of the analysis of multiple samples
collection of urine from a panel of healthy volunteers.5 In
this study, we analyzed the stability of the individual pheno-
types with respect to different timescales. Time resulted to play
a pivotal role in defining to which extent the individual
metabolic phenotype can be considered as a dynamic entity
and why. Although the modulation effects of symbiotic gut
microbes have been reported in the definition of human
phenotypes,6 timescale analysis of individual phenotypes as
derived from NMR spectra of human urines indicates that
although the genotype plays a role in defining the individual
metabolic phenotype, the latter is modulated by both gut
microflora and by response to external stimuli. In this light,
individual metabolic phenotypes describe the fact that each
individual possesses an unique adaptive response to the
environment. The constancy of the phenotype within a time
span of years is an important result that was not obvious to
predict. It strengthens the idea that an individual is stably
associated to a part of its metabolome. This justifies, for
instance, that drugs (i) may have different effects on different
individuals and/or (ii) may be metabolized differently, allowing
one to predict the adverse effects of drugs through metabolo-
mic analysis of urine of patients.25
Our analysis on such a relatively long timescale by means
of multiple collections allowed to minimize the effects of the
day-to-day variability of the individual metabolic fingerprint,
providing a dynamical picture of the contributions of genetics
and/or gut microflora to these phenotypes, and not only mere
snapshots. We have been able to identify fluctuations in gut
microflora contributions, described as waves and jumps in
metabolites, like hippurate and m-HPPA, that are directly
related to the activities of symbiotic microorganisms. We have
also shown that this kind of modulation is relatively minor with
respect to the stable core of the individual metabolic pheno-
type. By means of hierarchical cluster analysis, we showed that
genetically related individuals, like father and son and twins,
are closer in the component space than unrelated individuals,
and in the case of the twins, they are as close as is the same
individual to him/herself between different collections. Confu-
sion between metabolic phenotypes of the two twin sisters is
certainly to be ascribed to genetic influence, but may be also
due to the fact that, for genetic reasons, identical twins could
show amuch higher similarity in gut microbiota structures than
genetically unrelated individuals. The present work also strongly
supports the idea that the individual metabolic phenotype can
also be considered a metagenomic entity that links gut micro-
biome and host metabolic phenotype;26,27 that is, the composi-
tion of the gut microflora is compatible with the genome of
the host.
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SUMMARY 
Background: Prognostic tools in early breast cancer are inadequate. The evolving field of 
metabolomics may allow more accurate identification of patients with residual 
micrometastases. 
Patients and Methods: Forty-four early breast cancer patients with pre- and post-operative 
serum samples had metabolomic assessment by Nuclear Magnetic Resonance. Fifty-one 
metastatic patients served as control. Differential clustering was identified and used to 
calculate individual early patient ‘metabolomic risk’, calculated as inverse distance of each 
early patient from the metastatic cluster baricenter. Metabolomic risk was compared with 
Adjuvant!online 10-year mortality assessment.  
Results: Innate serum metabolomic differences exist between early and advanced 
patients. Pre-operative patients were identified, with 75% sensitivity, 69% specificity and 
72% predictive accuracy. Comparison with Adjuvant!online revealed discordance. Of 21 
patients assessed as high risk by Adjuvant!online, 10(48%) and 6(29%) were high risk by 
metabolomics in pre- and post-operative settings, respectively. Of 23 low risk patients by 
Adjuvant!online, 11(48%) pre- and 20(87%) post-operative patients were low risk by 
metabolomics. 
Conclusion: This study identifies metabolomic discrimination between early and advanced 
breast cancer. Micrometastatic disease may account for metabolomic misclassification of 
some early patients as metastatic. Metabolomics identifies more patients as low relapse 
risk compared with Adjuvant!online. Further exploration of this metabolomic fingerprint is 
warranted. 
 
KEYWORDS 
Breast Cancer; Metabolomics; Micrometastasis; Prognosis  
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INTRODUCTION: 
In early breast cancer, a critical issue is identification of individuals likely to benefit 
from adjuvant intervention. Better prediction of clinical outcomes is required to optimize 
and individualize our therapeutic approach. Current approaches, using traditional 
clinicopathological features or gene profiling, assess the primary tumor and estimate risk 
of recurrence based on the presumption of micrometastatic disease. These tools have 
limitations. Consequently, an individual’s risk may be over or underestimated.  
The pivotal Milan adjuvant chemotherapy trial compared classical 
cyclophosphamide, methotrexate and fluorouracil (CMF) with surgery alone in node- 
positive patients. Thirty-year follow up confirms a sustained benefit from chemotherapy, 
but also showed long term, relapse-free survival (RFS) in a significant number of high risk 
patients treated with surgery alone, RFS 29% vs 22% respectively (1). Similarly, 20-year 
follow up of intravenous CMF compared with surgery alone in node-negative, estrogen 
receptor (ER) negative disease reveals long term RFS in approximately 40% patients 
treated with surgery alone (1). The 21-gene OncotypeDx assay was assessed in 355 
placebo-treated patients from the NSABP-B14 trial in node-negative, ER positive disease. 
Ten-year distant-recurrence free survival for these patients treated with surgery alone, was 
86%, 62% and 69% for low, intermediate and high recurrence scores respectively (2). The 
70-gene Mammaprint applied to 151 lymph node-negative patients, only 10 of whom 
received any adjuvant therapy, showed differential 10-year distant metastases free 
survival between good and poor prognosis signatures, at 87% and 44% respectively (3). A 
striking feature of these studies is that some individuals, despite apparent high risk 
disease, clearly have excellent long term outcome. This reflects heterogeneity of disease, 
host and risk, and highlights overestimation of risk by current prognostic tools. 
An alternative to presuming residual disease is actual measurement of 
micrometastases. Studies of micrometastatic disease are intriguing, particularly isolated 
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tumor cells (ITC) in the bone marrow and circulating tumor cells (CTC) (4-11). Of particular 
interest is that not all patients with ITC or CTC develop clinically detectable metastatic 
disease. Possible hypotheses include lack of autonomous proliferation, unfavorable 
stromal environment and clearance of tumor by host immune mechanisms. Thus tumor 
survival depends on both favorable tumor and host characteristics. Indeed, assessment of 
this dynamic, multifactorial interaction is a strength of the evolving field of metabolomics. 
Metabolomics is a science that provides a dynamic portrait of metabolic status, 
assessing end products of gene expression and environmental influences. Metabolomics 
may be defined as ‘the quantitative analysis of all the metabolites of an organism or 
specified biological sample’(12). A review of this evolving field was previously presented 
by our group (13) 
Transformed human cells exhibit profound metabolic shifts, particularly reflecting  
induction of cell membrane phospholipids biosynthesis and breakdown, and preferential 
use of glucose through non oxidative pathways (14-20). Metabolomic analyses of patient 
serum and urine samples have been shown to delineate between healthy, benign and 
malignant conditions (21-25). Specifically with breast cancer there is cell line evidence of 
metabolomic distinction between normal and malignant, and even more specifically 
identification of malignant breast cell lines with greater metastatic potential. (26-30). With 
breast tissue, metabolomic analyses distinguish normal tissue, benign disease, carcinoma 
in situ and invasive carcinoma (31-34). The subsequent challenge is to capture the 
malignant metabolomic signal amongst the complex serum metabolomic fingerprint for an 
individual (35).  
A metabolomic fingerprint (36) may be determined from a variety of biological 
samples. Nuclear Magnetic Resonance (NMR)-based metabolomics in its most popular 
version consists of recording and analyzing one dimensional (1D) proton NMR profiles of 
serum and urine (37). Key elements, specifically hydrogen nuclei (1H), are influenced by 
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an external magnetic field. This magnetic influence is measurable and recorded as an 1H-
NMR spectrum. 1H-NMR spectra of biological fluids are extremely complex, essentially the 
superposition of the 1H-NMR spectra of a vast number of single metabolites, plus a 
number of food components and occasionally drug or drug-derived molecules, present in a 
sample at  > 1 µM concentration (38). Huge volumes of qualitative and quantitative data 
are obtained by primary analysis and chemometric methods then transform this to 
manageable and comparable data. 
At variance with knowledge-guided search of metabolites in pathological samples, 
NMR-based metabolomics makes no assumptions about the identity of the metabolites 
that are relevant for the selected pathology. Information on the metabolite pattern 
alterations that can be significantly associated to the pathology is directly obtained through 
statistical analysis of the NMR profiles (39). 
A metabolomic fingerprint may exist for micrometastatic disease. More specifically a 
fingerprint may exist which identifies the interaction between host and any residual 
disease. We have performed and compared metabolomic analyses in breast cancer 
patients with early and metastatic disease. Prognostic ability of the fingerprint has been 
explored by comparison with 10-year mortality rates determined by the current prognostic 
tool Adjuvant!online. The pilot model, developed in 44 early breast cancer patients, was 
then validated in a second cohort of 45 early breast cancer patients. 
 
PATIENTS and METHODS 
Patient selection 
 This series was recruited at our institution, The Department of Oncology, Hospital of 
Prato, Italy, between March 2006 and November 2008. Approval was granted by the 
Hospital of Prato Human Investigations Ethics Committee. All patients provided written, 
informed consent. All patients were older than 18 years old with histological confirmation of 
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breast cancer. Eligible early breast cancer patients had an Eastern Cooperative Oncology 
Group (ECOG) performance status between 0 and 2, no detectable macro-metastatic 
disease and no prior anti-cancer treatment. Eligible metastatic patients could have 
received chemotherapy and/or endocrine therapy prior to study entry. 
 Samples were collected from 3 patient categories: (1) 44 patients with early disease 
with pre-operative and post-operative samples; (2) 51 patients with metastatic disease, as 
the control group; (3) 45 patients with early disease provided only a post-operative sample, 
as the validation series. 
Sample collection and analysis 
All patients recorded their dietary intake and use of any medication on the day before 
sample collection. Ten mL of venous blood were collected after an overnight fast in serum-
separator tubes with gel. The tubes were centrifuged for 10 minutes at 1500xg at room 
temperature.  The serum was collected and transferred in 1 ml aliquots to pre-labelled 2ml 
cryovials (Nalgene, Rochester, USA). Three aliquots per patient were immediately frozen 
at -80°C until used. For the early patients, mean time elapsing between pre-operative 
serum collection and surgery was 16 days (range: 2 – 41 days) whilst for post-operative 
patients, the mean time between surgery and post-operative serum collection was 33 days 
(range 16 – 55). No patients received adjuvant systemic therapy prior to blood collection. 
For the metasatic patients, 22 had received prior chemotherapy for advanced disease. 
Mean time elapsing between last chemotherapy administration and sample collection was 
93 days (range: 5 - 484 days). 
Frozen serum samples were thawed at room temperature and shaken before use.  A 
phosphate buffer (70 mM, pH 7.4) was added in ratio 1:1 before analysis. One-
dimensional 1H-NMR spectra of serum samples were measured on a spectrometer 
operating at 600 MHz proton Larmor frequency using standardized protocols (NOESY1D 
and CPMG sequences).  
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Data reduction was obtained by means of Orthogonal Projection to Latent Structure 
(OPLS) (40). For the purpose of classification we used the Support Vector Machines 
(SVM) method (41)  applied on the OPLS  scores. To assess the prediction ability of the 
model, a double cross-validation scheme was adopted (42). Accuracy, sensitivity and 
specificity were estimated using standard definitions (43). All calculations were made using 
R (44). Details of analytical and statistical methods applied are given in Supplemental 
Material. 
 ‘Metabolomic Risk’ 
OPLS provided differential clusterization of early and metastatic patients. Two 
dimensional cluster plots gave a simple, visual representation of what is a complex 
multidimensional comparison. Each patient spectrum became one dot on the cluster plot. 
The position of each patient was determined by multispatial analysis of metabolites. 
Initially both NOESY1D and CPMG revealed similar results and subsequently only CPMG 
plots were used. 
We hypothesized that early patients with micrometastatic disease would be closer to 
the metastatic patients in their clustering position; conversely patients with fingerprints 
most distant from the metastatic patients would not have micrometastatic disease. 
‘Metabolomic risk’ for each early breast cancer patient was measured as their inverse 
Euclidean distance from the baricenter of the metastatic population. The distance for each 
patient was inversely proportional to their risk of micrometastatic disease. Thus, a patient 
with a short distance from the metastatic baricenter has a high metabolomic risk; a patient 
at a long distance has a low metabolomic risk.  
Metabolomic risk showed concordance with accuracy of disease stage prediction, i.e. 
early patients with low metabolomic risk were correctly classified as having early disease, 
whilst early patients with high metabolomic risk were misclassified as metastatic. This 
validated  subsequent use of metabolomic risk as a surrogate for relapse.  
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Comparison with Adjuvant!online 
Comparison of metabolomic risk with Adjuvant!online (Standard Version 8.0) was 
undertaken (45). Adjuvant!online is a web-based program that provides prognostic and 
predictive data based upon a patient’s clinicopathologic profile. It provides estimates of 10-
year risk of disease relapse and death (46). Although Adjuvant!online has limitations, 
particularly lack of the human epidermal growth factor receptor 2 (Her-2) and ki-67 status, 
poor characterization of small tumors and focus on ductal histopathology, it is a widely 
used, validated tool for risk assessment. To assess concordance, pre-operative 
metabolomic risk was plotted against 10-year risk of cancer mortality (in absence of 
adjuvant therapy) as calculated by Adjuvant!online.  
Using arbitrary thresholds of a 10% 10-year mortality by Adjuvant!online and the 
median metabolomic risk from the pre-operative samples, patients were categorized as 
high or low risk for each, with four possible resulting combinations: lowA/lowM (i.e. low risk 
by Adjuvant!online and metabolomics), lowA/highM, highA/lowM or highA/highM.  
Metabolomic risk shift 
 The best control for each post-operative specimen was its corresponding pre-
operative specimen. Using each patient as their own control had the distinct advantage of 
eliminating the confounder of inter-individual variation. This analysis was to explore the 
effect of surgical removal of the primary tumor on the metabolomic fingerprint. Each 
patient had their shift in metabolomic risk assessed, noting particularly whether their risk 
category, as described above, altered. 
Validation series 
 45 post operative patients had serum analysis by 1H-NMR and calculation of 
metabolomic risk, using the same metastatic control group as described. 10-year mortality 
by Adjuvant!online was compared with metabolomic risk, using the same Adjuvant!online 
and metabolomic thresholds as defined above, to validate the findings of the pilot group. 
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RESULTS 
Patient characteristics 
Patient characteristics are displayed in Table 1. Most patients were over 50 years of age, 
with ductal histology, ER-positive and Her-2 negative tumors. Review of dietary and 
medication history did not highlight any remarkable differences. 
Metabolomic fingerprints: Early patients vs. metastatic patients 
Metabolomic fingerprints of pre-operative patients and metastatic patients showed 
significant differential clustering, with near complete separation of the two groups. The 
clustering was provided by both the CPMG and NOESY1D spectra (Figure 1a). Using the 
2:8 ratio exclusion (detailed in supplementary material) double cross validation scheme, 
we were able to determine the percentage of times an individual sample was correctly 
classified as metastatic or pre-operative. Most individuals were reliably identified most of 
the time. Some patients however were consistently misclassified, that is, based on their 
metabolomic fingerprint, some early patients are consistently misclassified as metastatic, 
and vice versa. These analyses revealed a discrimination sensitivity of 75%, a specificity 
of 69% and a predictive accuracy of 72% using CPMG. Similar figures were obtained 
using NOESY1D, specifically sensitivity of 77%, a specificity of 68% and a predictive 
accuracy of 73%. 
Metabolomic risk was calculated for each pre-operative patient. This risk was 
plotted against disease stage prediction accuracy revealing reasonable concordance. That 
is, pre-operative patients with a high metabolomic risk were reliably misclassified as 
metastatic patients (Figure 1b).  
Correlation between metabolomic risk and 10-year breast cancer mortality estimates 
(in absence of systemic therapy) by Adjuvant!online 
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10-year mortality risk as calculated by Adjuvant!online and pre-operative 
retabolomic risk show poor concordance (Figure 2). Using the arbitrary thresholds 
previously described, patients were divided into 4 risk categories using Adjuvant!online 
10% mortality risk and the median pre-operative metabolomic risk of 49.86. Using these 4 
risk categories it is seen that in the pre-operative setting, of 21 patients assessed as high 
risk by Adjuvant!online, 10 are also high risk by metabolomics (48%). Of 23 patients 
assessed as low risk by Adjuvant!online, 11 are also low risk by metabolomics (48%). This 
pre-operative metabolomic fingerprint is taken in the presence of the primary tumor, with or 
without lymph node involvement and/or micrometastases. There was no pattern seen 
between likelihood of concordance with tumor size, grade, lymph node involvement, age, 
menopausal status, diet or medications (data not shown).  
Impact of tumor removal on the correlation between Metabolomics and 
Adjuvant!online in defining risk 
Within the 4 risk categories, the impact of primary tumor removal is presented in 
Figure 3. The main observation is that in 19 of 22 patients with high pre-operative 
metabolomic risk, surgical removal of the primary tumor reduced the metabolomic risk 
(86%). As shown, all 11 patients assessed as lowA/lowM pre-operatively remain lowA/lowM 
(100%), while 11 of 12 patients assessed as lowA/highM had a metabolomic risk reduction 
(92%). Similarly 8 of 10 patients assessed as highA/highM reveal a reduction in their 
metabolomic risk post surgery (80%). Four of 11 patients from the highA/lowM group 
curiously experienced a sizeable increase in metabolomic risk post surgery (92%). 
Post surgery, of 21 patients assessed as high risk by Adjuvant!online, only 6 (29%) 
are also assessed as high risk by metabolomics. Conversely of 23 patients assessed as 
low risk by Adjuvant!online, concordance markedly increased with 20 (87%) also low risk 
by metabolomics. Discordance persists for 15 cases with low metabolomic risk and high 
Adjuvant!online risk, and 3 cases with high metabolomic risk and low Adjuvant!online risk. 
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Validation of metabolomic risk in an independent cohort of early breast cancer 
patients 
 Comparison of metabolomic risk of 45 post-operative patients with 10-year mortality 
by Adjuvant!online confirmed the discrepancy seen in the pilot group.(See Figure 4). Of 14 
patients assessed as low risk by Adjuvant!online, 11 (79%) are also low risk by 
metabolomics. Of 31 patients assessed as high risk by Adjuvant!online, only 10 (32%) are 
also high risk by metabolomics.  
Metabolomic differences between early and metastatic patients 
Differential metabolites between metastatic and early patients were identified using 
a  Wilcoxon test with Bonferroni correction applied to a nominal P value of 0.05. Metastatic 
subjects were characterized by higher values of phenylalanine, glucose, proline, lysine and 
N-acetyl cysteine, and lower values of lipids, when compared to the spectra of both post-
operative and pre-operative patients.  
 
DISCUSSION 
The appeal of metabolomics is concurrent assessment of tumor and host. Indeed 
survival of a specific tumor in a specific host relies on a dynamic interaction, with evasion 
of normal host immunity and favorable stromal environment for metastatic deposits as key 
factors. A strength of metabolomics, as compared to current prognostic tools, may be 
confirmation rather than assumption of micrometastatic disease.  
Our results reveal differential metabolomic fingerprints for most early and metastatic 
breast cancer patients. Amongst the normal noise of the metabolomic fingerprint, most 
patients were distinguished based on metabolomic analysis of one serum sample.  
In our study, metabolomic analysis assigns more patients to low risk than are 
assigned by Adjuvant!online. Similarly, when compared with conventional clinical and 
pathological factors, prognostic gene expression signatures generally identify more 
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patients of low risk. The 21-gene OncotypeDx shows direct concordance of 36% in relapse 
risk stratification compared with an adjusted Adjuvant!online (47). The 70-gene 
Mammaprint, when compared with Adjuvant!online, had stronger predictive power and 
provided lower risk estimates for more patients (48). These low risk patients may be 
spared or receive less intensive adjuvant treatment.  
A small number of patients (N=4) with low metabolomic risk pre-operatively actually 
became high metabolomic risk post-operatively. One potential explanation for this 
observed increase, despite seeming counterintuitive, is that surgical removal of the 
primary tumor may increase risk of future disease. There is data suggesting this may occur 
(49-51). Analysis of post-operative serum and wound drainage fluid reveal growth factors 
that induce proliferation (51). Acute surgical stress induced immunosuppression and 
abundance of growth stimulating factors may trigger tumor growth (52,53). Of interest, all 4 
patients were assessed as high risk by Adjuvant!online 
The great challenge of metabolomics is innate variability of tumor and host. 
Variation exists between people for age, gender, race and hormonal status. For any one 
person, the profile may be affected by diet, diurnal rhythm, gastointestinal microflora, 
medication, toxins, disease, stress and exercise (35).  The critical issue is whether the 
malignant metabolomic signature is identifiable among the vast array and variation of 
metabolites from blood or urine.  
A potential mechanism to overcome the challenge of variability is collection of more 
than one sample for each patient (36). Multiple samples may reveal an invariant signal 
which is characteristic for each individual, with less variation or ‘noise’.  Other options are 
to examine tissue or perform a directed metabolite search, rather than examine systemic 
profiles from serum or urine. Certainly metabolomic analysis of tissue has been shown to 
distinguish normal, benign and malignant processes in several tissue types, including 
breast (16-18,31-34). Also targeted metabolite searches are reported, such as  targeted 
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urine analysis for identification of a specific metabolite linked with prostate cancer with a 
modest predictive value for progression (18). These latter processes limit variability at the 
expense of eliminating analysis of the host.  
Our results require validation in larger, independent cohorts to confirm their 
reproducibility. The discordance between Adjuvant!online and metabolomics must be 
explored by application of Adjuvant!online and metabolomics to a cohort with at least 10-
year follow up data, to examine which is a more accurate tool. From this pilot study we will 
move forward to validation with an external cohort of patients from the Memorial Sloan-
Kettering Cancer Center with long term follow up. Although our validation series confirmed 
the trend seen in the pilot group, our patients lack follow-up.  
In conclusion, we believe that the benefit of metabolomics is the incorporation of 
both a specific tumor profile with metastatic features and a specific host profile conducive 
to tumor growth. We have presented a preliminary exploration in a limited number of 
patients of a potential role for the evolving field of metabolomics in assessment of 
micrometastatic disease in early breast cancer. Clearly this approach requires refinement 
and validation, but the distinction identified between early and late disease and the 
prognostic role of the metabolomic fingerprint provide an exciting platform for further work. 
 
 
 
 
 
 
 
 
 
 14
Funding 
This work was supported by Associazione Italiana Ricerca Cancro, Milan, Italy; Breast 
Cancer Research Foundation, New York, USA; Associazione “Sandro Pitigliani”, Prato, 
Italy; Ente Cassa di Risparmio di Firenze to the FiorGen Foundation; Boehringer Ingelheim 
Italia [to L.T. through the FiorGen Foundation] and SFMET European Project [contract 
no.201640]. 
 
Acknowledgements 
The authors wish to acknowledge the contributions of Associazione Italiana Ricerca 
Cancro, Milan, Italy; Breast Cancer Research Foundation, New York, USA; and 
Associazione “Sandro Pitigliani”, Prato, Italy.  This work was also supported by grants from 
Ente Cassa di Risparmio di Firenze to the FiorGen Foundation, by a fellowship from 
Boehringer Ingelheim Italia (to L.T. through the FiorGen Foundation) and by the SFMET 
European Project (contract no.201640). We thank Hartmut Schaefer from Bruker BioSpin 
for helpful discussions. 
 
Conflict of Interest 
The authors have declared no conflict of interest 
 
 
 
 
 
 
 
 
 15
References 
(1) Bonadonna G, Moliterni A, Zambetti M, et al: 30 years' follow up of randomised studies 
of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330: 217.  
(2) Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the Recurrence Score 
assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen 
receptor positive breast cancer J Clin Oncol 2005; 23: s510 [abstract]. 
(3) van de Vijver MJ, He YD, van't Veer LJ, et al: A gene expression signature as a 
predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. 
(4) Braun S, Naume B. Circulating and Disseminated Tumor Cells. J Clin Oncol 2005; 
23:1623-1626. 
(5) Janni W, Rack B, Schindlbeck C, et al: The persistence of isolated tumor cells in bone 
marrow from patients with breast carcinoma predicts an increased risk for recurrence. 
Cancer 2005; 103: 884-891.  
(6) Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis 
in breast cancer. N Engl J Med 2005; 353: 793-802.  
(7) Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, 
and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.  
(8) Hayes DF, Cristofanilli M, Budd GT, et al: Circulating tumor cells at each follow-up time 
point during therapy of metastatic breast cancer patients predict progression-free and 
overall survival. Clin Cancer Res 2006 ; 12: 4218-4224.  
(9) Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-
19- positive cells in the peripheral blood of patients with operable breast cancer: evaluation 
of their prognostic significance. J Clin Oncol 2002; 20: 3404-3412.  
(10) Xenidis N, Vlachonikolis I, Mavroudis D, et al: Peripheral blood circulating cytokeratin-
19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with 
operable breast cancer. Ann Oncol 2003; 14: 849-855.  
 16
(11) Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 
update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 
2007; 25: 5287–5312. 
(12) Nicholson J. Global systems biology, personalized medicine and molecular 
epidemiology.   Mol Syst Biol 2006; 2: 52.  
(13) Claudino W, Quattrone A, Biganzoli L, et al. Metabolomics: Available Results, Current 
Research Projects in Breast Cancer, and Future Applications. J. Clin. Oncol 2007; 19: 
2840-2846.  
(14) Boros LG, Cascante M, Lee W-NP. Metabolic profiling of cell growth and death in 
cancer: applications in drug discovery.  Drug Discovery Today, 2002; 7: 364-372. 
(15) Griffin J, Shockcor J. Metabolic Profiles of Cancer Cells. Nature Reviews/Cancer  
2004; 4: 551 – 561. 
(16) Cheng LL, Lean CL, Bogdanova A, et al. Enhanced resolution of proton NMR spectra 
of malignant lymph nodes using magic angle spinning. Magn Reson.Med 1996; 36: 653-
658.  
(17) Cheng LL, Burns MA, Taylor JL, et al: Metabolic characterization of human prostate 
cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005 ; 65: 3030-3034.  
(18) Sreekumar A, Poisson L, Rajendiran T, et al. Metabolomic profiles delineate potential 
role for sarcosine in prostate cancer progression. Nature 2009 ; 457 : 910-914.  
(19) Denkert C, Budczies J, Weichert W, et al. Metabolite profiling of human colon 
carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008; 7: 72.  
(20) Ippolito J, Xu J, Jain S, et al. An integrated functional genomics and metabolomics 
approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad 
Sci U S A 2005; 102: 9901-9906. 
 
 17
(21) Fossel ET, Carr JM, McDonagh J. Detection of malignant tumors. Water-suppressed 
proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 1986; 315: 
1369-1376.  
(22) Odunsi K, Wollman RM, Ambrosome CB et al. Detection of epithelial ovarian cancer 
using 1H-NMR-based metabonomics. Int J Cancer 2005; 113: 782-788. 
(23) Yang J, Xu G, Zheng Y, et al: Diagnosis of liver cancer using HPLC-based 
metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J 
Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 59-65.  
(24) Bathen TF, Engan T, Krane J, Axelson D. Analysis and classification of proton NMR 
spectra of lipoprotein fractions from healthy volunteers and patients with cancer or CHD. 
Anticancer Res 2000; 20: 2393-2408.  
(25) Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic 
approach for identifying kidney cancer Anal Biochem 2007; 363: 185-195. 
(26) Aboagye E, Bhujwalla Z. Malignant Transformation Alters Membrane Choline 
Metabolims of Human Mammary Epithelial Cells. Cancer Research 1999; 59: 80-84.  
(27) Whitehead T, Monzavi-Karbassi B, Jousheghany F, et al. 1H-NMR metabolic markers 
of malignancy correlate with spontaneous metastases in a murine mammary tumor model. 
Int J Oncol 2005; 27: 257-263.  
(28) Yang C, Richardson A, Smith J, Osterman A: Comparative Metabolomics of Breast 
Cancer. Pac Symp Biocomput 2007; 181-192. 
(29) Belouche-Babari M, Jackson L, Al-Saffar, et al. Identification of magnetic resonance 
detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase 
signalling in human breast cancer cells. Mol Cancer Ther 2006; 5:187-196.  
(30) Katz-Brul R, Seger D, Rivenson-Segal D et al. Metabolic markers of breast cancer: 
enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer 
Res 2002; 62: 1966-1970.  
 18
(31) Sitter B, Lundgren S, Bathen T, et al. Comparison of HR MAS MR spectroscopic 
profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006; 19: 30-40.  
(32) Cheng LL, Chang IW, Smith BL et al. Evaluating human breast ductal carcinomas 
with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J 
Magn Reson 1998; 135:194-202.  
(33) Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign 
breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. 
Radiology 1997; 204: 661-666.  
 (34) Mountford CE, Somorjai RL, Malycha P et al. Diagnosis and prognosis of breast 
cancer by magnetic resonance spectroscopy of fine needle aspirates analysed using a 
statistical classification strategy. Br J Surg 2001; 88: 1234-1240. 
(35) Bollard ME, Stanley EG, Lindon JC, et al. NMR-based metabonomic approaches for 
evaluating physiological influences on biofluid composition. NMR Biomed 2005; 18: 143-
162.  
(36) Assfalg M, Bertini I, Colangiuli D, et al. Evidence of different metabolic phenotypes in 
humans. Proc Natl Acad Sci U S A 2008; 105: 1420-1424.  
(37) Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body 
fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr 
Opin Chem Biol 2003; 7: 648-654.  
(38) Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic 
Acids Res 2007; 35: D521-D526. 
(39) Bertini I, Calabrò A, De Carli V, et al. The metabonomic signature of celiac disease. J. 
Proteome Res  2009; 8: 170-177. 
(40) Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J. 
Chemometrics 2002; 16: 119-128.  
 19
 (41) Vapnik VN.  The Nature of Statistical Learning Theory. New York: Springer-Verlag, 
1995. 
 (42) Westerhuis J, Hoefsloot H, Suzanne Smit S, et al. Assessment of PLSDA cross 
validation. Metabolomics 2008; 4: 81-89.  
(43) Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ 1994; 308: 
1552.  
(44) Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. J Comput Stat 
Graph 1996; 5: 299-314.  
(45) Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making 
decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 
19: 980–991.  
(46) Olivotto I, Bajdik C, Ravdin P, et al: Population-Based Validation of the Prognostic 
Model ADJUVANT! for Early Breast Cancer. J Clin Oncol 2005; 23: 2716-2725.  
(47) Goldstein L, Gray R, Badve S, et al: Prognostic Utility of the 21-Gene Assay in 
Hormone Receptor–Positive Operable Breast Cancer Compared With Classical 
Clinicopathologic Features. J Clin Oncol 2008; 26: 4063-4071.  
 (48) Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene 
prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 
2006; 98: 1183-1192.  
(49) Baker D, Masterson T, Pace R, et al. The influence of the surgical wound on local 
tumor recurrence. Surgery 1989; 106: 525-532. 
(50) Hofer S, Shrayer D, Reichner J, et al. Wound-induced tumor progression: a probable 
role in recurrence after tumor resection. Arch Surg 1998; 133: 383-389.  
(51) Taglibue E, Agresti R, Carcangui M, et al. Role of HER2 in wound-induced breast 
carcinoma proliferation. The Lancet 2003; 362: 527-533.  
 20
(52) Cole WH. The increase in immunosuppression and its role in the development of 
malignant lesions. J Surg Oncol 1985; 30: 139-144.  
(53) Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum 
following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.  
 
FIGURES 
-0,3
-0,2
-0,1
0
0,1
0,2
0,3
0,4
-0,3 -0,2 -0,1 0 0,1 0,2 0,3
Predictive Scores
O
rth
o
go
n
a
l S
co
re
s
Pre-operative
Metastatic
-0,3
-0,2
-0,1
0
0,1
0,2
0,3
-0,8 -0,6 -0,4 -0,2 0 0,2 0,4 0,6 0,8
Predictive Scores
O
rth
o
go
n
a
l S
co
re
s
Pre-operative
Metastatic
-10
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100
Metabolomic Risk
Ac
cu
ra
cy
 
o
f d
is
e
a
se
 
st
a
ge
 
pr
e
di
ct
io
n
.
 
(A)
(B)
 
 
 21
FIGURE 1 
(A). Orthogonal Projection to Latent Structure (OPLS)  of pre-operative and metastatic 
patients showing near complete separation of patient groups; CPMG (above)  and 
NOESY1D (below) techniques 
 (B). Concordance between accuracy of classification of disease stage (y-axis, %) and 
metabolomic risk (x-axis, MR) in pre-operative patients 
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10-year mortality by Adjuvant!online vs. Metabolomic Risk 
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FIGURE 2.   
Correlation between 10-year breast cancer mortality estimates by Adjuvant!online (A) and 
metabolomic risk (M)  for pre-operative patients (pts). 
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FIGURE 3 
Impact of surgical removal of primary tumor on metabolomic risk. Each bar represents an 
early breast cancer patient. Bar length indicates absolute change in metabolomic risk 
between the pre- and post-operative samples. Bar pattern indicates effect on risk category. 
Most patients remain low risk or become low risk by metabolomics.  
A: Adjuvant!online; M: metabolomic risk 
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10-year mortality by Adjuvant!online vs Metabolomic Risk 
(validation cohort of post-operative pts)
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FIGURE 4.  
Correlation between 10-year breast cancer mortality estimates by Adjuvant!online and 
metabolomic risk  for independent cohort of 45 post-operative patients. The discordance 
seen in the pilot group between high risk patients by Adjuvant!online and low risk by 
metabolomics is also seen in this cohort. 
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TABLE 1 
PATIENT CHARACTERISTICS 
EARLY - Pilot 
(pre and post operative) 
N=44 (%) 
METASTATIC - Control 
 
N=51(%) 
EARLY - Validation 
(post operative) 
N=45 (%) 
Age (years) 
Mean  
Range 
    <40 
    40-50 
    ≥50 
 
58 
34 – 76 
1     (2) 
10  (23) 
33  (75) 
 
59 
38 – 86 
3    (5.5) 
10  (20) 
38  (74.5) 
 
54   
30-85 
 4    (9) 
 15 (33) 
 26 (58) 
Post menopausal 
Pre menopausal 
35  (80) 
 9   (20) 
41  (80) 
10  (20) 
26 (58)   
19 (42) 
Size (mm) 
Mean 
Range 
        ≤ 20 
        > 20 
 
15 
1.6 – 45 
33 (75) 
11 (25) 
 
 
 
17 
3.5 - 45 
35 (78) 
10 (22) 
Grade 
1 
2 
3 
 
4    (9) 
31 (71) 
 9  (20) 
 
 
 
 3   (7) 
19 (42) 
23 (51) 
Estrogen receptor status 
Positive 
Negative 
 
37 (84) 
7   (16) 
 
39  (76) 
12  (24) 
 
35 (78) 
10 (22) 
Progesterone receptor status 
Positive 
Negative 
n/a 
 
29  (66) 
15  (34) 
 
27  (53) 
23  (45) 
1    (2) 
 
13  (29) 
32  (71) 
Her2 
Positive 
Negative  
n/a 
 
4    (9) 
40 (91) 
 
15  (29) 
32  (63) 
4    (8) 
 
9   (20) 
36 (80) 
Histology: 
Ductal 
Lobular  
Other 
n/a 
 
42 (95) 
2   (5) 
 
 
44  (86) 
3    (6) 
2    (4) 
2    (4) 
 
40 (89) 
 5  (11) 
 
No. positive lymph nodes: 
0 
1-3 
≥ 4 
 
28 (64) 
13 (29) 
 3   (7) 
  
24 (53)  
14 (31) 
 7  (16) 
ECOG  performance status 
0 
1 
2 
3 
 Range 0-3 
25  (49) 
17  (33) 
7    (14) 
2    (4) 
 
Visceral involvement 
No visceral involvement 
 31  (61) 
20  (39) 
 
Prior adjuvant chemotherapy 
Prior adjuvant endocrine therapy 
 30  (59) 
25  (49) 
 
Prior chemotherapy for advanced disease 
No. lines of treatment: 
   0  
   1 
   2 
   ≥ 3 
  
 
29  (57) 
8    (15.5) 
8    (15.5) 
6    (12) 
 
Prior endocrine therapy for advanced disease 
   No. of lines of treatment 
   0 
   1 
   ≥2 
  
 
26  (51) 
10  (20) 
15  (29) 
 
TABLE 1. Summary of patient characteristics and clinical data; n/a = not available 
SUPPLEMENTAL MATERIAL AND METHODS 
NMR Sample preparation and spectra acquisition 
Frozen serum samples were thawed at room temperature and shaken before use.  
300 µl of a phosphate sodium buffer (70 mM Na2HPO4; 20% v/v 2H2O; 0.025% v/v NaN3; 
0.8% w/v sodium trimethylsilyl [2,2,3,3-2H4]propionate (TSP); pH 7.4) were added to 300 µl 
of each serum sample and the mixture was homogenized by vortexing for 30 seconds (s).  
450 µL of this mixture were transferred into a 4.25 mm NMR tube (Bruker BioSpin srl) for 
analysis. 
1H-NMR spectra for all samples were acquired using a Bruker 600 MHz metabolic 
profiler (Bruker BioSpin) operating at 600.13 MHz proton Larmor frequency and equipped 
with a 5mm CPTCI 1H-13C/31P-2H cryoprobe including a z axis gradient coil, an automatic 
tuning-matching (ATM) and an automatic sample changer. A BTO 2000 thermocouple 
served for temperature stabilization at the level of approximately 0.01 K at the sample. 
Before measurement, samples were kept for at least 3 minutes inside the NMR 
probehead, for temperature equilibration (300 K).  
For each sample, two one-dimensional NMR spectra were acquired with water peak 
suppression: (i) a standard pulse sequence (NOESY1Dpresat; Bruker), using 64 free 
induction decays, 64k data points, a spectral width of 20.0306 ppm, an acquisition time of 
2.7 s, a relaxation delay of 4 s, and a mixing time of 100 ms; (ii) a Carr-Purcell-Meiboom-
Gill (CPMG; Bruker) spin-echo sequence to suppress signals arising from high molecular 
weight molecules and a standard pulse sequence (same acquisition parameters as with 
NOESY1Dpresat)  
Spectral Processing.  
Free induction decays were multiplied by an exponential function equivalent to a 1.0 
Hz line-broadening factor before applying Fourier transform. Transformed spectra were 
manually corrected for phase and baseline distortions and calibrated (TMSP peak at 0.00 
ppm) using TopSpin (Version 2.1, Bruker). Each 1D spectrum in the range between 0.02 
and 10.00 ppm was segmented into 0.02-ppm chemical shift bins and the corresponding 
spectral areas were integrated using AMIX software (version 3.8.8, Bruker BioSpin). 
Regions between 6.0 and 4.5 ppm containing residual water signal was removed. The total 
spectral area was calculated on the remaining bins and normalization was carried out on 
the data prior to pattern recognition. Standard binning reduced the dimension of the 
system to 416 bins (variables) 
Statistical Analysis 
Data reduction was obtained by means of Orthogonal Projection to Latent Structure 
(OPLS) (1) on the mean-centered data without scaling, using the algorithm implemented in 
the R-library “kopls” (2) and using a linear kernel.  
 For the purpose of classification we used the Support Vector Machines (SVM) 
method (3)  applied on the OPLS  scores. The “libsvm” module (LIBSVM: a Library for 
Support Vector Machines) of the R-library “e1071” was used (4).  
To assess the prediction ability of the model, a double cross-validation scheme was 
adopted (5). In order to avoid bias in the estimation of the prediction error, we performed 
two nested loops of cross-validation.  The original data sets were split according to a 2:8, 
that is, randomly removing 20% of samples, used as test set. Parameter selection (best 
number of predictive and orthogonal components for OPLS and kernel parameters for 
SVM) was carried out in the inner loop by means of 7-fold cross validation on the 
remaining 80%. With the best parameters we created a model which was then used to 
predict the excluded 20%.  This procedure was repeated 100 times. We averaged the 
error on the test sets in order to obtain an estimation of the accuracy of the model and an 
accuracy for each individual. Accuracy, sensitivity and specificity were estimated using 
standard definitions (6). 
To assess which bins were significantly different between the metastatic and early 
patients, a non parametric Wilcoxon test was used. A conservative estimate of significative 
levels of 1.201 × 10-4 was derived by using the Bonferroni correction on a nominal value of 
0.05. The bins whose values appeared to be significantly different from the above 
statistical analysis were manually checked to identify the associated resonance peak(s). 
All resonances of interest were then manually checked and signals were assigned on 
template one-dimensional NMR profiles by using matching routines of AMIX 3.8.8 (Bruker 
BioSpin) in combination with the BBIOREFCODE (Version 2-0-0; Bruker BioSpin) 
reference database and published literature when available.  
All calculations were made using R (7) scripts developed in-house. 
 
SUPPLEMENT REFERENCES 
 (1) Trygg J., Wold S., Orthogonal projections to latent structures (O-PLS). J. 
Chemometrics  2002 ; 16: 119-128. 
(2). Bylesjö M, Rantalainen M, Nicholson JK, et al. K-OPLS package: kernel-based 
orthogonal projections to latent structures for prediction and interpretation in feature space, 
BMC Bioinformatics 2008; 19: 106  
(3) Vapnik VN.  The Nature of Statistical Learning Theory. New York: Springer-Verlag, 
1995. 
(4) Chang and Lin, 2001, LIBSVM: a Library for Support Vector Machines 
(5) Westerhuis J, Hoefsloot H, Suzanne Smit S, et al. Assessment of PLSDA cross 
validation. Metabolomics 2008; 4: 81-89.  
(6) Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ 1994; 
308:1552.  
(7) Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. J Comput Stat 
Graph 1996; 5: 299-314.  
Are Patients with Potential Celiac Disease Really Potential? The
Answer of Metabonomics
Patrizia Bernini,†,§ Ivano Bertini,*,†,‡ Antonio Calabro`,|,⊥ Giancarlo la Marca,#,∇ Gabriele Lami,|
Claudio Luchinat,*,†,‡ Daniela Renzi,|,⊥ and Leonardo Tenori§
Magnetic Resonance Center (CERM), University of Florence, Via L.Sacconi 6, 50019 Sesto Fiorentino, Italy,
Department of Chemistry, University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy, FiorGen
Foundation, Via L. Sacconi 6, 50019 Sesto Fiorentino, Italy, Gastroenterology Unit, Department of Clinical
Pathophysiology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy, Tuscany Referral Center for
Adult Celiac Disease, Viale Morgagni 85, 50134 Florence, Italy, Department of Pharmacology, University of
Florence, Viale Pieraccini 6, 50139 Florence, Italy, and Mass Spectrometry, Clinical Chemistry and
Pharmacology Labs, Clinic of Pediatric Neurology, A. Meyer University Children’s Hospital, Viale Pieraccini 24,
50134 Florence, Italy
Received September 1, 2010
Celiac disease (CD) is an autoimmune disorder caused by a permanent sensitivity to gluten in genetically
susceptible individuals. Accurate diagnosis of CD at an early stage and its treatment with a gluten-free
diet (GFD) are important for optimum treatment and prognosis. Recently, by employing a noninvasive
metabonomic approach, we have shown that CD has a well-defined metabonomic signature. Here we
address potential CD patients, defined as subjects who do not have, and have never had, a jejunal
biopsy consistent with clear CD, and yet have immunological abnormalities similar to those found in
celiac patients. Sixty-one overt CD patients at diagnosis, 29 patients with potential CD, and 51 control
subjects were examined by 1H NMR of their serum and urine: out of 29 potential CD patients, 24 were
classified as CD and 5 as control subjects. Potential CD largely shares the metabonomic signature of
overt CD. Most metabolites found to be significantly different between control and CD subjects were
also altered in potential CD. Our results demonstrate that metabolic alterations may precede the
development of small intestinal villous atrophy and provide a further rationale for early institution of
GFD in patients with potential CD, as recently suggested by prospective clinical studies.
Keywords: Potential Celiac Disease • Metabolomics • Metabonomics • Nuclear Magnetic Resonance
Introduction
Celiac disease (CD) is a common autoimmune disorder
triggered by the ingestion of gluten and related prolamins, plant
storage proteins found in wheat, barley, and rye, in genetically
susceptible individuals.1 Patients display various degree of
intestinal inflammation, ranging from mere increase in the
number of intraepithelial lymphocytes (lymphocytic enteritis)
to elongation of crypts (crypt hyperplasia), severe mononuclear
cell infiltration of the lamina propria and overt villous atrophy.
Accordingly, clinical manifestations range from completely
asymptomatic forms (so-called silent CD patients) to symptoms
and signs of global malabsorption.
In the majority of cases, a gluten-free diet (GFD) leads to
disappearance of clinical symptoms, recovery of normal mu-
cosal histology, disappearance of the serological signs, and the
prevention of complications, while reintroduction of gluten into
the diet, at any stage, causes reactivation of the disease.2-7
Small-bowel mucosal villous atrophy has traditionally been
considered the conditio sine qua non for diagnosing CD.8 As a
logical consequence, although there is a general consensus on
dietary treatment for symptomatic subjects with enteropathy,
it is not so for potential cases (i.e., patients with positive CD-
associated serology, but no enteropathy).9 However, accumu-
lating evidence suggests that celiac patients may suffer from
gluten-sensitive symptoms even before villous atrophy has
developed,10-13 and an increased risk of osteoporosis has been
reported also for this group of patients.10
In a recent work, Bertini et al. have examined a cohort of
CD patients, before and after gluten free diet GDF, and healthy
controls, by 1H NMR metabolic profiling of their serum and
urine samples.14 Through multivariate analysis, they were able
to demonstrate the existence of a clear metabonomic15 signa-
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ture of CD and to identify a number of serum and urine
metabolites whose levels were significantly different in CD at
diagnosis as compared to controls. The metabonomic signature
as well the levels of most metabolites reverted to normal within
12 months of a strict GFD. The metabonomic fingerprint of
CD has two components not directly linked to malabsorption:
one related to energy metabolism, and the other related to
alterations of gut microflora. Using this metabolic fingerprint,
it is possible to make predictions about the CD status wit
reasonably good accuracy (about 84%).
These results, although extremely encouraging, are not
particularly helpful from a merely diagnostic point of view,
since serology by blood test already achieves a sensitivity of
about 98% and a specificity of over 95%.16 Moreover, profes-
sional guidelines recommend that a positive blood test should
still be followed by an endoscopy, and this would pick up false
positives as well as offer alternative explanations for the
symptoms.17-19 However, the clear discrimination between
patients and healthy subjects and patients and follow-up cases,
achieved by metabolic fingerprinting, undoubtedly demon-
strates the existence of a metabolic signature for CD both in
serum and urine.
Under the inclusive definition of celiac disease, or gluten-
sensitive enteropathy, the concepts of silent, latent, and
potential CD have been introduced over 15 years ago by
Professor Anne Ferguson.20 While silent CD is marked by severe
damage to the jejunal mucosa in the absence of clinical
symptoms, both latent and potential CD are characterized by
jejunal mucosa that would be reported as normal by most
clinical pathologists in an individual on a gluten-containing
diet. Latent subjects sometimes in their life have had a flat
jejunal biopsy which recovered on a gluten-free diet. Latent
CD patients are often symptomatic; neither high titers of gliadin
antibodies nor mucosal changes (including raised intraepithe-
lial lymphocyte counts) are obligate features of latent CD,
although the presence of elevated anti-endomysial antibodies
(EmA) is probably the best predictor of progression toward
villous atrophy.21
The term potential CD has been proposed for those subjects
who, as opposed to latent CD patients, do not have, and have
never had, a jejunal biopsy consistent with clear CD, and yet
have immunological abnormalities similar to those found in
celiac patients. Good markers of potential CD include the
presence of serum endomysial antibodies, a high count of
intraepithelial lymphocytes, and subtle pathological alteration
such as increased density of intraepithelial lymphocytes ex-
pressing gamma delta T cell receptor, signs of activated
mucosal cell-mediated immunity, celiac-like intestinal antibody
pattern, and positive rectal gluten challenge.21
Our interest in potential CD subjects stems from the fact
that they have all the typical immunoclinical features of clear
CD, in the absence of any apparent intestinal damage. The aim
of this work is to investigate whether (and to what extent)
potential CD patients share the same metabolic fingerprint of
overt CD patients, thereby addressing an as yet open question:
are the metabolic alterations associated to CD due to malab-
sorption (i.e., intestinal damage) or are they independent of
mucosal injury and therefore intrinsic to the pathology? In
other words, our aim is to clarify if we are effectively looking
at a metabolic signature of CD or if we are simply following
the metabolic modification due to intestinal malabsorption. To
this end, a suitable cohort of potential CD subjects is ideal
because, by definition, they do not have villous atrophy.
Recent prospective studies on both adults and children
classified as potential CD patients have addressed the question
of whether GFD prevents development of villous atrophy and/
or alleviates the symptoms. There is increasing evidence that
GFD has a beneficial effect, although the effect can be more22,23
or less24 marked. The comparison of the fingerprint of potential
CD subjects with overt CD subjects and healthy controls can
thus contribute to the open debate about whether or not it is
necessary to put these patients on a GFD.
Materials and Methods
Volunteers Recruitment and Samples Collection. The vol-
unteers participating in this study were recruited by the
Tuscany Referral Center for Adult CD. In total, 141 adult (35
males, 106 females, mean age 38.3 ( 13.9 years) participated
in this study. Among the celiac group, 61 patients (10 males,
51 females, mean age 39.8 ( 13.9 years) were affected by overt
CD, and 29 were diagnosed as having potential CD (6 males,
23 females, mean age 34.4 ( 14.3 years). The diagnosis of CD
was based on positive serology and confirmed by histological
examination of small bowel biopsies taken from the distal part
of the duodenum. Small intestinal mucosal damage was
graduated according to the classification of Marsh modified
by Oberhuber.25 According to the hystology, 7 patients with
overt CD had partial villous atrophy (Marsh 3A), 7 subtotal
villous atrophy (Marsh 3B), and 16 total villous atrophy (Marsh
3C). Patients with potential CD were all positive for anti-tissue
transglutaminase antibodies (tTGA); all but one were also EmA
positive; histological examination revealed an apparently nor-
mal mucosa (Marsh 0) in 9 subjects, just an increase in
intraepithelial lymphocytes (Marsh 1) in 12 and increased
intraepithelial lymphocytes coupled with crypt hyperplasia
(Marsh 2) in 8 patients. The control group consisted of 51
nonceliac subjects (19 males, 32 females, mean age 36.6 ( 14.2
years): 34 (13 males, 21 females, mean age 37.6 ( 14.8 years)
were healthy controls from the medical staff of the Gastrointes-
tinal Unit and 17 (6 males, 11 females, mean age 30.9 ( 12.5
years) were patients with clinical suspicion of celiac disease;
they were all EmA and tTGA negative. Therefore, for ethical
reasons, the 34 controls that were from the medical staff did
not undergo intestinal biopsy; in the remaining 17 cases,
gastrointestinal endoscopy was performed only when it was
considered necessary to the diagnosis. The clinical character-
istics of all the subjects, including those examined in the
previous work14 are reported in Supporting Table S1.
Each subject had fasted overnight, and urine and blood were
collected in the morning preprandial. Venous blood samples
were collected into plastic serum tubes (6 mL), with increased
silica act clot activator, silicone-coated interior (Becton
Dickinson, Plymouth, U.K.). Samples were allowed to clot by
standing tubes vertically at room temperature (22 °C) for 60
min. Tubes were centrifuged at 1800 RCF for 10 min at room
temperature. Within 15 min of centrifugation, the supernatant
(serum) was transferred in 500 µL aliquots to prelabeled 1 mL
cryovials (Bruker BioSpin, Milan, Italy). Three aliquots per
patient were immediately frozen and stored at -80 °C until
used.
First morning preprandial urine void was used for the
collection period. Patients were supplied with appropriate
collection instructions and information on fasting, diet and
medication restrictions when necessary. The urine samples
were collected into prelabeled sterile collections cups. One
milliliter of urine samples was transferred into prelabeled 1 mL
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sterile cryovials (Nalgene, Rochester, NY). Three aliquots per
patient were immediately frozen and stored at -80 °C until
used.
Additionally, CD patients and healthy controls were asked
to record their dietary intake and the use of any medication
(either prescribed or self-administered) on the day before each
visit, and to fast from midnight until blood samples and urine
were collected the following morning.
Genotyping. Potential CD patients were analyzed for CD-
related genes following the procedure already reported.14 They
were all genetically susceptible: in particular 22 were DQ2, 3
DQ8, and 4 DQ2.2 positive (i.e., they carried the HLA genes
DRB1 *07, DQB1 *0202 and DQA1 *0201, see Supporting Table
S2). In the course of our previous work,14 we had checked that
among healthy subjects those who were DQ2/DQ8 positive
were not statistically distinguishable from the negative ones,
while they were distinguishable from the CD patients.
Antibody Testing. Anti-tissue transglutaminase antibodies
were measured by a commercially available enzyme-linked
immunosorbent assay kit (EutTG, Eurospital, Trieste, Italy) that
employs human recombinant tTG as antigen; EmA were
determined by indirect immunofluorescence, using tissue
section of monkey esophagus (Eurospital), as previously de-
scribed.26
Citrulline Assay. Labeled standards of citrulline were pur-
chased from Cambridge Isotope Laboratories, Andover, MA; a
stock solution was made in methanol. The standard concentra-
tion was 500 µmol/L. To obtain working solutions, daily
dilutions (1:100) were made using methanol-water 85:15. All
chemicals and solvents were of the highest purity available from
commercial sources and were used without any further
purification.
A dried serum spot was punched into a 1.5 mL tube or a 96
well plate and 200 µL of methanol containing labeled standard
was added. The sample was shaken on a vortex system for 20
min, and was then dried under a nitrogen flow at 50 °C. The
extracted amino acid was derivatized to butyl-ester using
n-butanol and HCl (3 M) at 65 °C for 25 min. After derivatiza-
tion, the sample was dried under nitrogen flow at 55 °C and
then recovered using 200 µL of water/acetonitrile (1:1) contain-
ing 0.1% formic acid. A total of 40 µL of the diluted sample
was injected in FIA (Flow Injection Analysis) mode for the
MS/MS experiments.
An Applied Biosystems-Sciex (Toronto, Canada) API 4000
triple-quadrupole mass spectrometer equipped with a Tur-
boIonSpray source was employed for this study. The TurboIon-
Spray source was operated in positive ion mode with a needle
potential of +5900 V and with a “turbo” gas flow of 10 L/min
of air heated at 400 °C (nominal heating-gun temperature).
Mass calibration and resolution adjustments on the resolving
quadrupoles were performed automatically by using a PPG 10-7
mol/L solution introduced via the built-in infusion pump. The
peak width was set on both resolving quadrupoles at 0.7 Th
(measured at 1/2 height) for all MS and MS/MS experiments.
Collision Activated Dissociation (CAD) MS/MS was performed
in the LINAC Q2 collision cell, operating with 10 mTorr pressure
of nitrogen as collision gas. The declustering potential (DP) and
collision energy (CE) were automatically optimized for amino
acids using the Analyst 1.3.2 software. The resulting DP was
+20 eV, and optimal CE was found to be 25 eV.
MS and MS/MS spectra were collected in continuous flow
mode by connecting the infusion pump directly to the Tur-
boIonSpray source. The quantitation experiments were per-
formed using a Series 1100 Agilent Technologies (Waldbronn,
Germany) CapPump coupled to an Agilent Micro ALS au-
tosampler, both fully controlled from the API 4000 data system.
Experimental flow rate was 50 µL/min using water/acetonitrile
(1:1) mixture containing 0.1% formic acid. The eluent from the
column was directed to the TurboIonSpray probe. The acquired
data were processed using the Analyst 1.4.1 proprietary software
including the “Explore” option (for chromatographic and
spectral interpretation) and the ChemoView software (for
quantitative information generation).
NMR Sample Preparation. Frozen serum samples were
thawed at room temperature and shaken before use. A total of
300 µL of a phosphate sodium buffer (70 mM Na2HPO4; 20%
(v/v) 2H2O; 0.025% (w/v) NaN3; 0.8% (w/v) sodium trimethylsilyl
[2,2,3,3-2H4]propionate (TSP); pH 7.4) was added to 300 µL of
each serum sample, and the mixture was homogenized by
vortexing for 30 s. A total of 550 µL of this mixture was
transferred into a 4.25 mm NMR tube (Bruker BioSpin srl) for
analysis.
Frozen urine samples were thawed at room temperature and
shaken before use. Samples were centrifuged at 1.4 × 104g for
5 min and 540 µL of the supernatant was added to 60 µL of
sodium phosphate buffer (0.2 M Na2HPO4; 0.2 M NaH2PO4 in
100% 2H2O; pH 7.0) also containing 10 mM TSP, and 30 mM
NaN3. A total of 450 µL of the mixture was pipetted into 4.25
mm NMR tubes (Bruker BioSpin srl).
NMR Analysis. 1H NMR spectra for all samples were acquired
using a Bruker 600 MHz spectrometer (Bruker BioSpin) operat-
ing at 600.13 MHz proton Larmor frequency and equipped with
a 5 mm CPTCI 1H-13C/31P-2H cryo-probe including a z-axis
gradient coil, an automatic tuning-matching (ATM) and an
automatic sample changer. A PT 100 thermocouple provided
temperature stabilization at the level of approximately 0.1 K
for the sample. Before measurement, samples were kept for at
least 3 min inside the NMR probehead, for temperature
equilibration (300 K).
For each urine sample, a one-dimensional NMR spectrum
was acquired with water peak suppression using a standard
pulse sequence (NOESYpresat; Bruker), using 64 free induction
decays (FIDs), 64k data points, a spectral width of 12 019 Hz,
an acquisition time of 2.7 s, a relaxation delay of 4 s, and a
mixing time of 100 ms.
One-dimensional spectra of serum samples were acquired
using a Carr-Purcell-Meiboom-Gill (CPMG; Bruker)
spin-echo sequence to suppress signals arising from high
molecular weight molecules and a standard pulse sequence
(NOESYpresat, same acquisition parameters as in the case of
urine samples).
Spectral Processing. Free induction decays were multiplied
by an exponential function equivalent to a 1.0 Hz line-
broadening factor before applying Fourier transform. Trans-
formed spectra were manually corrected for phase and baseline
distortions and calibrated (TMSP peak at 0.00 ppm) using
TopSpin (Version 2.1, Bruker). Each 1-D spectrum in the range
between 0.02 and 10.00 ppm was segmented into 0.02-ppm
chemical shift bins, and the corresponding spectral areas were
integrated using AMIX software (Bruker BioSpin). Regions
between 6.0 and 4.5 ppm containing residual water and urea
signals were removed. The total spectral area was calculated
on the remaining bins and normalization was carried out on
the data prior to pattern recognition.
Statistical Analysis. Data reduction was obtained by means
of Kernel Orthogonal Projection to Latent Structure (KOPLS),27
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using the algorithm implemented in the R-library “kopls”28
using a Gaussian kernel.
For the purpose of classification, we used the Support Vector
Machines (SVM) method29 applied on the KOPLS scores. The
“libsvm” module (LIBSVM: a Library for Support Vector Ma-
chines) of the R-library “e1071” was used.30
The statistical procedure used is a combination of KOPLS
for data reduction (i.e., to reduce the initial number of variables
and to have a clear depiction of the class separation) followed
by SVM on the KOPLS scores. SVM are used with the default
“C-classification” settings.
Accuracy, specificity, and sensitivity were estimated using
standard definitions. The global accuracy for classification was
assessed by means of double cross-validation scheme.31 The
original data set was spit in a training set (90%) and a test set
(10%) prior to any other step of statistical analysis. Parameter
selection was carried out by 3-fold cross-validation on the 90%
training set. The whole procedure was repeated 100 times
Figure 1. Clusterization of overt CD patients (open circles) and healthy controls (filled circles) obtained with kopls for cpmg serum
spectra (A), NOESY serum spectra (B), and NOESY urine spectra (C). Potential CD patients (triangles) are projected on the kopls
component, predicted by SVM, and filled or not accordingly to the results.
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inside a Monte Carlo cross-validation scheme. From this
procedure, we obtain unbiased generalization error estimation.
To avoid overtraining and to speed up the calculations, in the
inner loop of the cross-validation (parameter selection),
the SVM was kept with the default settings, varying only the
number of components and the kernel sigma parameter for
KOPLS.
To assess which buckets (that is, resonance peaks) were
significantly different between different groups, a univariate
wilcoxon test was used. A P-value e 0.05 was considered
statistically significant. The buckets whose values appeared to
be significantly different from the above statistical analysis were
manually checked to identify the associated resonance peak(s).
All resonances of interest were then manually checked and
signals were assigned on template one-dimensional NMR
profiles by using matching routines of AMIX 6.8 (Bruker
BioSpin) in combination with the BBIOREFCODE (Bruker
BioSpin) reference database and published literature when
available. All calculations were made using homemade scripts
written in R language.32 Serum citrulline concentrations in the
three groups were analyzed by two-way ANOVA, followed by
Tukey’s multiple comparison test, and a P-value of less than
0.05 was accepted to denote statistical significance.
Ethical Issue. The study was approved by the Internal Review
Board of the Department of Clinical Pathophysiology of the
University of Florence, and informed consent was obtained
from all patients and healthy volunteers.
Results
The clusterization of controls and overt untreated CD
patients for the three sets of experiments (serum CPMG, serum
NOESY, and urine NOESY) is shown in Figure 1. It appears that
the best clusterization is provided by the serum CPMG spectra.
The statistical models applied proved to be effective in
discriminating between patients and control subjects. These
results are in line with our previous work,14 where for the first
time the existence of a metabolic fingerprint of celiac disease
was demonstrated, both in serum and urine. Although the best
recognition accuracy is slightly less than previously reported
(81.2 vs 83.4 for serum CPMG spectra), these new data
undoubtedly confirm the existence of the metabolic signature
of CD, both in serum and in urine. In Table 1, the values for
classification accuracy for each experiment are reported.
If the potential CD patients are treated as blind samples and
are subjected to classification by the previous statistical model,
24 out of 29 are classified as CD patients using CPMG serum
spectra. Those results strongly suggest that potential CD
subjects are more similar to overt CD than to healthy controls.
Moreover, when the statistical analysis is used to discriminate
potential from overt CD patients, the accuracy is significantly
lower (57.8%). Furthermore, as shown in Table 2, this result is
highly asymmetric with high sensitivity (>70%) but poor
specificity (ca. 20%). Again potential CD subjects show a
behavior that is much more similar to overt CD.
When comparing spectra of serum samples of overt un-
treated CD patients and nonceliac controls, we find that CD
patients are characterized (P < 0.05) by lower levels of choline,
creatinine, isoleucine, lactate, leucine, methionine, valine,
lipids, and glycoproteins (from their N-acetyl signal) and higher
levels of glucose, citrate, serine, and phenylalanine.
In the case of urine, overt CD patients are characterized by
higher levels of acetoacetate, choline, glutamate/glutamine,
indoxyl sulfate (IS), meta-hydroxyphenyl-propioni acid (mH-
PPA), phenylacetylglycine (PAG), 3-hydroxybutyric acid, me-
thylamine, valeric acid, sarcosine, p-cresolsulfate, and 1-me-
thylnicotinamide. These data are summarized in Table 3. Even
though minor differences are present (due to the different data
set and slightly different statistical analysis), this pattern is
coherent with the previous work and corroborates the previous
findings.14
Comparing the serum spectra of overt CD with those of
potential CD, we find that potential CD patients are character-
ized by lower levels of dimethylglycine and higher levels of
glutamate and lipids (P < 0.05); no other metabolites are found
significantly different in serum. In urine, more differences are
found, in particular potential CD patients shows lower levels
of glutamate/glutamine, IS, mHPPA, PAG, p-cresolsulfate, and
citrate (see Table 3).
The metabolic differences between potential CD and non-
celiac controls in serum are quite similar to those between overt
CD and controls: potential CD subjects have lower levels of
creatinine, leucine, dimethylglycine, arginine, and lipids and
higher levels of glucose, proline, and glutamate. In urine,
potential CD subjects show lower levels of hippurate and higher
levels of dimethylamine, 1-methylnicotinamide, and citrate.
These data are summarized in Table 3.
Several of the potential CD patients analyzed here were put
on a GFD, although solely based on medical considerations
and not on the results frommetabolomics. At the present stage,
we have been able to examine again 13 of them, after an
average period of GFD of 6 months (Supporting Table S2): all
but three had negative TGA. By processing the follow-up serum
samples with the same statistical model built for the discrimi-
nation, we found that all of them, except for one of the three
positive to TGA, had reverted to a normal metabonomic profile.
In addition to metabolomic analysis, with the aim of obtain-
ing more information able to better characterize the clinical
Table 1. Cross-Validation Classification Results Obtained
Using CPMG and NOESY Serum Spectra and NOESY Urine
Spectra of Overt CD Patients and Nonceliac Controls (NC)
overt CD NC accuracy
Serum CPMG Spectra
overt CD 80.5% 19.5%
81.2%
NC 18.0% 82.0%
Serum NOESY Spectra
overt CD 77.4% 22.6%
75.5%
NC 26.7% 73.3%
Urine NOESY Spectra
overt CD 77.5% 22.5%
74.7%
NC 29.0% 71.0%
Table 2. Cross-Validation Classification Results Obtained
Using CPMG and NOESY Serum Spectra and NOESY Urine
Spectra of CD Patients and Potential CD Subjects
overt CD potential CD accuracy
Serum CPMG Spectra
overt CD 71.1% 28.9%
57.8%
potential CD 70.2% 29.8%
Serum NOESY Spectra
overt CD 67.6% 32.3%
55.2%
potential CD 71.1% 28.9%
Urine NOESY Spectra
overt CD 81.4% 18.6%
57.4%
potential CD 89.7% 10.3%
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phenotype of potential CD patients, we monitored and com-
pared the citrulline levels of the three kind of subjects (30 overt
CD, 51 controls, and 29 potential CD). Serum citrulline level is
in fact an indirect measure of the enterocyte mass and it was
proposed as a clinical biomarker for enterocyte dysfunctions
in many diseases.33-36 Although the idea of observing citrulline
levels of celiac patients is not new,37 this is, at the best of our
knowledge, the first time that such analysis is done in potential
CD patients. The results are extremely interesting because a
statistically significant difference (P < 0.001) is obtained not
only between CD patients and the control group (as expected),
but also between potential CD subjects and controls. Moreover,
the difference between CD patients and potential CD subjects
is not statistically significant (Figure 2).
Discussion
The present work classifies potential CD subjects (29) on the
basis of a learning set of controls and CD subjects that has been
considerably expanded with respect to the previous study14 (61
+ 51). The global accuracy obtained in discriminating nonceliac
control subjects and patients is good enough (81.2%) to allow
us to try to make predictions about the metabolic status of
potential CD subjects. It is important to stress here that in doing
so we are not proposing an alternative diagnostic test for the
screening of difficult cases, sometimes challenging also for
expert clinicians. Rather, this exercise is useful to have a
qualitative answer to the title question. Using CPMG serum
spectra, the result of the prediction is remarkably clear: out of
29 potential CD subjects, 24 are classified as CD and 5 are
classified as controls. Furthermore, three of the latter are
located near the cluster boundary (e.g., they are borderline
subjects) and only two are clearly classified as controls (Figure
1A). Although it is not possible to give a rationale for these
differences, the answer of metabolomics is straightforward:
potential CD subjects are extremely similar to overt CD
patients, at least in their metabolic profile.
If we build a statistical model optimized for the discrimina-
tion between celiac patients and potential subjects, the clas-
sification accuracy is very low: 57.8% for serum CPMG spectra,
55.1% for serum NOESY spectra, and 57.4% for urine. In all
cases, we have high sensitivity but a high rate of false discovery,
so the specificity is very poor (29%, 29%, and 10%). In other
words, it is impossible to separate overt CD from potential CD
subjects, based on metabolomics.
The analysis of the metabolic profiles reveals interestingly
similar behavior of overt CD and potential CD. Only few serum
metabolites differentiate potential from overt CD, and none of
these metabolites are relative to energy metabolism. In par-
ticular, it appears that, as in untreated CD patients, glycolysis
is somehow impaired. Impairment of glycolysis explains both
a lowering of lactate levels and an increase of glucose levels in
blood. This is confirmed by the metabolic pattern that dif-
ferentiates potential CD and nonceliac controls: most of the
significant metabolites are the same that differentiate overt CD
from control group.
In urine, there are many more metabolites that differentiate
potential CD from overt CD than from controls. Especially, the
key differences are in the metabolites originating from the gut
microflora (m-HPPA, IS, and PAG), suggesting a relationship
between overt CD, villous atrophy, and bacterial consortia of
the host. It is also reported38 that particular bacterial strains
may work in conjunction with gluten to cause an increased
immune response which is responsible of the development of
CD. A distinctive ‘microbial signature’ in celiac pediatric
patients is also reported.39
The similarity of the metabolic pattern in serum, and the
dissimilarity in urine, between overt and potential CD subjects
allow us to hypothesize that while the alterations in the urine
profile may follow intestinal damage, gluten intolerance exists
as such before an evident intestinal damage occurs.
Table 3. Metabolites Found To Be Statistically Different
(P < 0.05) in Sera (A) and Urine (B) of Untreated Overt CD
Patients, Potential CD Patients, and Nonceliac Controls (CD)a
metabolite
CD patients
vs NC
potential
CD vs NC
overt CD vs
potential CD
(A) Serum
Choline -
Creatinine - -
Glucose + +
Glycoproteins -
Isoleucine -
Lactate -
Leucine - -
Lipids - - -
Methionine -
Valine - -
Citrate +
Serine +
Phenilalanine +
Glutamate + + +
Dimethylglycine - +
Proline +
Arginine -
(B) Urine
Acetoacetate +
Choline +
Glutamate/Glutamine + +
Indoxyl Sulfate + +
mHPPA + +
PAG + +
3-OH-butirate +
Methylamine +
Valerate +
Sarcosine +
p-cresolsulfate +
1-methylnicotinammide + -
Citrate + - +
Hippurate -
a The + and - indicate, respectively, higher and lower levels of
metabolites concentrations in the first group of each classification, with
respect to the other.
Figure 2. Serum citrulline concentrations in the three groups of
subjects. In overt and potential CD, the mean serum citrulline
concentration was significantly lower (15.97 + 4.62 SD and 17.38
+ 3.70 SD) than in nonceliac controls (22.30 + 5.39 SD, *p
< 0.001). One-way analysis of variance followed by Tukey’s post
test was applied to the results.
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To clarify this aspect and to shed more light on the present
findings, we performed a serum citrulline assay. In humans,
citrulline is an amino acid involved in intermediary metabolism
and is not incorporated in proteins.40-42 Circulating citrulline
is mainly produced by enterocytes of the small bowel.43 For
this reason, plasma or serum citrulline concentration has been
proposed as a biomarker of residual small bowel mass and
function.44
Our data, in line with previous findings, clearly show that
citrulline levels in the CD patients are significantly lower than
in the control group. But, more strikingly, also potential CD
subjects, that from endoscopy do not show any manifest sign
of villous atrophy, have lower levels of citrulline than controls.
Indeed no statistically significant difference is found between
citrulline levels in CD patients and potential CD subjects
(Figure 2).
According to clinical experience, if a celiac subject has a
positive antibody test but does not show macroscopic alter-
ations of intestinal mucosa, there can be only two possibilities:
(1) a (limited) intestinal damage is present but the endoscopy
was not able to detect it (i.e., we admit some error in the
sampling procedure) or (2) the intestinal mucosa is really intact
and the subject is a so-called “potential CD subject”.
The interpretation of our data (both frommetabonomics and
from citrulline assay) suggests a third option: potential CD
subjects are, indeed, not potential at all. They already experi-
ence some subtle alteration of the enterocytes (at the micro-
scopic functional level but not at the macroscopic level) and
metabolically appear similar to overt CD also without any
histological evidence of intestinal damage. If this hypothesis
holds, the core result from our investigation would be that
metabolomics can detect CD also when its clinical manifesta-
tion is not fully evident. Moreover, these findings may bear the
important medical implication that the metabolic and entero-
cyte alterations of CD arise before macroscopic intestinal
damage and/or villous atrophy and precede the observable
modification of jejunal mucosa. In this context, the observation
that potential CD subjects are characterized by a similar serum
metabonomic fingerprint as overt CD patients provides a
further, more biological, rationale for the medical evidence-
based choice of putting potential CD subjects on a GFD.
Moreover, if the metabolic changes are (at least partially)
independent from the bowel malabsorption (i.e., metabolites
of gut microflora and energetic pathway), a deeper analysis of
this fingerprint can be helpful to infer more information on
the biochemistry of the development of the disease.
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Supporting Table S1. Demographic and clinical data on study patients. 
________________________________________________________________________ 
                  overt CD          potential CD           nonceliac controls 
                    n = 61    n = 29        n = 51 
________________________________________________________________________ 
 
Female, n (%)       51 (83.6)             23 (79.3)       32 (62.7) 
 
Mean age (SD) yrs               39.8 (13.9)           34.4 (14.3)      36.6 (14.2) 
 
Abdominal complaints*, n (%)         38 (62.3)            13 (44.8)        10 (16.4)  
 
Malabsorption†, n (%)                 26 (42.6)    6 (20.7)         5 (9.8) 
 
Atypical symptoms‡, n (%)                     21 (34.4)    7 (24.1)         5 (9.8) 
          
Screening of risk groups§, n (%)        6 (9.8)     3 (10.3)         2 (11.7) 
 
Family history of CD, n (%)              19 (31.1)              6 (20.79)         2 (3.9) 
 
__________________________________________________________________________ 
 
*Chronic diarrhea, flatulence, abdominal pain 
†Weight loss, anaemia 
‡Aphthous stomatitis, cryptogenic hypertransaminasemia, polyneuropathy, migraine, 
arthralgia, alopecia, infertility, recurrent miscarriage 
§Type 1 diabetes, autoimmune thyroid disease, Sjögrens syndrome, osteoporosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supporting Table S2. Demographic data, genotyping, antibodies levels and metabolomic 
classification of the 29 potential CD subjects. 13 of them where analyzed again after GFD. 
 
 
N° Age (yr) Gender 
HLA  
genotyping 
tTG IgA 
Before GFD 
EMA IgA 
Before GFD 
CPMG 
classification 
Before GFD 
tTG IgA 
After 
GFD 
EMA IgA 
After GFD 
CPMG 
classification 
After GFD 
1 63 M DQ2/DQ2.2 > 100 POS CD 6 NEG Healthy 
2 36 M DQ2/DQ2 > 100 POS CD 12 Low POS Healthy 
3 50 F DQ2/DQ7 17.0 POS CD 6.4 NEG Healthy 
4 15 F DQ2/DQ5 18.6 POS CD    
5 16 F DQ2/DQ7 18.6 POS Healthy    
6 32 F DQ2/DQ7 22.4 NEG CD    
7 19 F DQ2/DQ8 > 100 POS CD 9.5 NEG Healthy 
8 18 F DQ2/DQ2.2 16.6 POS CD 4.3 NEG Healthy 
9 39 F DQ8/DQ6 19.4 POS CD    
10 44 F DQ2/DQ7 38.6 POS CD    
11 26 F DQ2/DQ7 31.5 POS CD    
12 49 F DQ8/DQ7 32.3 POS CD    
13 51 F DQ2/DQ7 26.0 POS CD    
14 23 F DQ2.2/DQ5 21.8 POS CD 4.7 NEG Healthy 
15 18 M DQ2/DQ5 38.1 POS CD    
16 34 F DQ2/DQ2.2 > 100 POS CD 14.2 POS Healthy 
17 30 F DQ2.2/DQ5 28.1 POS Healthy 3.9 NEG Healthy 
18 37 F DQ2/DQ7 19.5 POS CD 8.2 Low POS Healthy 
19 35 F DQ2.2/DQ6 32.5 POS CD    
20 45 M DQ2.2/DQ5 > 100 POS Healthy 25.2 POS Healthy 
21 44 F DQ2/DQ5 24.7 POS Healthy    
22 66 F DQ2/DQ7 38.2 POS Healthy 21 POS CD 
23 39 F DQ2/DQ2.2 16.1 POS CD 6.7 NEG Healthy 
24 48 F DQ2/DQ6 18.7 POS CD 16.9 POS Healthy 
25 20 M DQ2/DQ7 46.3 POS CD    
26 20 F DQ2/DQ7 80.4 POS CD    
27 35 M DQ2/DQ7 28.6 POS CD    
28 44 F DQ2/DQ7 23.1 POS CD    
29 38 F DQ2/DQ2.2 23.7 POS CD    
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Abstract 
 
Background: The identification and the present wide acceptance of 
cardiovascular risk factors such as age, sex, hypertension, hyperlipidemia, smoking, 
obesity, diabetes, and physical inactivity have led to dramatic reductions in 
cardiovascular morbidity and mortality. However, novel risk predictors present 
opportunities to identify more patients at risk and to more accurately define the 
biochemical signature of that risk. Method and Results: In this paper we present a 
comprehensive metabolic analysis of 864 plasma samples from healthy volunteers, 
from which we have inferred a pattern of metabolic alteration that correlates with 
accepted cardiovascular risk factors. From this pattern a novel link between classical 
cardiovascular risk indicators and oxidative stress of hepatic  cell mitochondria 
seems to emerge. Conclusions: A metabolic signature of cardiovascular risk exists, 
and its analysis may provide novel insight into the associated biochemical pathways 
and the current prevention therapies. 
 
Key Words: metabolism, risk factors, spectroscopy, cardiovascular diseases. 
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Introduction 
Cardiovascular diseases (CVDs) are the most common cause of death in the 
developed world. Each year, heart disease kills more Americans than cancer1. The 
morbidity, mortality, and socioeconomic importance of CVDs make timely accurate 
diagnosis and cost-effective management of the utmost importance. 
In most people, CVD stem from the combined effect of a number of causal risk 
factors. For this reason, risk estimation systems have been developed to assist 
clinicians to assess the effects of risk factor combinations in planning management 
strategies. Since it was first proposed in New Zealand in 1993, estimating 
cardiovascular risk has become an integral part of determining the eligibility for 
treatment with aspirin, antihypertensives or statins2. 
To date, the Framingham cardiovascular equation remains the most widely used 
method of assessing cardiovascular risk. This equation was derived from a large 
cohort study in the United States. It determines cumulative incidence (risk) of any 
vascular event in individuals free from cardiovascular disease, using a combination of  
predictors such as age, sex, systolic blood pressure, smoking status, total cholesterol 
level and high-density lipoprotein (HDL) cholesterol level and diabetic status3. 
Cardiovascular risk estimation is therefore a diagnostic test that has become a part of 
routine clinical practice. 
The major and independent risk factors for CVD are cigarette smoking, elevated 
blood pressure, elevated serum total cholesterol and low-density lipoprotein 
cholesterol (LDL), low serum HDL cholesterol, diabetes mellitus, and advancing age. 
The major risk factors are additive in predictive power. Accordingly, the total risk of a 
person can be estimated by a weighted sum of the risk imparted by each of the major 
risk factors. Other factors are associated with increased risk for CVD. These are of 
two types: conditional risk factors and predisposing risk factors. The conditional risk 
factors (elevated serum triglycerides, elevated serum homocysteine, elevated serum 
lipoprotein, prothrombotic factors (eg, fibrinogen), inflammatory markers (eg, C-
reactive protein)) are associated with increased risk for CVD although their causative, 
independent, and quantitative contributions to CVD have not been well documented. 
The predisposing risk factors (obesity, abdominal obesity, physical inactivity, family 
history of premature heart disease, ethnic characteristics and psychosocial factors) 
are those that aggravate the independent risk factors. The adverse effects of obesity 
are worsened when it is expressed as abdominal obesity, an indicator of insulin 
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resistance4. Abdominal obesity and insulin resistance (two significant predisposing 
factors) are a manifestation of the so called “metabolic syndrome” which in turn is a 
key in the evolution of cardiovascular disease. There is debate regarding whether 
obesity or insulin resistance is the cause of the metabolic syndrome or if they are 
consequences of a more far-reaching metabolic derangement. A number of markers 
of systemic inflammation, including C-reactive protein, are often increased, as are 
fibrinogen, interleukin 6 (IL–6), tumor necrosis factor-alpha (TNFα), and others. 
Some have pointed to a variety of causes including increased uric acid levels caused 
by dietary fructose4. 
Until now, no exhaustive metabolomic investigation of cardiovascular risk factors 
or, somewhat ironically, of the metabolic syndrome as such, has been reported, 
despite the major risk factors are essentially altered blood metabolites. The only 
exception is given by blood pressure that is already investigated by Nicholson at al6. 
However, because all of these alterations are of metabolic nature, we hypothesized 
that metabolomics would be an effective tool for a deeper investigation of the 
molecular mechanism and biochemical pathways involved in the composition of 
cardiovascular risk. 
Metabolomics has established itself as a useful complement to the 
characterization of pathologies. The metabolome can be considered the downstream 
of genome, transcriptome and proteome, and it is the best representation of a healthy 
or diseased phenotype of an organism. The metabolome, in fact, amplifies changes7-
9
 caused by a biological perturbation. As opposed to metabolomics, which places a 
greater emphasis on comprehensive metabolic profiling, metabonomics is more often 
used to describe multiple (but not necessarily comprehensive) metabolic changes 
caused by a biological perturbation. Metabonomics has been defined as “the 
dynamic multiparametric metabolic response of living systems to pathophysiological 
stimuli or genetic modification”10. 
Nuclear Magnetic Resonance (NMR)-based metabonomics offers evident 
advantages in contrast with knowledge-guided search of metabolites. NMR-based 
metabonomics makes no assumptions on the identity of the metabolites that are 
relevant for the selected pathology. Information on the metabolite pattern alterations 
that can be significantly associated to the pathology is directly obtained through 
statistical analysis of the NMR profiles. Usually, metabonomics does not rely on the 
measurement of a single metabolite-associated peak(s) but analyze the spectrum as 
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whole: in principle, an NMR profile contains qualitative and quantitative information of 
thousands different small molecules present in the sample11. Small changes in 
enzyme concentrations can be reflected in considerable alterations in intermediate 
products.  In addition, those metabolic networks are connected by few high crowded 
nodes, which can be investigated by NMR-based metabonomic analysis of biological 
fluids such as serum, plasma, and urine. 
NMR-based metabonomic studies have provided significant information on a wide 
range of pathologies, like cancer12-14, meningitis15, neurological disorders16, 
diabetes17, as well as a variety of gastrointestinal diseases18-20. 
In this study, we have examined the metabolic profile of 864 healthy volunteers 
with the aim of investigating the metabolic alterations characteristic of an increased 
cardiovascular risk. 
Methods 
 
Volunteers Recruitment 
The volunteers participating in this study were recruited by the Tuscanian section 
of the Italian Association of Blood Donors (AVIS). In total 864 adult healthy 
volunteers (678 males, 186 females, mean age 40.87 ± 11.0 yrs, Table 1), 
participated in this study.  
Plasma samples were obtained from the Transfusion Service of Pistoia Hospital, 
following the Standard Operating Procedures (SOPs) defined for blood donation in 
Italy. Each subject had fasted overnight, and blood samples were collected in the 
morning preprandial. The SOPs require that a separate backup tube of plasma from 
donors is stored at +4 °C during the following 24 hours, in case of necessity of further 
clinical analysis. Normally these tubes are disposed after that time. These tubes 
where instead collected and stored at -80 °C for our metabolic analyses.   
Written informed consent was obtained from all volunteers. 
 
NMR Samples Preparation 
Frozen plasma samples were thawed at room temperature and shaken before 
use. 300 µl of a phosphate sodium buffer were added to 300 µl of each plasma 
sample, and 450 µL of this mixture were transferred into a 4.25 mm NMR tube 
(Bruker BioSpin srl) for analysis. Full details are reported in Supplemental Material. 
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NMR Analysis and spectral processing 
One-dimensional 1H-NMR spectra of plasma samples were measured on a 
spectrometer operating at 600MHz proton Larmor frequency using standardized 
protocols (see Supplemental Material). Each spectra in the region 10.00-0.02 ppm 
was segmented into 0.02-ppm chemical shifts bins prior any statistical analysis. 
 
Statistical Analysis 
The statistical procedure used is a combination of Partial Least Square, followed 
by Canonical Correlation Analysis (CA), followed by Support Vector Machines (SVM) 
on the CA scores. SVM are used both for classification and for regression.  
The accuracy for classification and regression was assessed by means of a 
double cross-validation scheme21. From this procedure we obtain unbiased error 
estimations for both classification and regression. For regression we reported also 
the R2 between the true clinical values and the mean cross-validated predicted 
values for each sample.  
For classification purposes the groups are created by dividing samples in two 
classes represented by the highest and the lowest quintiles, respectively, relative to 
the target variable: HDL <44 and >63 (42 vs. 44 individuals, respectively), LDL <100 
and >160 (42 vs. 44 samples), TC <174 and >232 (153 vs.153), TC/HDL ratio <3 and 
>4.90 (40 vs. 40),  triglycerides <60 and >131 (150 vs. 151), glycaemia <78 and >105 
(148 vs. 153), Framingham score <1.25 and >7.00 (40 vs. 40). For regression 
analyses all the available samples were used: 206 for HDL, 199 for LDL, 715 for TC, 
205 for TC/HDL ratio, 709 for triglycerides, 693 for glycaemia and 201 for 
Framingham score. Different numbers of individuals in each class are due to the fact 
that not for all individuals all clinical parameters were available. 
To assess which buckets (that is, resonance peaks) were significantly different 
between different groups a univariate wilcoxon test was used. A P-value ≤ .001 (with 
Bonferroni correction for multiple tests) was considered statistically significant.  
All calculations were made using home-made scripts written in R language22. 
Further references and information on statistical methods are reported in 
Supplemental Material. 
Results 
We have performed several through statistical analyses in order to ascertain 
whether metabolic fingerprint of the plasma samples contain predictive information 
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about the global status of the individuals. As a first inspection we have done a 
classification analysis, using as predictor the full NMR profile, with respect to the total 
cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides, and glycaemia. The 
results are shown in Tables 2-8 for CPMG and noesy spectra and in Supplemental 
Tables S1-S6 for diffusion edited spectra. Values of sensitivity, specificity and 
accuracy, obtained from a non-biased double cross-validation procedure21, are 
reported. As we can see, all the accuracy values are very good, always higher than 
95% for all classifications and kind of 1-D spectra (CPMG, NOESY, diffusion edited), 
except for glycaemia, with accuracy around 85%. The separation obtained plotting 
the CA scores is also very clear (Figure 1). With these encouraging results, a more 
sophisticated regression analysis was also attempted, with the aim of establishing a 
quantitative relationship between clinical data and NMR spectra. Figures 2 and 3 
show the agreement between the predicted values of HDL and LDL cholesterol with 
the “true” values given by the clinical analysis. The mean relative error is less than 
10% in both cases. These striking results are not completely unexpected, because 
the NMR spectra (especially NOESY and diffusion edited) contain several strong 
peaks directly related to the lipidic components of the plasma. To confirm that 
metabolomics is able to extract also more subtle metabolic information, we tested 
whether we could classify individuals with high and low values of TC or glycaemia 
even after removing from the spectra all signals arising from lipids or glucose, 
respectively. The good accuracy obtained (75% in both case) is a convincing 
indicator that the changes in the blood composition are global phenomena that 
involve several metabolic alterations, and that metabolomics is able to outline all 
these effects simultaneously. 
As it is well known that low levels of HDL cholesterol and high levels of TC 
correlated to high risk of developing CVDs, we performed the same analyses also for 
the TC/HDL ratio. Again the results, both for classification and regression, are 
extremely good, with accuracy for classification even higher than for the two risk 
factors taken separately (Table 7), and R2 of 0.88 for regression (Figure 4). 
Analogously good values are obtained for the HDL/LDL ratio.  
Finally, having in hands the clinical data of the subjects, we decided to calculate 
also the well established Framingham score for each individual, using the equation of 
Wilson et al3. This score combines age, sex, systolic blood pressure, smoking status, 
TC level, HDL level and diabetic status in order to derive a probability of major 
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cardiovascular event in the following ten years. A classification was again performed 
by splitting the data into the quintiles with the highest score and the quintiles with the 
lower score. The accuracy is high (over 89% with the NOESY spectra) but lower than 
in the previous analysis (Table 8). This may due to the fact that the Framingham risk 
score considers also non-analytical variables, but it can derive also from the fact that 
we are able to extract a far richer and more complex metabolic pattern. 
These findings confirm that the metabolomic approach to the study of blood 
composition is feasible and provides a comprehensive picture of the underlying 
multifactorial mechanisms arising from the interactions between genomics and 
environment.  
In order to identify the metabolites that are most characteristic of the metabolic 
fingerprint of cardiovascular risk we apply a univariate wilcoxon test on the different 
groups, using a significance level of P<.001, after applying a Bonferroni correction. 
We find that individuals with high plasma levels of HDL are characterized by lower 
levels of creatinine and threonine, and by higher levels of 3-hydroxybutirrate (3-HB). 
Individuals with high plasma levels of LDL are characterized by lower levels of α-
ketoglutarate and dimethylglycine. Individuals with high levels of TC are 
characterized by lower levels of α-ketoglutarate, dimethylglycine and serine. 
Individuals with high levels of triglycerides have a more complex pattern, with lower 
levels of several metabolites: acetate, creatine, creatinine dimethylglycine, 3-HB, 
isoleucine, methionine, phenylalanine and serine, and higher levels of threonine. 
Because 3-HB signals in 1-D spectra are partially covered by other signals, the 
significance value of 3-HB has been also confirmed using J-RES projection were this 
signal is well resolved. 
The complete chart of the most significant metabolites found is reported in Table 
9. Because our aim is to find a metabolic pattern that correlates with an increase of 
cardiovascular risk we performed the same analysis only considering subjects with 
high level of HDL and low levels of LDL cholesterol (i.e. the “lowest risk” people), 
ordered by the HDL/LDL ratio. This metabolic pattern is strongly characterized by 
lower levels of creatinine and threonine, and by higher levels of 3-HB. 
 
Discussion 
The statistical results obtained by classification and regression analysis are 
extremely encouraging, suggesting that the whole plasma spectrum profile contains 
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meaningful information about the metabolic status of individuals. Also CPMG spectra 
(that essentially do not contain peaks associated with lipoproteins) are able to predict 
with high accuracy the clinical data. This reinforces the view that we are effectively 
following global metabolic changes and not only obvious patterns of lipids and 
lipoproteins peaks. In order to prove this statement we also tried to completely 
remove spectral regions with peaks associated with lipid fractions (for TC analysis) 
and with glucose (for glycaemia analysis). Although the accuracy decreases around 
75% (both for TC and glycaemia), it is still highly significant, especially if we consider 
that we have removed more than 100 spectral buckets (25% of the total) in order to 
be on the safe side.  
These results allow us to explore the metabolite composition of plasma profiles, in 
order to characterize what is typical of an undoubtedly a “low risk” status (high HDL 
levels, low LDL levels, low triglycerides and low glycaemia) and what is typical of a 
high risk status (the reverse). From the point of view of this comprehensive metabolic 
analysis it seems that the “low risk” pattern is mostly constituted by high levels of 3-
HB and low levels of threonine and creatinine. On the other hand the “high risk” 
pattern is more complex, and is characterized by low levels of several metabolites, in 
particular α-ketoglutarate, dimethylglycine and serine.   
Having in hand the results of metabolite profiling one might already attempt to 
elaborate new hypothesis about the origin of the metabolic syndrome and its 
connection with cardiovascular risk. In particular our findings seem to highlight the 
role of 3-HB, α-ketoglutarate, threonine and dimethylglycine as the key to disentangle 
the fingerprint associated to high or low cardiovascular risk. All these metabolites are 
related to the mitochondrial activity. 
3-HB is generated by fatty acid beta-oxidation, a process involving a 
mitochondrial oxido-reductase superfamily, with fatty acid-CoA thioesters as 
substrates. The enzyme 3-hydroxybutyrate dehydrogenase maintains the equilibrium 
between 3-HB and acetoacetate. The equation is  
 
3-hydroxybutyrate + NAD+    acetoacetate + NADH + H+ 
 
It is known that the ketone bodie 3-HB has a protective role in a broad spectrum 
of cerebral injuries and diseases and they preserve neuronal cell integrity and 
stability in vitro23-25. From these observations it was inferred that mitochondrial 
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dysfunction plays a significant role in common neurological diseases26. In the same 
way our data show that high levels of circulating 3-HB correlate with a high HDL/LDL 
ratio that, in turn, is related to a reduced risk of cardiovascular event. Analogously, 
the role of mitochondria can be invoked. The acetoacetate to 3-hydroxybutyrate ratio 
is a good indicator of the mitochondrial NAD+/NADH redox ratio in the mitochondria 
of hepatic cells27,28. Usual values of the ratio in healthy subjects are highly variable 
and ranges between 0.96 to 2.5529.  
In our findings, because the level of acetoacetate seems not to vary as a function 
of the HDL/LDL ratio, but 3-HB show a positive correlation, the final ratio between the 
acetoacetate and 3-HB decreases in the case of the “low risk” profile. Although the 
use of ketone bodies ratio is not new in the literature (expecially for monitoring the 
mitochondrial activity in the liver of patients with hepatic failure30), at the best of our 
knowledge this is the first time that this figure is related with LDL and HDL levels in 
the blood and, in turn, with metabolic syndrome and enhanced risk of cardiovascular 
disease. We can hypothesize that oxidative stress enhance the oxidation of 3-HB to 
acetoacetate, reducing its plasma level. 
The mechanism that correlates “low risk” plasma parameters with high levels of 3-
HB may be related to the ability of 3-HB to bind the HM74A receptor expressed in 
adipocytes, resulting in inhibition of the lipolysis and thereby reducing free fatty acids 
plasma levels. This receptor is know to bind nicotinic acid, the first drug available for 
lowering LDL levels while, concomitantly, raising the HDL levels. Although the clinical 
use of nicotinic acid goes back to the fifties31, remarkably, its putative mechanism of 
action has only been recently proposed32. This receptor responds to both nicotinic 
acid and the ketone body 3-HB, and the latter is thought to be the probable 
endogenous ligand for HM74A. Hence the occupancy of HM74A receptor by 
circulating 3-HB could represent a physiological feedback cycle for the control of 
lipolysis rate33. 
 
α-ketoglutarate is a key intermediate in the Krebs cycle, coming 
after isocitrate and before succinyl CoA.  The cycle can be filled at this juncture by 
synthesizing α-ketoglutarate through the action of glutamate dehydrogenase on 
glutamate. 
The first information about the influence of α-ketoglutarate on blood serum 
cholesterol was presented by Bazzano & Bazzano34 in 1972. The authors 
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documented a 66% lower level of cholesterol in the blood serum of male Mongolian 
gerbils treated with α-ketoglutarate. Additionally, they observed a 15 % decrease in 
body weight in animals fed with an experimentally prepared diet containing 
α-ketoglutarate. More recently35 it was proved that oral treatment with α-ketoglutarate 
can decrease the risk of hypercholesterolaemia developing, decrease the blood 
serum concentration of the LDL cholesterol, increase the concentration of HDL 
cholesterol, and can lower the body weight. 
Because, in our findings, low levels of α-ketoglutarate are associated with 
increased cardiovascular risk, we can hypothesise an imbalance of the 
concentrations of the redox substrates of glutamate dehydrogenase due to some 
alteration of the mitochondrial redox potential. 
 
In addition to these considerations, it is interesting to note that most of the 
aminoacids concentrations are lower with high levels of triglycerides, with the 
exception of threonine. 
Intriguingly, the catabolism of threonine is regulated by threonine deydrogenase 
(THD), which is a mitochondrial enzyme which catalyzes NAD+-dependent oxidation 
of threonine to 2-amino-3-oxobutyric acid, which in turn is very rapidly metabolized by 
2-amino-3-oxobutyrate-CoA ligase to glycine and acetyl-CoA36. The formation 
of acetyl-CoA from ligase is so fast that acetyl-CoA in practice is considered a 
product of TDH36. Acetyl-CoA is derived from TDH, but also from fatty acids by β-
oxidation. Excessive formation of acetyl-CoA by TDH would inhibit both the β-
ketothiolase reaction and β-oxidation by the law of mass action, playing a biological 
role in the regulation of fatty acid breakdown, biosynthesis, and in ketone bodies 
formation. A fine regulation balances threonine concentration under different 
conditions and TDH is the target of selective, feedback inhibition by all compounds 
derived from its major product, acetyl-CoA and,  remarkably, by 3-HB36. 
 
Dimethylglycine is a tertiary amino acid, which is an intermediary metabolite in the 
choline pathway, as it is formed in liver mitochondria by removal of one methyl group 
from betaine37. It can be metabolized in liver mitochondria, rendering both its methyl 
groups through transmethylation of tetrahydrofolate, and free glycine38,39. Recently it 
was found that a dietary supplement of dimethylglycine in chickens diet significantly 
reduces the deposition of dietary fat into abdominal depot tissue and the fasted non-
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esterified fatty acid plasma level significantly decreased with increasing 
dimethylglycine level40. Coherently, we found that patients with high levels of 
triglycerides have lower levels of plasma dimethylglycine.   
 
It is hypothesised in41 that a mitochondrial dysfunction can be the starting point for 
the development of insulin resistance in adolescents with familiar history of type-2 
diabetes, reporting that rates of mitochondrial substrate oxidation were decreased by 
30% in lean, insulin-resistant offspring compared with insulin-sensitive control 
subjects. This observation can be easily linked to our findings, moving the starting 
point of obesity, insulin resistance, and of the risk of developing cardiovascular injury 
to the mitochondrial activity. 
Although a full clarification of a so complex machinery is far away, we can 
suggest that an imbalance in the mitochondrial redox potential (caused by oxidative 
stress), can lead to an alteration of the fatty acids beta-oxidation pathway with an 
increased secretion of LDL lipoproteins in the blood. We can also hypothesize that 
this mechanism amplify itself by the complementary action of the discussed 
metabolites, as show in Figure 5.  
 
Finally, the good agreement with the calculated values of Framingham score 
supports the idea that metabolomic analysis of plasma samples can be an effective 
tool for monitoring the individual healthy status, and, in particular the risk of 
developing metabolic syndrome and cardiovascular disease. The mismatches 
between our prediction and the true Framingham values can be due to our ability to 
unravel subtle metabolic changes, which are not included in the classical risk scores. 
Our observations strongly suggest that metabolomic analyses should be included in 
future year-long prospective studies and new (and possibly more efficient) 
cardiovascular score will be formulated on the basis of the whole metabolic 
fingerprint and/or on the basis of the plasma concentration of the discussed 
metabolites. 
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Figure Legends 
 
Figure 1. Clusterization of high (triangles) and low (circles) quintiles of TC (A), LDL 
(B), HDL (C), and triglycerides (D) and glycaemia (E) values. 
 
Figure 2. Correlation between true values (x axis) and predicted on the basis of 
noesy spectra (y axis) for HDL levels. (R2=0.83) 
 
Figure 3. Correlation between true values (x axis) and predicted on the basis of 
noesy spectra (y axis) for LDL levels. (R2=0.88) 
 
Figure 4. Correlation between true values (y axis) and predicted on the basis of 
noesy spectra (x axis) for TC/HDL levels. (R2=0.88) 
 
Figure 5. Metabolic effect of the discussed metabolites in high risk subjects. 
 18 
Table 1. Average clinical data for recruited volunteers. 
 
Female = 186 Mean St. Deviation Max Min 
Age 41.81 11.92 65 19 
Glycaemia 87.85 13.94 175 45 
Creatinine 0.773 0.108 1.14 0.54 
Cholesterol 211.8 39.04 366 139 
Triglycerides 85.15 54 556 39 
HDL 65.08 13.46 98 43 
LDL 134 40.63 219 69 
Blood pressure 
Max 119.1 10.48 160 110 
Blood pressure 
Min 77.77 7.05 100 65 
Cardiac 
Frequency 71.74 5.47 88 52 
 
 
Male = 678 Mean St. Deviation Max Min 
Age 40.62 10.8 71 19 
Glycaemia 90.14 12.54 226 65 
Creatinine 0.97 0.124 1.54 0.32 
Cholesterol 201.8 38.05 339 75 
Triglycerides 106.87 64.53 635 30 
HDL 51.6 11.35 99 29 
LDL 129.86 36.39 231 42 
Blood pressure 
Max 124.4 10.71 160 100 
Blood pressure 
Min 81.44 7 100 60 
Cardiac 
Frequency 69.66 6.14 90 48 
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Table 2. Confusion matrices for TC classification. 
 
CPMG Low Values  (< 174) 
High Values  
(> 232) N = 306 (153 vs 153)   
Low 96.13% 3.87%   Sensitivity 
High 3.22% 96.78%   Specificity 
      96.50% Accuracy 
 
NOESY Low Values  (< 174) 
High Values  
(> 232) N = 306 (153 vs 153)   
Low 97.60% 2.40%   Sensitivity 
High 1.94% 98.06%   Specificity 
      98.07% Accuracy 
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Table 3. Confusion matrices for LDL classification. 
 
CPMG Low Values  (< 100) 
High Values  
(> 160) N = 85 (42 vs 43)   
Low  99.01%  0.99%   Sensitivity 
High  3.27%  96.73%   Specificity 
       98.30% Accuracy 
 
NOESY Low Values  (<100) 
High Values  
(>160) N = 85 (42 vs 43) 
Low  100% 0%   Sensitivity 
High  2.04%  97.96%   Specificity 
       98.94% Accuracy 
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Table 4. Confusion Matrices for HDL classification. 
 
CPMG Low Values  (< 44) 
High Values  
(> 63) N = 82 (42 vs 40)   
Low  92.87% 7.13%   Sensitivity 
High  5.14% 94.86%   Specificity 
       92.80% Accuracy 
 
NOESY Low Values  (<44) 
High Values  
(>63) N = 82 (42 vs 40) 
Low  98.87% 1.33%   Sensitivity 
High 1.15%  98.85%   Specificity 
       98.81% Accuracy 
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Table 5. Confusion Matrices for triglycerides classification. 
 
CPMG Low Values  (< 60) 
High Values  
(> 131) N = 351 (150 vs 151)   
Low 97.77% 2.23%   Sensitivity 
High 3.09% 96.91%   Specificity 
      97.48% Accuracy 
 
NOESY Low Values  (< 60) 
High Values  
(> 131) N = 351 (150 vs 151)   
Low 98.18% 1.82%   Sensitivity 
High 2.95% 97.05%   Specificity 
      97.37% Accuracy 
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Table 6. Confusion Matrices for glycaemia classification. 
 
CPMG Low Values  (<81) 
High Values  
(>96) N = 301 (148 vs 153)   
Low 85.89% 14.11%   Sensitivity 
High 14.68% 85.32%   Specificity 
      85.65% Accuracy 
 
NOESY Low Values  (<81) 
High Values  
(>96) N = 301 (148 vs 153)   
Low 76.8% 23.2%   Sensitivity 
High 20.8% 79.2%   Specificity 
      78.02% Accuracy 
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Table 7. Confusion Matrices for TC/HDL ratio classification. 
  
CPMG Low Values  (< 3) 
High Values  
(> 4.90) N = 80 (40 vs 40)   
Low  98.15% 1.85%   Sensitivity 
High  1.06% 98.94%   Specificity 
      98.19% Accuracy 
 
NOESY Low Values  (<3) 
High Values  
(>4.90) N = 80 (40 vs 40) 
Low  100% 0%   Sensitivity 
High 2.25%  97.75%   Specificity 
       98.69% Accuracy 
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Table 8. Confusion Matrices for Framingham risk score classification. 
 
CPMG Low Values  (< 1.25) 
High Values  
(> 7.00) N = 80 (40 vs 40)   
Low 88.40% 11.92%   Sensitivity 
High 11.54% 88.07%   Specificity 
      88.21% Accuracy 
 
NOESY Low Values  (< 1.25) 
High Values  
(> 7.00) N = 80 (40 vs 40)   
Low 89.17% 10.83%   Sensitivity 
High 8.83% 91.17%   Specificity 
      89.68% Accuracy 
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Table 9. Statistically significant metabolites. Plus or minus signs means that the 
selected metabolite is high or low where the levels of clinical variabiles are high.  
 
 LDL TC TRI HDL HDL/LDL 
3-HB    + + 
Acetate   -   
Alfa Ketoglutarate - -    
Citrate   -   
Creatine   -   
Creatinine   - - - 
Dimethylglycine - - -   
Glucose   -   
Isoleucine   -   
Methionine   -   
Phenylalanine   -   
Serine  - -   
Threonine   + - - 
Tyrosine   -   
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Figure 1. Clusterization of high (triangles) and low (circles) quintiles of TC (A), LDL 
(B), HDL (C), and triglycerides (D) and glycaemia (E) values. 
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Figure 2. Correlation between true values (x axis) and predicted on the basis of 
noesy spectra (y axis) for HDL levels. (R2=0.83) 
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Figure 3. Correlation between true values (x axis) and predicted on the basis of 
noesy spectra (y axis) for LDL levels. (R2=0.88) 
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Figure 4. Correlation between true values (y axis) and predicted on the basis of 
noesy spectra (x axis) for TC/HDL levels. (R2=0.88) 
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Figure 5. Metabolic effect of the discussed metabolites in high risk subjects. 
 
 
 
 
Supplemental Material 
 
Supplemental Methods 
 
NMR Samples Preparation 
Frozen plasma samples were thawed at room temperature and shaken before 
use.  300 µl of a phosphate sodium buffer (70 mM Na2HPO4; 20% v/v 2H2O; 0.025% 
v/v NaN3; 0.8% w/v sodium trimethylsilyl [2,2,3,3-2H4]propionate (TSP); pH 7.4) were 
added to 300 µl of each plasma sample, and the mixture was homogenized by 
vortexing for 30 s. 450 µL of this mixture were transferred into a 4.25 mm NMR tube 
(Bruker BioSpin srl) for analysis. 
 
NMR Analysis 
1H NMR spectra for all samples were acquired using a Bruker 600 MHz 
spectrometer (Bruker BioSpin) operating at 600.13 MHz proton Larmor frequency 
and equipped with a 5 mm CPTCI 1H-13C/31P-2H cryo-probe including a z axis 
gradient coil, an automatic tuning-matching (ATM) and an automatic sample changer. 
A BTO 2000 thermocouple served for temperature stabilization at the level of 
approximately 0.1 K at the sample. Before measurement, samples were kept for at 
least 3 min inside the NMR probehead, for temperature equilibration (310 K). 
One-dimensional (1-D) spectra of plasma samples were acquired using a 
Carr−Purcell−Meiboom−Gill (CPMG; Bruker) spin−echo sequence to suppress 
signals arising from high molecular weight molecules, a standard pulse sequence 
(NOESYpresat), diffusion edited sequence using a diffusion time of 120 ms and fast 
two-dimensional (2-D) J-Resolved experiments (J-RES). 
 
Spectral Processing 
Free induction decays were multiplied by an exponential function equivalent to a 
1.0 Hz line-broadening factor before applying Fourier transform. Transformed spectra 
were automatically corrected for phase and baseline distortions and calibrated 
(TMSP peak at 0.00 ppm) using TopSpin (Version 2.1, Bruker). Each 1-D spectrum 
in the range between 0.02 and 10.00 ppm was segmented into 0.02-ppm chemical 
shift bins, and the corresponding spectral areas were integrated using AMIX software 
(Bruker BioSpin). Regions between 6.0 and 4.5 ppm containing residual water were 
removed. The total spectral area was calculated on the remaining bins and 
normalization was carried out on the data prior to statistical analysis. The projection 
of each 2-D J-RES spectrum was segmented and processed as described below for 
the 1-D spectra. 
 
Statistical Analysis 
Data reduction was obtained by means of Partial Least Square (PLS) on the 
mean-centred data without scaling, using the classical SIMPLS algorithm1 as 
implemented in the R-library “plsgenomics”. Canonical Correlation Analysis (CA) was 
performed using standard R functions. For the purpose of regression and 
classification we used the Support Vector Machines (SVM) method2 applied on the 
CA scores. The “libsvm” module3 of the R-library “e1071” was used.  
The statistical procedure used is a combination of PLS for data reduction (i.e. to 
reduce the initial number of variable and denoise the data) followed by CA (for further 
reduction and to have a clearer picture of the discrimination rule) followed by SVM on 
the CA scores. SVM are used both for classification and for regression (“C-
classification” and “eps-regression” settings) 
Sensitivity, specificity and accuracy, were estimated using standard definitions4. 
The accuracy for classification and regression was assessed by means of a double 
cross-validation scheme5. The original data set was split in a training set (90%) and a 
test set (10%) prior to any step of statistical analysis. Parameter selection (best 
number of PLS components, kernel type and cost of constraints violations for SVM) 
was carried out by 7-fold cross validation on the 90% training set. The whole 
procedure was repeated 100 times inside a Monte Carlo cross validation scheme. 
From this procedure we obtain unbiased error estimations for both classification and 
regression. For regression we reported also the R2 between the true clinical values 
and the mean cross-validated predicted values for each sample.  
For classification purposes the groups are created by dividing samples in two 
classes represented by the highest and the lowest quintiles, respectively, relative to 
the target variable: HDL <44 and >63 (42 vs. 44 individuals, respectively), LDL <100 
and >160 (42 vs. 44 samples), TC <174 and >232 (153 vs.153), TC/HDL ratio <3 and 
>4.90 (40 vs. 40),  triglycerides <60 and >131 (150 vs. 151), glycaemia <78 and >105 
(148 vs. 153), Framingham score <1.25 and >7.00 (40 vs. 40). For regression 
analyses all the available samples were used: 206 for HDL, 199 for LDL, 715 for TC, 
205 for TC/HDL ratio, 709 for triglycerides, 693 for glycaemia and 201 for 
Framingham score. Different numbers of individuals in each class are due to the fact 
that not for all individuals all clinical parameters were available. 
To assess which buckets (that is, resonance peaks) were significantly different 
between different groups a univariate wilcoxon test was used. A P-value ≤ .001 (with 
Bonferroni correction for multiple tests) was considered statistically significant. All 
resonances of interest were then manually checked, and signals were assigned on 
template one-dimensional NMR profiles by using matching routines of AMIX 7.3.2 
(Bruker BioSpin) in combination with the BBIOREFCODE (Version 2-0-0; Bruker 
BioSpin) reference database and published literature when available.  
All calculations were made using home-made scripts written in R language6. 
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Supplemental Tables 
 
Table S1. Confusion matrices for TC classification using diffusion edited spectra. 
 
DIFF Low Values  (< 174) 
High Values  
(> 232) N = 305 (152 vs 153)   
Low 97.75% 2.25%   Sensitivity 
High 1.81% 98.19%   Specificity 
      97.91% Accuracy 
 
Table S2. Confusion matrices for LDL classification using diffusion edited spectra. 
 
DIFF Low Values  (<100) 
High Values  
(>160) N = 85 (42 vs 43) 
Low  98.97% 1.03%   Sensitivity 
High 2.88% 97.12%   Specificity 
      98.85% Accuracy 
 
Table S3. Confusion matrices for HDL classification using diffusion edited spectra. 
 
DIFF Low Values  (<44) 
High Values  
(>63) N = 82 (42 vs 40) 
Low  97.52% 2.48%   Sensitivity 
High 2.03% 97.97%   Specificity 
      97.83% Accuracy 
 
Table S4. Confusion matrices for triglycerides classification using diffusion edited 
spectra. 
 
DIFF Low Values  (< 60) 
High Values  
(> 131) N = 350 (149 vs 151)   
Low 98.28% 1.72%   Sensitivity 
High 2.73% 97.27%   Specificity 
      97.42% Accuracy 
 
Table S5. Confusion matrices for TC/HDL ratio classification using diffusion edited 
spectra. 
 
DIFF Low Values  (<3) 
High Values  
(>4.90) N = 80 (40 vs 40) 
Low  98.68% 1.32%   Sensitivity 
High 0.17% 99.83%   Specificity 
      99.35% Accuracy 
 
Table S6. Confusion matrices for Framingham risk score classification using diffusion 
edited spectra. 
 
DIFF Low Values  (< 1.25) 
High Values  
(> 7.00) N = 80 (40 vs 40)   
Low 87.73% 12.27%   Sensitivity 
High 9.63% 90.37%   Specificity 
      88.91% Accuracy 
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Effects of Ozone Blood Treatment on the
Metabolite Profile of Human Blood
Valter Travagli,1 Iacopo Zanardi,1 Patrizia Bernini,2 Stefano Nepi,2
Leonardo Tenori,2 and Velio Bocci1
Abstract
Metabonomic characterization of the effects caused by ozone and other stressors on normal human blood was performed.
Samples of blood obtained from healthy subjects were treated ex vivo with increasing concentrations of ozone and/or with
UV radiation and heat. 1H-NMR analysis of plasma samples after treatments showed the quantitative variation of some metabo-
lites and the formation of new metabolites normally absent. Both the increment of some metabolites like formate, acetoacetate,
and acetate and the decrement of pyruvate were of particular interest. Moreover, the oxidation of ascorbic acid and the trans-
formation of uric acid into allantoin after ozonation within the therapeutic concentration range were observed. In the ozonated
spectra, 2 unidentified peaks appeared at 2.82 ppm and 8.08 ppm. They are related to the direct antioxidant activity of albumin in
the presence of ozone and they could be considered as specific markers of the blood ozonation.
Keywords
ozone toxicity, 1H-NMR, reactive oxygen species, oxidative stress, metabonomic profile
Reactive oxygen species (ROS) represent an area of intensive
research and include both free radicals and nonradical species,
among which ozone plays an important role (Table 1).1 In the
stratosphere, ozone constitutes the protective layer around the
planet, whereas at ground level ozone is a pollutant. Previous
results2-5 show that ozone causes lipid peroxidation and can
generate a variety of compounds, as summarized in Figure 1.
At the same time, because of its fungicidal, virucidal, and bac-
tericidal properties, ozone is used to purify the drinking water
in many municipalities.6
Ozone for therapeutic purposes has been used on a rather
empirical basis by many practitioners in the world. There are
specific applications of ozone therapy in a number of patholo-
gies, such as vascular diseases, ulcers, and acute and chronic
viral diseases. On the basis of some biochemical studies7-10
performed during the last 15 years, a framework for under-
standing the basic mechanisms of action of ozone when it
comes in contact with human blood at appropriate doses is now
available. These data have been critically reviewed,11,12 and
the following biological responses can be summarized: (a)
improvement of blood circulation and oxygen delivery to
ischemic tissue, owing to the concerted effect of nitric oxide
and CO and a variable increase of intraerythrocytic (2,3-dipho-
sphoglycerate) 2,3-DPG level13,14; (b) enhancement of the gen-
eral metabolism13; (c) upregulation of the cellular antioxidant
enzymes and induction of heme oxygenase 1 (HO-1) and heat
shock protein-70 (HSP-70)14,15; (d) induction of a mild activa-
tion of the immune system7,8 and enhancement of the release of
growth factors from platelets16; and (e) excellent disinfectant
activity when topically used in water and oils,17,18 although this
is negligible in the circulation owing to the potent blood anti-
oxidant capacity.19 Moreover, adequate ozone treatments do
not induce acute or chronic side effects, and often patients
report a feeling of wellness.13 However, an in-depth evaluation
of ozone impact on blood by studying the formation of
metabolites appears to be valuable.
In this specific case, metabonomics has been often used to
describe multiple metabolic changes caused by a biological
perturbation. Metabonomics has been defined as ‘‘the dynamic
multiparametric metabolic response of living systems to
pathophysiological stimuli or genetic modification.’’20
Nuclear magnetic resonance (NMR)–based metabonomics
offers evident advantages in contrast with knowledge-guided
search of metabolites in biofluid samples. NMR-based metabo-
nomics makes no assumptions about the identity of the metabo-
lites that are relevant for the investigated aspects. Information
on the metabolite pattern alterations is directly obtained
through statistical analysis of the NMR profiles. Usually,
metabonomics does not rely on the measurement of a single
metabolite-associated peak but analyzes spectra as a whole:
metabonomic profiles essentially are the superposition of the
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1H-NMR spectra of tens to thousands of different small mole-
cules (up to 2500 in the case of urine and up to 200 in the case
of blood) present in the sample at greater than 1 mM concentra-
tion.21 In principle, an NMR profile contains qualitative and
quantitative information on all of them.1 Small changes in
enzyme concentrations can cause considerable alterations in
intermediate products, and owing to the fact that metabolic net-
works are interconnected, NMR-based metabonomic analysis
of biological fluids such as serum, plasma, and urine can be
very useful.
NMR-based metabonomic studies have provided significant
information on a wide range of pathologies, such as cancer,22 as
well as a variety of gastrointestinal pathologies.23 Not surpris-
ingly, the latter are more likely to be associated with metabolic
alterations, among them Helicobacter pylori infection.24
Recently, therapeutic ozone application in clinical dentistry
by high-resolution 1H-NMR has been studied.25
The purpose of the present study was to investigate ex vivo
the effect on the plasma metabonomic profile as obtained by
(1) blood ozonation within the therapeutic concentration,
(2) blood ozonation at high concentrations, and (3) blood
ozonation at abnormally high concentration associated with
other stressors, as performed by Torre-Amione et al.26 The
present investigation appears to be significant in that it defines
definite alterations and toxicity regarding the amount of
metabolites and suggests specific markers of oxidative stress
induced by ozone blood treatment. In a future work, after rein-
fusing ozonated blood in the donor, we will investigate whether
these metabolites appears in the circulation or in excreta.
Methods
Ozone Generation
Ozone was generated frommedical-grade oxygen using electri-
cal corona arc discharge, by 2 generators:
1. Ozonline ECO3 (Torino, Italy), which delivers ozone con-
centrations between 0.1 and 3.0 mg/mL of gas, with a gas
flow ranging from 100 mL/min (15 L/h) up to 1 L/min
(60 L/h).
2. Ozonosan PM 100K (Hansler GmbH, Iffezheim, Ger-
many), which can deliver to either blood, plasma, or other
samples ozone concentrations up to 80 mg/mL with a gas
flow ranging between 1 and 8 L/min.
In all cases, the ozone concentration is monitored continuously
by photometry at 600 nm (Chappuis band), periodically
checked by iodometric titration, as recommended by the Stan-
dardization Committee of the International Ozone Association.
The photometer was periodically checked by using the iodo-
metric titration in observance of the rules established by Inter-
national Ozone Association. Blood ozonation must be carried
out only using medical oxygen and not filtered air because it
contains 78% of nitrogen with the inherent formation of nitro-
gen oxides.
Single-use silicon treated polypropylene syringes (ozone-
resistant) and tygon polymer tubing were used throughout the
reaction procedure to ensure containment of ozone and consis-
tency in concentrations.
Collection of Human Blood
Several blood samples of 60 mL were taken from 2 healthy,
nonsmoking, male blood donors in the morning. Either sodium
citrate 3.8% (1 mL/9 mL of blood) or EDTA (final concentra-
tion, 1.35 mg/mL) was used as the anticoagulant, and blood
samples were immediately subdivided and introduced in
ozone-resistant syringes (5 mL) or in a quartz vessel (10 mL)
with a thermostat. The experimental program was allowed by
the Ethical Committee on the basis of informed consent signed
by 2 (V.T. and I.Z.) of the experimenters.
Sample Treatments
In experiment A, blood was treated with a single dose of ozone
(concentration per volume) ex vivo as follows: A predeter-
mined volume of a gas mixture composed of oxygen (95%-
99%) and ozone (1%-5%), at ozone concentrations 20, 40,
80, 160, 240, 320, and 800 mg/mL (from 0.42 to 16.8 mmol/mL),
was collected with a syringe and immediately introduced via a
multidirectional stopcock into another syringe containing the
blood sample. When possible, a blood sample/gas volume at a
1:1 ratio was used. The final gas pressure remained at normal
atmospheric pressure. Controls were represented by both
Table 1. Nomenclature of Reactive Oxygen Species
Free Radicals Nonradicals
Superoxide, O2
– (110-3, 110-6 in presence of superoxide
dismutase)
Hydroxyl, HO (110-9)
Hydroperoxyl, HO2
Peroxyl, RO2 (0.1-7)
Carbonate, CO3
–
Carbon dioxide, CO2
–
Nitric oxide, NO (0.1-5)
Hydrogen peroxide, H2O2 (fairly stable in H2O, 2.5 in plasma, <1 in blood)
Hypobromous acid, HOBr
Hypochlorous acid, HOCl (fairly stable)
Ozone, O3
Singlet oxygen, 1O2 (110-6)
Organic peroxides, ROOH
Peroxynitrite, ONOO– (1-4)
Peroxynitrous acid, NOOH
Numbers in parentheses represent half-life values, in seconds, at 37C.
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untreated blood samples and as treated with medical-grade oxy-
gen. All control samples were normal.
In experiment B, samples of human albumin (4%, Kedrion,
Barga, Italy) alone or in the presence of physiological concen-
trations of uric acid (300 mM) and/or ascorbic acid (50 mM)
were treated with ozone. Gas delivery was performed as
experiment A, at ozone concentrations of 5, 10, 20, 40, 80, and
160 mg/mL (from 0.105 to 3.6 mmol/mL). Control samples
were treated with medical-grade oxygen. Samples containing
albumin (4%) together with scalar concentrations of
Figure 1. The cascade of compounds generated during ozone interaction in a biological environment. In particular, the sequence of reactions
occurring during lipid peroxidation with production of malondialdehyde (MDA) and 4-hydroxy-2,3 trans-nonenal (HNE) is shown.
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4-hydroxynonenal (4-HNE) (from 0.08 to 3.2 mM) were also
studied by NMR analysis.
In experiment C, treatments were performed in a thermo-
statted quartz vessel equipped with a gas inlet, a baffle plate
at about half-height to limit blood foaming, and a silicon stop-
per. For each experiment, the device was loaded with 10 mL of
blood, and 3 stressful agents were continuously (20 minutes)
supplied, alone or in combination: (1) ozone, (2) ozone þ
UV rays, (3) ozone þ heat, (4) ozone þ UV rays þ heat, (5)
UV rays, (6) heat, and (7) UV rays þ heat. The gas outlet was
connected to an ozone destructor. Specifically, the temperature
was set at 42.5C, the total amount of ozone insufflated was 60
mg, and the source of UV rays (Multirays, Helios Italquartz,
Milan, Italy) consisted of 10 lamps (254 nm) of 15 W each
(length 43 cm, diameter 2.6 cm). These lamps were fixed in
a special lamp-holder at a distance of about 10 cm from the
sample.
NMR Analysis
Blood was immediately centrifuged at 2000g for 5 minutes at
room temperature to sediment erythrocytes and to collect the
plasma as supernatant. Plasma samples as well as samples of
experimentBwere stored frozen (–80C)untilNMRexamination.
Frozen plasma samples were thawed at room temperature
and vortexed before use. Next 300 mL of a phosphate sodium
buffer (70 mM Na2HPO4; 20% vol/vol
2H2O; 0.025% vol/vol
NaN3; 0.8% wt/vol sodium trimethylsilyl [2,2,3,3-
2H4]propio-
nate [TSP]; pH 7.4) was added to 300 mL of each plasma sam-
ple, and the mixture was homogenized by vortexing for
30 seconds. Then 450 mL of this mixture were transferred into
a 4.25-mm NMR tube (Bruker BioSpin srl)2 for analysis.
23
1H-NMR spectra for all samples were acquired using a
Bruker 600 MHz spectrometer (Bruker BioSpin) operating at
600.13 MHz proton Larmor frequency and equipped with a
5-mm CPTCI 1H-13C/31P-2H probe including a z-axis gradient
coil, automatic tuning matching (ATM), and an automatic sam-
ple changer. A Pt100 thermoresistance served for temperature
stabilization at the level of approximately 0.01 K at the sample.
3 Before measurement, samples were kept for at least 3 minutes
inside the NMR probe head for temperature equilibration
(300K). One-dimensional spectrawere acquired using a standard
pulse sequence (nuclear Overhauser enhancement spectroscopy;
NOESYpresat; Bruker), using 64 free induction decays (FIDs),
64k data points, a spectral width of 12 019 Hz, an acquisition
time of 2.7 seconds, a relaxation delay of 4 seconds, a mixing
time of 100 milliseconds, and a Carr-Purcell-Meiboom-Gill
(CPMG; Bruker) spin-echo sequence to suppress signals
arising from high-molecular-weight molecules with the same
acquisition parameter of NOESYpresat.
Spectral Processing
Free induction decays were multiplied by an exponential func-
tion equivalent to a 1.0-Hz line-broadening factor before apply-
ing Fourier transform. Transformed spectra were manually
phased and corrected using cubic spin lines with TopSpin 2.1
(Bruker BioSpin srl), taking the CH3-doublet of lactate as ref-
erence (centered at 1.330 ppm).23 All resonances of interest
were assigned on template 1-dimensional NMR profiles by
using matching routines of AMIX 3.8.4 (Bruker BioSpin) in
combination with the BBIOREFCODE (version 2-0-0; Bruker
BioSpin) reference database and published literature when
available.
All spectra were normalized using the area of the doublet of
CH3-alanine peak (between 1.50 and 1.47 ppm), which after
scaling to the total area results fixed in intensity and shift for
all samples analyzed, except the albumin spectra that are nor-
malized to the area of a doublet of albumin (between 2.76 and
2.73 ppm). Peak area measurements of the metabolites are
obtained using R 2.8.127 with house-made script for the calcu-
lation of the integrals of interest.
Spectroscopic Determination
Blood was immediately centrifuged at 2000g for 5 minutes at
room temperature to sediment erythrocytes and to collect
the plasma as supernatant. Plasma samples were stored frozen
(–80C) until determination.
The absorbance was determined with a Perkin Elmer
Lambda 2B UV-VIS spectrophotometer equipped with
10-mm quartz cells. 4The absorption spectra were obtained over
the range 700 to 400 nm. A data interval of 1 nm was selected,
with a signal averaging time of 0.5 seconds for each data point
(resulting in a scan time of 150 seconds). All data were
acquired with UV WINLAB software. Precisely, the adopted
wavelengths for the determination of hemoglobin concentra-
tion were 414, 541, and 576 nm, whereas methemoglobin was
evaluated at 630 nm.10 Before any determinations, samples
were centrifuged at 3000g for 20 minutes in order to read the
clear supernatants, and, when necessary, the samples were
appropriately diluted. All scans were performed by the same
operator and carried out at 21C + 0.5C.
Viscosity Evaluation
Viscomate VM10AL (CBC Europe Ltd) 5is an innovative tor-
sional oscillating viscometer characterized by constant shear
Table 2. Correlation Factor (Expressed as r2 Parameter) for the Vari-
able Metabolites
Peak r2 Value Trend
Acetate (1.93 ppm) 0.96063 Linear
Acetoacetate (2.29 ppm) 0.97061 Linear
Pyruvate (2.35 ppm) 0.86745 Linear
Oxidized albumin (2.82 ppm) 0.95027 Linear
Allantoin (5.40 ppm) 0.94049 Hyperbolic
Oxidized albumin (8.08 ppm) 0.99535 Linear
Formate (8.47 ppm) 0.99244 Linear
9
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stress systems driven by a piezoelectric ceramic source. This
instrument measures viscosity by sensing a change in oscilla-
tion amplitude of a liquid-immersed detector, based on con-
stant input voltage. An original phase-locked loop circuit
maintains instrument resonant frequency of 1 kHz; the detector
oscillation amplitude with no resistance is 1 mm. Angular accel-
eration of the detector is measured and reported as dynamic
viscosity with the range 0.400 to 1000 mPa/s. The probe
dimension was 9 mm with respect to the diameter.28
The viscosity of treated blood (experiments A and C) was
immediately evaluated. All the determinations were conducted
into polystyrene Technicon sample cups (Kartell,6 nominal
capacity 2 mL). Temperature was accurately monitored during
the experiments (37.0C + 0.1C). Viscosity values were
recorded for 6 minutes (data collection every 5 seconds) by
PC connection through an RS-232 port.
Statistical Analysis
Results were expressed as the mean (percentage coefficient of
variance [CV%] <2)7 of at least 3 independent measurements.
Statistical evaluations were performed by a 1-way analysis of
variance (ANOVA) using a statistics software (Instat software,
version 3.0 GraphPAD Software, San Diego, Calif). Bonferroni
test was used after ANOVA to evaluate statistical difference
between individual means. Significance was defined as a
P value less than .05. The correlation graphs are obtained using
OriginPro 8, the correlation factors are expressed with the
r2 parameter.
Results
A preliminary overview of the changes caused by blood ozona-
tion is shown in Figure 2. Both CPMG and NOESY1D spectra
were analyzed. The examination of spectra of the control sam-
ples treated with pure oxygen did not yield particular differ-
ences with respect to basal samples, except a small increment
of pyruvate peak at 2.35 ppm. However, samples treated with
increasing amounts of ozone (from 0 to 16.8 mmol/mL) showed
variations in the concentration of several metabolites (Figure
2).
In particular, a strong increase of the peaks at 8.45 ppm
(CH-formate), 5.40 ppm (CH-allantoin), 2.29 ppm (CH3-acet-
oacetate), and 1.93 ppm (CH3-acetate) were observed as well
as a drastic decrease of the 2.35 ppm peak (CH3-pyruvate),
which disappeared at an ozone concentration of 320 mg/mL. All
the variations of these metabolites are strongly correlated with
the concentration of insufflated ozone (Figure 3 and Table 2).
The variations of pyruvate and acetate are chemically corre-
lated, in fact, acetate is formed by a direct ozone oxidation of
pyruvate; formate is the last product of the oxidative process
of carbohydrates, and allantoin comes from oxidation of uric
acid,25,29 which behaves as a ‘‘sacrificial’’ molecule in the pres-
ence of a strong oxidant such as ozone.14,30 Acetoacetate is often
formed in plasma by oxidation of g-hydroxybutyrate.25,31
Additional tests were performed to (1) confirm the trends of
variations of each metabolites at higher concentrations of
ozone and (2) confirm the specificity of the obtained results for
the ozone treatment in comparison to other kinds of oxidative
stress (treatment C).
The increase of the ozone concentration up to 800 mg/mL of
gas per 1 mL of blood confirmed our findings for all the previ-
ous metabolites. For the nontherapeutic, high ozone concentra-
tions (240, 320, and 800 mg/mL), the disappearance of the
pyruvate signal from the spectrum was caused by the excessive
oxidative process.
A further analysis of the spectra highlighted the presence of
unidentified new peaks. These peaks occurred at 2.82 and
8.08 ppm and were not present in untreated plasma. Thus, these
peaks were due to specific products directly linked to the ozone
activity and indeed their amounts in the plasma are related to
different ozone concentration (Figures 2 and 4).
The correlations between the areas of each peak and the con-
centration of insufflated ozone were very high. These data sug-
gest that these peaks may represent markers of oxidative stress.
To express a hypothesis about the origin of these 2 peaks,
other tests were performed (experiment B). It is well known
that ozone causes lipid peroxidation, yielding several alde-
hydes among which HNE is quantitatively relevant.32 This
aldehyde has a double bond in b and it is not stable. It reacts
easily with free thiol groups of cysteine, glutathione, and other
metabolites normally present in plasma to form adducts easily
eliminable from the organism with the urine.32,33 A recent
study indicated an interaction of HNE with Cys34 present in
albumin.34 Starting from these data, some samples obtained
with the addition of scalar concentration of HNE (from
0.08 mM up to 3.2 mM) to a solution of 4% human albumin
in saline were analyzed. After the addition of HNE to albumin,
the 2 peaks at 2.82 ppm and 8.08 normally present after blood
ozonation were absent, as well as the aldehydic signals of HNE.
On the other hand, direct ozonation of a 4% albumin solution in
saline allowed the detection of these 2 peaks, which increased
in intensity in relation to the amount of ozone concentrations,
indicating that these 2 signals are due to the direct oxidant
activity of ozone on the albumin. Indeed, albumin has been
called a sacrificial molecule. Whether albumin undergoes
dimerization35 or allows the formation of sulfenic acid36 has
not been clarified.
As for the experiments with albumin plus uric acid (300 mM)
and/or ascorbic acid (50 mM), an increased formation of allan-
toin was obtained. The peak at 4.5 to 4.6 (ascorbic acid),
although present when in the control sample, disappeared as
soon as ozone (20 mg/mL) was added. These results suggest
that uric acid is oxidized to allantoin and ascorbic acid is oxi-
dized to dehydroascorbate. Additionally, the presence of for-
mate and the appearance of both 2.82 and 8.08 ppm peaks
were evidenced.
On the basis of the very harsh ozonation of blood (about
6 mg/mL of blood) plus UV radiation and heat (42.5C)
recently reported,26 it was of interest to evaluate the spectra
after blood treatment with (1) O3, (2) O3 þ UV rays, (3) O3
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þ heat, (4) O3þ UV raysþ heat, (5) UV rays, (6) heat, and (7)
UV rays þ heat. No appreciable influence of heat and/or UV
treatments on the metabolites present in the blood was detected,
except that at 4.43 and 8.19 ppm in the case of heat. These sig-
nals were not present in ozone-treated samples. The remaining
other types of treatments (1-4) showed the typical fingerprint
Figure 2. Snapshot of Carr-Purcell-Meiboom-Gill spectra containing some principal variable metabolites in human serum treated with ozone
(control, 80 mg/mL, 800 mg/mL).
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alterations already seen in previous tests (formate, acetoace-
tate, acetate, and allantoin increase; pyruvate decreases; peaks
occur at 2.82 ppm and 8.08 ppm) to indicate that the principal
stressor is due to ozone. Considering the different areas of the
previous defined marker peaks at 2.82 ppm, a classification of
samples based on the insufflated quantity of ozone is possible.
To confirm metabonomic results on the effects of blood oxi-
dative stress on the erythrocytic membrane and the possible cell
damage with intraerythrocytic material release according to both
treatments A and C, physicochemical investigations based on
hemolysis as well as viscosity were performed. In the first set
of experiments, only increasing amounts of 1 single dose of
Figure 3. Variations of several metabolites in relation to increasing ozone dosages (n ¼ 3; CV% <2).
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ozone, according to treatment A protocol, were evaluated. A sta-
tistically significant increase of hemolysis (>5%) was observed
at 800 mg/mL, whereas viscosity variations started at 160 mg/
mL (Figure 5, a and b, respectively). In the second set of experi-
ments, variable results were obtained, depending on the type and
number of stressors applied. The combination of ozone þ UV
(condition 2) as well as ozone þ UV þ heat (condition 4)
yielded the highest values of hemolysis (Figure 5c, samples ii
and iv). The viscosity markedly increased only in the ozone þ
UV combination (Figure 5d, sample ii).
Figure 4. Linear trends of appearance of 2 unidentified peaks in relation to ozone dosages: signal areas at 2.82 ppm (left) and at 8.08 ppm
(right) (n ¼ 3; CV% <2).
Figure 5. Hemolysis (left) and viscosity (right) variations in treatments a (top) and c (bottom). Statistical analysis: 3 symbols, P < .001, 2
symbols P < .01, 1 symbol P < .05, not significant P > .05; star symbol vs control; sharp symbol vs sample 1 (n ¼ 5).8
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Discussion
Metabonomics is very useful to evaluate large and small dif-
ferences in metabolic profiles, as demonstrated in urine for
oxidative kidney damage.24 The present work demonstrates
that the metabonomic approach is a valid instrument to detect
alterations in plasma profile due by oxidative stress induced
by ozone and other stressors. Information on the oxidative
stress was obtained from the CPMG spectra, in which signals
arising from large macromolecules such as lipids are sup-
pressed. This observation suggests that although ozone causes
lipid peroxidation, ozone treatment causes neither visible
alteration in lipid composition of blood nor hemolysis in the
range of the well-documented therapeutic concentrations of
ozone, namely between 10 mg/mL blood, or 0.21 mmol/mL
and 80 mg/mL blood, or 1.68 mmol/mL.14 It is unlikely that
changes in metabolites are caused by hemoglobin degrada-
tion. Moreover Shinriki et al30 excluded any erythrocytic
membrane peroxidation with ozone concentration up to 100
mg/mL per mL of blood.30 The first changes in the lipidic
component appear only with high ozone concentrations
(240 mg/mL upward) not normally used for therapeutic pur-
poses. Moreover, after treatment with an ozone concentration
of 800 mg/mL, changes in several peaks, both NOESY1D and
in CPMG spectra, were observed, leading us to hypothesize
damage to cell membranes caused by lipid oxidation with pos-
sible cytolysis. This supposition would explain both changes
in the lipid component in the spectrum, well visible in NOE-
SY1D spectrum at the highest concentrations of ozone and in
the component given by small metabolites, better visible in
CPMG spectrum.
The principal product of lipid peroxidation (HNE) it doesn’t
alter the metabonomic profile of serum. The present alterations
are only due to direct oxidation of some molecules (as pyruvate
and carbohydrates) and antioxidants such as uric acids and
ascorbic acid as well as to the so-called sacrificial behavior
of albumin.
In this study the metabolic profile of blood samples
treated with ozone has been defined: the principal metabolic
variation with the possible markers of oxidative stress due
to ozone treatment has been indicated; and blood alterations
due to ozone have been demonstrated to be strictly corre-
lated to the concentration of insufflated ozone. When ozone
concentrations were within the therapeutic range, only a few
alterations were detected and were not associated to signif-
icant damages. However, several stresses, such as the asso-
ciation of ozone with heat and/or UV, appear deleterious, as
exemplified in Figure 5. It appears that the denominated
Celacade procedure consisting of a harsh treatment of blood
with an enormous ozone dose plus UV rays and heat stress26
causes extensive blood cell destruction with no beneficial
effect on patients with chronic heart disease. This meaning-
less procedure must be proscribed.37 If ozone therapy is to
be safely used, it requires precise and well-calibrated ozone
concentrations and the avoidance of ozone bubbling as well
as additional stressor.
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Abstract   
1H NMR metabolic profiling of urine, serum and plasma has been used to monitor the impact of the 
pre-analytical steps on the sample quality and stability in order to propose standard operating 
procedures (SOPs) for deposition in biobanks. We analyzed the quality of serum and plasma 
samples as a function of the elapsed time (t = 0- 4 hours) between blood collection and processing 
and of the time from processing to freezing (up to 24 h). The stability of the urine metabolic profile 
over time (up to 24 h) at various storage temperatures was monitored as a function of the different 
pre-analytical treatments like pre-storage centrifugation, filtration, and addition of the bacteriostatic 
preservative sodium azide. Appreciable changes in the profiles, reflecting changes in the 
concentration of a number of metabolites, were detected and discussed in terms of chemical and 
enzymatic reactions for both blood and urine samples. Appropriate procedures for blood derivatives 
collection and urine preservation/storage that allow maintaining as much as possible the original 
metabolic profile of the fresh samples emerge, and are proposed as SOPs for biobanking. 
 
 
 
 
Keywords:  metabolomics, NMR spectroscopy, serum, plasma, urine, biobanks 
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Introduction 
Metabolomic research is an emerging area focused on measuring the ensemble of the metabolites in 
biospecimens (Fiehn 2002; Nicholson et al. 1999). The objects of interest of metabolomic 
researches are the low-molecular weight compounds (MW < 1500 Da) that serve as substrates 
and/or products in various metabolic pathways. These small molecules include compounds such as 
lipids, sugars, amino acids, nucleotides, and a number of different organic molecules, that are the 
reactants, intermediates or products of biochemical reactions as well as building blocks for all other 
biochemical species including proteins, nucleic acids and cell membranes (German et al. 2005). The 
number of different metabolites in humans is unknown; estimates range from a minimum of 2,000-
3,000 to a maximum of around 20,000 metabolites (browsing the Human Metabolome Database, 
HMBD, www.hmbd.ca), to be compared with estimated 30,000 genes (from www.ensembl.org) and 
about 40,000 proteins (browsing the protein database of the National Center for Biotechnology 
Information, NCBI,  www.ncbi.nih.gov and disregarding splicing variants and post-translational 
modifications). Most metabolomic studies involve common biofluids as urine and serum/plasma 
that are obtainable from mammals, especially from humans, in a non- or minimally-invasive way 
and are easily available because commonly used for many other clinical analyses. A standard 
approach in metabolomics is that of measuring monodimensional 1H NMR spectra at medium/high 
magnetic fields. Such spectra, often called metabolic profile, constitute a “fingerprint” of the NMR 
detectable part of the whole metabolome. The potential of metabolomics for disease diagnosis, 
prognosis and, in a clinical trial setting, for monitoring drug therapy relies on its ability to extract a 
disease signature from the multivariate analysis of the metabolic profiles of statistically relevant 
ensembles of samples derived from different donors (Oakman et al. 2010;  Sreekumar et al. 2009; 
Bertini et al. 2009;  Akira et al. 2008;  Holmes et al. 2008; Bartsch et al. 2008; Gao et al. 2008; 
Fearnside et al. 2008; Makinen et al. 2008; Teichert et al 2008; Coolen et al. 2008; Claudino et al. 
2007; Schnackenberg et al. 2007; Marchesi et al. 2007; Griffin et al. 2007; Constantinou et al. 2007; 
Coen et al. 2005; Lindon et al. 2004; Brindle et al. 2002). Clearly, the reliability of the approach 
requires that the chemical nature and the relative concentration of all the metabolites present in the 
biofluids are neither affected by the preanalytical treatment used to store the samples nor by the 
analytical methodology. Conversely, as depicted in Scheme 1, metabolomics itself is assuming a 
growing importance in the definition of operating procedures aimed at collecting and preserving 
biological samples and for standardizing protocols (Barton et al. 2008; Dunn at al. 2008; Jackson at 
al. 2008; Peakman et al. 2008; Saude et al. 2007). The definition of suitable Standard Operating 
Procedures (SOPs) is therefore essential to allow data comparison worldwide. Biobanks, that are 
infrastructures devoted to the collection, cataloguing and storing of biological samples in order to 
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make them available for medical and clinical research, represent an irreplaceable support for all 
those studies in which the impact of the results is linked to the large number of the collected 
samples. At the same time, they have to guarantee that the quality of the stored biological samples 
remains as close as possible to the fresh sample for any possible future studies, including 
metabolomics.  
 
 
Scheme 1. 
 
Among the different metabolomic tools, NMR represents the technique of choice (Nicholson et al. 
2008) for the definition of pre-analytical procedures. Indeed, NMR is a high-throughput 
methodology requiring only minimal sample handling before spectra acquisition and allowing 
collection of the whole metabolic profile, i.e. the simultaneous detection of a large number of 
metabolites with different physiochemical properties e.g., hydrophobicity/hydrophilicity, 
acidity/basicity, redox reactivity. The variety of detectable molecules allows the monitoring of 
residual enzymatic activities and/or chemical reactions that may alter the NMR profile of the 
analyzed sample, which becomes not representative any longer of the metabolome before 
collection. These alterations could seriously bias the results of studies based on samples having 
different collection, treatment and storage histories. 
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Standardization and improvement of pre-analytical tools and procedures for in-vitro molecular 
diagnostics is the main goal of the European Union FP7 project SPIDIA (www.spidia.eu), which 
involves a consortium of public research organizations and private companies, and a standards 
organization. As a partner of the consortium, we performed the present research focusing on the 
most commonly studied biofluids: urine, serum and plasma. 
Urine might be regarded as a biospecimen with little scientific value, but it is assuming an 
increasing importance as a bio-bankable sample thanks to metabolomics studies. Browsing PubMed 
for metabolomics/metabonomics publications resulted in 250 publications based on urine, 147 
publications on serum, 185 on plasma and 185 on tissues. Use of urine as a first choice object of 
study is justified by the fact that the collection method is simple and is the least invasive one: these 
characteristics permit multiple collection schemes that greatly improve the reliability of the 
statistical analysis. Indeed, some of us have recently shown that NMR fingerprinting of multiple 
urine samples from the same donors is able to reveal individual metabolic phenotypes (Assfalg et al. 
2008, Bernini et al. 2009). Several methods of urine sample processing (centrifugation, filtration, 
addition of preservatives) as well as sample storage temperature (at -80 °C or in liquid nitrogen) 
were tested in several combinations and found to have significant effects on the metabolome, as 
detected by 1H-NMR fingerprinting. The presence of host cells or bacterial cells in urine is 
identified as a potential major source of alteration of the metabolic profile, and appropriate 
countermeasures emerge. 
Blood derivatives like serum and plasma are also very common biofluids in metabolomics studies. 
The disadvantage with respect to urine is that the collection of blood samples is slightly more 
invasive. Therefore, it may be more difficult to obtain multiple collections from patients, and even 
more from healthy volunteers. On the other hand, blood is less affected by daily variations and daily 
diet than urine. We analyzed here the quality of serum and plasma samples as a function of the time 
delay (0-4 h) and storage temperature (25 °C and 4 °C) before processing. Moreover, changes in the 
NMR profiles of these two biofluids after serum and plasma preparation were monitored for a 
further 24 hours, to simulate the effect of the time between processing and freezing. A number of 
metabolites which are often used as disease biomarkers in metabolomics studies are heavily 
affected by the tested variation factors, and again, appropriate countermeasures emerge. 
The present results, taken together, contribute to the definition of standard operating procedures for 
specimen collection that represent a step forward with respect to the available recommendations for 
biobanking procedures (Yuille et al. 2010). These SOPs are being implemented at the local da Vinci 
European Biobank (www.davincieuropeanbiobank.org) and proposed for adoption by the European 
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Biobanking and Biomolecular Resources Research Infrastructure (BBMRI, www.bbmri.eu) 
presently in the preparatory phase. 
 
Materials and methods 
Sample collection 
Urine samples were collected from 6 healthy donors (3 females and 3 males) following the standard 
procedure for urine culture and kept not more than a half hour at 2-8 °C before further processing 
(as detailed in the Results section). Urine from each donor was aliquoted in 1.0 mL fractions, and 
each aliquot was treated independently. Different centrifugation speeds were tested (see Results and 
Discussion); during centrifugation samples were kept at 4 °C. For filtration a 0.20 µm filter was 
used; such a cut-off is small enough to ensure removal of cells and large particles still avoid 
problems of obstruction of the pores that may slow down urine processing and lead to sample loss. 
Sodium azide was added to the sample until a final concentration of 3 mM, as described in our 
previous metabolomics studies (Weckwerth et al. 2007, Assfalg et al. 2008, Bertini et al. 2009, 
Bernini et al. 2009) 
Blood samples were withdrawn from healthy donors using different BD Vacutainers® for plasma or 
serum isolation: K2E 5.4 mg and SSTTM II Adavance respectively. Multiple 5 mL aliquots were 
taken at the same time from each patient and treated in parallel afterwards. We tested different time 
delays (0-4 h) between blood withdrawal and processing for serum/plasma preparation; during these 
time intervals the vacutainers were incubated at 4 °C and 25 °C. In the case of serum t=0 was 
considered to be 30’ at room temperature after blood collection, as required for clotting. After the 
incubation, vacutainers for plasma collection were centrifuged at 820 RCF (Relative Centrifugal 
Force) for 10’ at 4 °C, while vacutainers for serum collection were centrifuged at 1500 RCF for 10’ 
at 25 °C. In both cases, after centrifugation, the supernatants were collected and used for the 
preparation of NMR samples. 
NMR sample preparation 
According to a commonly used protocol (Assfalg et al. 2008, Bernini et al. 2009), urine samples 
were shaken before use and 630 µL were centrifuged at 14000 RCF for 5 min. 540 µL of the 
supernatant were added to sixty microliters of potassium phosphate buffer (buffer 1: 1.5 M K2HPO4 
and 10 mM sodium trimethylsilyl [2,2,3,3-2H4] propionate, TMSP,  in 100% 2H2O, pH 7.4). 540 
µL of the mixture were pipetted into 4.25 mm NMR tubes (Bruker BioSpin srl). 
Blood-derivative NMR samples were prepared adding 300 µl of phosphate sodium buffer (buffer 2: 
70 mM Na2HPO4, 38 mM NaN3 and 55 mM TMSP in 20% 2H2O, pH 7.4) to 300 µl of plasma or 
serum. A total of 450 µl of this mixture was transferred into a 4.25 mm NMR tube (Bruker BioSpin 
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srl). In the follow-up of blood derivates over time, we used a buffer with the same composition and 
concentration described above. 
NMR spectra 
All 1H-NMR spectra were acquired using a Bruker 600 MHz spectrometer operating at 600.13 MHz 
proton Larmor frequency and equipped with a 5 mm CPTCI 1H-13C/31P-2H cryo-probe including a 
z-axis gradient coil, an automatic tuning-matching (ATM) and an automatic sample changer.  A PT 
100 thermocouple served for temperature stabilization at the level of approximately ±0.1 K at the 
sample. Before measurement, samples were kept for 3-5 min inside the NMR probehead, for 
temperature equilibration i.e., 300.0 K for urine samples, 310.0 K for serum/plasma samples; the 
highest temperature for blood derivatives is used for better detection of lipidic profiles (Suna et al. 
2006). 
For each urine sample, a one-dimensional (1D) NMR spectrum was acquired with water peak 
suppression using a standard pulse sequence (NOESYpresat; Bruker), 64 scans, 64 k data points, a 
spectral width of 12,019 Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a mixing time 
of 100 ms. 1H-1H J-resolved (J-res) spectra were also acquired in order to get more information 
about signal multiplicity and coupling patterns. For each serum/plasma sample 1D NOESYpresat 
spectra were recorded; 1D spectra were acquired also with the Carr-Purcell-Meiboom-Gill (CPMG; 
Bruker) spin-echo sequence to suppress signals arising from high molecular weight molecules. In 
this case NOESYpresat spectra consisted of 64 scans, 98 k data points, a spectral width of 18,028 
Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a mixing time of 100 ms. CPMG 
spectra consisted of 64 scans, 74 k data points, a spectral width of 12,019 Hz, an acquisition time of 
3.1 s, a relaxation delay of 4 s and a mixing time of 100 ms. 
Spectral processing and analysis 
Free induction decays were multiplied by an exponential function equivalent to a 1.0 Hz line-
broadening factor before applying Fourier transform. Transformed spectra were automatically 
corrected for phase and baseline distortions and calibrated using TopSpin 2.1 (Bruker Biospin srl). 
In the case of serum and plasma, spectra were calibrated assigning a value of 1.5 ppm to the alanine 
peak.  Calibration of urine spectra was achieved by aligning the signal of the pH-invariant 
resonance of trigonelline at 9.12 ppm; with this approach, the other signals of trigonelline and those 
of other pH-insensitive metabolites such as 1-methylnicotinammide and hippurate do not shift with 
pH. Each 1D spectrum in the range between 0.02 and 10.00 ppm was segmented into 0.02-ppm 
chemical shift bins, and the corresponding spectral areas were integrated using AMIX software 
(Bruker BioSpin). Regions between 6.0 and 4.5 ppm containing residual water and urea signals 
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were removed. The total spectral area was calculated on the remaining bins and normalization was 
carried out on the data prior to pattern recognition. 
All resonances of interest were assigned on template one-dimensional NMR profiles by using 
matching routines of AMIX 3.8.4 (Bruker BioSpin) in combination with the BBIOREFCODE 
(Version 2-0-0; Bruker BioSpin) reference database and published literature when available. All 
calculations were made using MATLAB 7.6.0 and AMIX 3.8.4. 
Statistical analysis 
Various kinds of multivariate statistical techniques were applied on the obtained buckets: PLS 
(Partial Least Squares)-regression and PCA (Principal Component Analysis) for data analysis, 
manova (One Way analysis with Multiple Responses) for data reduction, kNN (k-Nearest 
Neighbour) as classification method, Kruskal-Wallis test (for the determination of the meaningful 
metabolites) (Madsen at al. 2010).  
Urine culture tests 
Urine culture tests were performed by using Linearcount6® Urinocoltura: this is an integrated 
system that allows the bacterial count, the bacterial isolation and the presumed identification of 
bacteria present in the urine.  
 
Results and discussion 
Urine The starting point for this research are the Recommendations on Biobanking Procedures for 
urine processing and management recently published by the European Consensus Expert Group 
Report (Yuille et al. 2010). According to this document, biobanking procedures for urine should 
consider the following general consensus recommendations: i) cells and particulate matter should be 
removed (e.g. by centrifugation); ii) samples should be stored at -80 °C or below; iii) time limits for 
the processing should have been defined experimentally and should be appropriate to the analytes to 
be measured; iv) unless specified for a particular downstream analysis, urine samples should be 
stored without additives. As the authors pointed out, advances in new downstream analytical 
platforms may impose specific requirements related to the nature of the targeted analytes, thus 
leading to specific revision/elaboration of the general procedures. Here we address the above 
critical issues in relation to the consequences for downstream metabolomics applications.  
Fresh urine is characterized by the presence of human cells (erythrocytes, leucocytes, urothelial 
cells, epithelial cells), bacteria, fungi, sperm counts, non cellular components (mucus filaments, 
cylinders, cylindroids, pseudocylindres, crystals, urates). The protocol for the analysis of urinary 
sediment proposes a speed around 1600 RCF for the centrifugation (Koukoulaki et al. 2008) in 
order to avoid the breaking of the frailest elements like cylinders. On the other hand, to avoid the 
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presence of any particulate components in the NMR samples that will affect the spectral quality, 
standard protocols (Beckonert et al. 2007) for the immediate NMR analysis of urine require a 
centrifugation of the sample at 14000 RCF for 5 minutes at 4 °C. Such a high speed may induce cell 
breaking and release of cellular components into the biofluid. We thus analyzed the advantage of 
applying a mild centrifugation (pre-centrifugation) to fresh urine before the high-speed 
centrifugation needed by the preparation of NMR samples for immediate use. Multiple aliquots 
from two different donors were collected and treated, as detailed below and summarized in Fig. 1: 
one aliquot per donor had no pre-centrifugation, the other aliquots were pre-centrifuged at 450, 
1000, 3000 and 11000 RCF (Fig. 1A). After pre-centrifugation, the supernatant was recovered and 
analyzed immediately, following the protocol described in the section Materials and Methods for 
the preparation of the NMR samples. PLS (Partial Least Squares)-regression coupled with CA 
(Canonical Analysis) was performed on the obtained spectra as a function of the pre-centrifugation 
speed. To visualize the distance between the spectra of differently treated samples, the value of the 
first component for the non pre-centrifuged sample was taken equal to zero and the absolute value 
of the difference between the value of the first component in the pre-centrifuged samples and in the 
non pre-centrifuged sample was calculated. The plot of these values as a function of the pre-
centrifugation speed (Fig. 2) shows an interesting behavior. The most distant from non pre-
centrifuged samples are the aliquots pre-centrifuged at a speed in the 1000-3000 RCF range, while 
aliquots pre-centrifuged at >11000 RCF are slightly closer to the samples that do not undergo any 
pre-centrifugation. Apparently, the proposed 5-minutes 14000 RCF-centrifugation of the NMR 
protocol is too harsh; speeds ≥ 11000 RCF at the pre-centrifugation level induce at least partial 
breaking of the cellular components and release of their soluble constituents, thus affecting the 
NMR profile. If a mild pre-centrifugation (between 1000-3000 RCF, Fig. 2) is applied, the cellular 
components are spun down and the subsequent 14000 RCF centrifugation of the supernatant is 
useful for the elimination of other suspended, mainly inorganic, particles. On the other hand, a too 
mild pre-centrifugation (450 RCF) is not effective in eliminating the cellular components. The 
importance of the pre-centrifugation step of course depends upon the content in cellular components 
of the analyzed samples, and may therefore be very different from one individual to another (Fig. 
2). 
The differences in metabolic profile between pre-centrifuged or non pre-centrifuged samples are 
essentially ascribable to chemical shift changes in signals that are extremely sensitive to pH 
variations such as the Hε1 signal of histidine and of Nτ- and Npi-methyhistidine (Fig. S1A). For 
example, using a pre-centrifugation speed in the range defined by us as mild pre-centrifugation, 
namely 2500 RCF, the largest chemical shift variation was observed for the well resolved (in this 
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pH range) Hε1 signal of Nτ-methyhistidine and found to be statistically relevant by Kruskal-Wallis 
test. The observed changes are consistent with a pH increase (Fig. S1B). The extent of the observed 
pH variation is different from one donor to another and is larger for samples containing larger 
amount of cells. However, no resonances attributable to new metabolites or increase in intensity of 
existing signals could be observed. This suggests that soluble components released by cells in fresh 
urine are below the detection limit of the method (because they are low in concentration and/or are 
high molecular weight components) but their presence is still able to alter the physiochemical 
properties of the solution.  
The presence of cellular components has an impact on the NMR profiles even if non-fresh urine 
samples are analyzed, and the importance of the observed change depends upon the storage 
temperature (Fig. 1B). NMR metabolic profiles of non pre-centrifuged samples stored for a week at 
–80 °C do differ from those that have undergone a mild (600-2500 RCF) pre-centrifugation before 
freezing at the same temperature. The effect is less severe if urine samples are stored in liquid 
nitrogen. This result is not unexpected because rapid freezing in liquid nitrogen i.e., below the 
critical ice crystal temperature (–130 °C) avoids crystal formation which may cause cell breaking. 
For example, from a PLS analysis of the spectral shift variation for samples not pre-centrifuged and 
pre-centrifuged at 2500 RCF and analyzed either i) fresh, or ii) after one week at -80 °C and iii) 
after one week at liquid nitrogen (Fig. 1B), it results  that the largest difference occurs for the 
samples stored at -80 °C. Assigning a value of 100% to the changes observed between pre-
centrifuged and not pre-centrifuged samples stored at -80 °C for a week, the corresponding changes 
between pre-centrifuged and not pre-centrifuged samples analyzed fresh or after a week of storage 
in liquid nitrogen are much smaller and of comparable extent ( 9% and 8%, respectively).  
PLS analysis of the discussed samples shows that the recognition capability of the model, i.e. the 
accuracy in assigning different aliquots to the same sample, is not seriously affected by any of these 
treatments (Fig. S2). Nevertheless, reducing any possible external sources of variations is vital for 
specific studies whose results depend on revealing differences in the relative concentration of a 
limited set of metabolites. 
Finally, we evaluated the two most commonly used preservation methods (Saude and Sykes 2007): 
filtration and addition of sodium azide. They were used as such or in combination with a pre-
centrifugation step at 1000 RCF, as summarized in Fig. 1C. Differently treated aliquots of the same 
sample were analyzed either fresh or after storage for a week at -80 °C, i.e. at the temperature that is 
most commonly used in biobanking. Spectral variations were followed for 24 h after urine 
processing or thawing after a week of storage at -80°C. Changes over time are observed for pH-
sensitive metabolites that undergo chemical shift variations. In particular, the shift variations for the 
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Hε1 N-methylhistidine (Fig. S1) are consistent with an alkalinisation of the samples; the chemical 
shifts of the resonances of xantine also change with time. Changes in the relative concentration of 
some molecules are also observed: succinate and acetate increase with time; urea, lactate and 
glutamate/glutamine decrease (Fig. S3). The extent of their variations depends upon the 
preservation method, pre-centrifugation and storage. Consistent with available literature data (Saude 
and Sykes 2007), filtration is the method that makes the NMR spectra more stable over time. 
In order to evaluate the origin of the changes that affect the NMR spectra of samples over time, we 
tested three working hypothesis 
- The chemical hypothesis: reactions (e.g. oxidations) occur with time. 
- The bacterial hypothesis: the bacteria present in urine grow over time with the consequent 
production of bacterial metabolites. 
- The enzymatic hypothesis: the enzymatic activities of urine cause the consumption of 
certain metabolites and the increase of others. 
In order to test the chemical hypothesis, as far as possible oxidation reactions are concerned, the 
samples were kept under inert atmosphere for the entire duration of the experiment and compared 
with the corresponding aliquots kept under normal atmosphere. The effect of the inert atmosphere 
over the 24 hours in which the samples were followed is modest. The only difference is a slight 
reduction in the increase of succinate concentration.  
In order to test the bacterial hypothesis, in parallel with the analysis by NMR, we performed urine 
culture tests. The results of these tests (Tables S1 and S2) show that pre-centrifugation, addition of 
sodium azide and storage at -80 °C have a disinfectant effect, but they do not eliminate completely 
the bacterial load. The effect of sodium azide is more clearly visible after 6 hours at room 
temperature, whereas the effect of storage is more clearly visible when temperature-sensitive 
bacteria like coliforms are present. The fact that non-precentrifuged samples have the highest 
decrease in glutamate concentration suggests that degradation of this metabolite is mainly 
attributable to bacteria. The reduced degradation of lactate in samples stored at -80 °C can be 
explained considering that coliforms bacteria, sensitive to the low temperatures, are the main source  
of its transformation. Filtration, alone or in combination with pre-centrifugation, completely 
eliminates bacteria from urine; nevertheless NMR spectral changes are not fully quenched in 
filtered samples. Therefore, the bacterial growth is not the only source of the observed spectral 
changes occurring with temporal progression.  
The enzymatic hypothesis is justified by the notion that some activities due to human enzymes such 
as γ-glutamyltransferase, alkaline phosphatase and N-acetylglucosaminidase are present in the urine 
of healthy adults (Jung and Pergande 1983). The presence of γ-glutamyltransferase is a good proof 
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of the disappearance of glutamate/glutamine in urine with time. On the other hand, a residual 
activity of urease and of isocitrate lyase, two metalloenzymes of bacterial origin, could be the cause 
of the decomposition of urea and of the increase of succinate, respectively. In order to test this 
hypothesis, we tried two different inhibitors. A 50 mM concentration of acetohydroxamic acid 
(AHA), a known inhibitor of urease, does inhibit the decrease of urea. A similar concentration of 
the bivalent metal chelator EDTA is also effective in inhibiting urea decomposition and partially 
inhibits the increase of succinate, acting on both urease and isocitrate lyase. The increase of acetate 
is also inhibited by EDTA. Because acetate is the main product of several bacterial fermentations, 
this result suggests that also the increase of acetate is at least in part due to metal-dependent 
bacterial enzymatic activities. 
The three working hypotheses suggested above help us in understanding the observed variations of 
the NMR signals, but it is also important to highlight that all three mechanisms are present and their 
effects may partially overlap. 
On the basis of the results of our experiments, we propose the following procedures for the optimal 
processing and management of urine samples to maintain as much as possible their original 
metabolome (Scheme 2): i) removal of cells and particulate matters through the combined use of a 
mild pre-centrifugation 1000-3000 RCF (5’ at 4 °C) and filtration; ii) long-term storage of samples 
in liquid nitrogen (or liquid nitrogen vapour) to avoid breaking of residual cells; iii) fast processing 
(within 2 hours for collection); iv) storage at 4 °C between collection and processing. 
Recommendations at points iii) and iv) aim at reducing the effects of any possible 
enzymatic/cellular activities. Addition of additives (like enzyme inhibitors) should be avoided  
because the required concentrations will introduce signals in the NMR spectra covering the 
resonance of metabolites and may also induce changes in pH, ionic strength, etc. thus further 
affecting the original NMR profiles.  
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Scheme 2.  
 
With respect to the general recommendations in Yuille et al., our studies permitted the definition of 
the best practices for the removal of cells and particulate matter. Nevertheless, as complete removal 
of cells is never achieved, long-term storage temperatures below the critical ice crystal temperature 
would be advisable. Changes in metabolite concentrations at room temperatures are relatively fast 
(Fig. S3); reduction of time between collection and processing and the temperature at which urine 
samples are kept during this time delay is critical for the maintainance of the metabolome of the 
fresh samples. Annotation of time delays and temperatures for the entire history of each sample will 
add statistical value. 
    
Blood  
According to the same recommendations document mentioned in the urine section (Yuille et al. 
2010), in the plasma/serum processing and management one should consider the following aspects: 
i) use of  EDTA or citrate as anticoagulant, not heparin; ii) sample storage at a temperature of -80 
°C, or below if e.g. critical ice crystal formation is problematic; iii) recording of the time from 
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collection through processing; iv) experimental definition of time limits that are appropriate to the 
analytes to be measured. These guidelines for blood derivatives biobanking focus on the use of 
stored samples for future extraction of DNA for genetic analysis. Although the latter still represents 
the main application for biobanked serum and plasma, new analytical platforms are assuming 
increasing importance and specific requirements for appropriate samples for new biomarker 
analysis have to be defined. Here we test the validity of best practices proposed for DNA analysis in 
the context of metabolomics and evaluate whether additional procedures may be needed for the 
optimal maintainance of the original metabolome. 
The time limits for processing whole blood were examined (Fig. 3A) by evaluating the effect on the 
NMR metabolic profile of serum and plasma-EDTA samples, prepared according to the standard 
protocols described in Materials and Methods. PLS-CA analysis was again used at the descriptive 
level and showed that the spectral patterns of serum and plasma samples processed at different 
times carry meaningful differences (Fig. 4A,B and D,E). The PLS analysis with information of time 
delays from collection through processing was performed assuming the mean of the value of the 
first component as zero at time zero and consequently calculating the values corresponding to the 
following tested times. Plots C and F in Fig. 4 show the changes in the main component of PLS for 
serum and plasma samples at 4 °C and at 25 °C. Degradation processes are time-dependent and 
temperature-dependent both for serum and plasma samples: in both cases incubation at 25 °C 
causes deeper changes in the NMR profile. In order to unravel the main mechanisms at the basis of 
the degradation processes occurring from collection through processing, we singled out the 
significant buckets (P≤0.05) by Kruskal-Wallis test. They correspond to the resonances of glucose, 
lactate and pyruvate. The intensities derived from integrals of the NMR peaks of these metabolites 
were normalized with respect to the alanine signal at 1.5 ppm, which has a constant intensity under 
the tested conditions. Average values are reported in Fig. S4. As a general trend, a decrease in 
glucose concentration is observed. Glycolysis is expected to represent about 90% of glucose 
consumption by erythrocytes (Baynes et al. 2010). The decrease in glucose concentration is more 
important in serum, most probably because EDTA in plasma tubes exerts an inhibitory effect on 
metalloenzymes and metal-dependent enzymes involved in glycolysis. An increase in lactate, the 
end product of the anaerobic glycolysis is observed, which is steeper than the decrease in glucose, 
roughly in agreement with the expected stoichiometry of the reaction. More complex is the trend in 
the concentration of pyruvate that is an intermediate metabolite of glycolysis: in plasma it is slightly 
decreasing/constant at 4 °C and it increases at 25 °C; in serum, it decreases at 4 °C and is almost 
constant at 25 °C. In clinical analyses, the standard for the measurement of glycaemia is represented 
by fluoride/oxalate coated vacutainers. It has been reported that glucose concentrations in plasma 
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from blood collected into EDTA coated vacutainers showed no significant differences with glucose 
concentrations in plasma from fluoride/oxalate coated vacutainers (which represent the standard for 
the measurement of glycaemia) up to 36 h (Peakman and Eliott 2008; Jackson et al. 2008). 
Comparison of  the changes in concentration of glucose and its derivatives during the time from 
collection through processing of citrate, EDTA and fluoride/oxalate plasma in the present work did 
not show meaningful differences. Therefore, none of these three anticoagulants solves the problem 
of glucose degradation and we can just suggest that for a reliable evaluation of glucose, lactate and 
pyruvate whole blood should be processed within 2 h from collection, keeping it at 4 °C, although 
the latter may still not be the best procedure for pyruvate.  
The choice of the anticoagulant for metabolomic studies of plasma via NMR is not so obvious and 
represents a study-specific additional procedure. Citrate and EDTA are commonly used but have 
some drawbacks. Citrate is by itself a metabolite, identified as a relevant biomarker as it is involved 
in the energy metabolism and found to undergo changes in our degradation studies. On the other 
hand EDTA is not present in blood, but its presence as an anticoagulant covers a number of 
metabolite resonances (choline, dimethylamine and one signal of citrate). From the point of view of 
NMR metabolomics, use of fluoride/oxalate coated vacutainers as plasma collection tubes would 
have the advantage that the anticoagulant does not introduce any additional signal in the 1H NMR 
spectra (however, see additional discussion below).  
Possible degradation processes occurring in blood derivatives after processing were analyzed using 
5 plasma and 5 serum samples of different patients (Fig. 3B). Each sample was split in multiple 
aliquots and NMR spectra of each aliquot were acquired in the time range 0-24 hours keeping the 
samples at room temperature. 
A PLS-CA analysis of the CPMG spectra of plasma and serum samples acquired over time 
provided the clustering reported in Fig. 4G and H; a better discrimination is observed for serum. 
Although the PLS-CA first component of the spectra gradually shift in the same direction during the 
24 h of monitoring time, the effects are larger for serum (Fig. 4I). In order to single out the 
significant buckets (P≤0.05), and thus the corresponding metabolites that are responsible of this 
time progression, we performed the Kruskal-Wallis test. From this procedure we identified the 
following metabolites as markers of the time changes (Fig. S5): triglycerides, proline, choline, 
citrate and histidine. The Hε1 signal of His shifts with time, consistently with a pH variation 
increase of about 0.1 units. The signals of the other metabolites, but citrate, decrease in intensity. 
Albumin and LDL/VLDL (low-density-lipoproteins/very-low-density lipoproteins) also contribute 
to the variations of the NMR profile in NOESY spectra; although an accurate quantitation of the 
observed effect for such broad signals is not possible, a clear decreasing trend is observed. The 
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decrease in concentration for fatty acids and LDL/VLDL is attributable to oxidation reactions, as 
the effect is attenuated if samples are kept under inert atmosphere. The chemical shift variations 
observed for the signals of citrate (Fig. S6) are consistent with literature data about saliva (Silwood 
et al. 2002) where the observed behavior has been rationalized in terms of a competition between 
calcium(II) and magnesium(II) binding to this chelator. Consistently, no chemical shift changes are 
detected in the present work for citrate in  plasma EDTA-samples. The decrease in concentration 
observed in serum of all these molecules, but proline and choline, parallels that observed in plasma. 
No meaningful decrease in proline concentration is visible in plasma EDTA and citrate samples, 
whereas proline decreases sizably in plasma fluoride/oxalate samples. The latter observation 
indicates that EDTA or citrate are still preferable with respect to fluoride/oxalate-containing 
samples. The signals of choline is covered by EDTA resonances and its behavior cannot be 
followed.  In summary, plasma appears to be slightly more stable than serum when kept at room 
temperature. 
Collection, transport, handling, storage and analysis of serum and plasma samples may imply 
different times of exposure to light for different samples. In order to verify whether this translates 
into meaningful changes in the 1H NMR metabolic profiles, spectra have been acquired to monitor 
possible differences between samples kept in the dark or exposed to light. A set of 7 serum samples 
was used: after addition of the buffer, each sample was split into two aliquots. One of them was 
utilized to follow the degradation mechanisms at room temperature in the light and the other while 
kept in the dark. Multiple and consecutive NMR spectra were acquired over a total period of 24 
hours. Exposure to light was found not to induce any difference in the degradation processes that 
occur with time. 
Based on the above findings, we  propose the following procedures for the optimal processing and 
management of blood and its derivatives when they have to be used for future metabolomic NMR 
studies (Scheme 3):  i)  either EDTA or citrate can be used as anticoagulant for plasma samples; ii) 
time between collection and processing should not exceed 2 h; iii) during this time delay samples 
should be kept at 4 °C; iv) any handling procedure of plasma and serum should be performed under 
inert atmosphere; v) samples should be frozen immediately after processing; vi) long term storage 
should be done at -80 °C (no need of lower temperature once erythrocytes have been removed). 
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Scheme 3.  
 
Conclusions 
The primary objective of biobanks is not merely archiving but also distributing conserved and 
documented biological samples for research. The quality of biological samples is crucial for the 
outcome of subsequent studies. Sample quality is directly related to pre-analytical variations, whose 
impact depends on its end use. The molecules constituting the metabolome are generally more 
sensitive to handling and storage procedures than e.g. nucleic acids; in addition changes in 
metabolites due to residual enzymatic activity in biofluid samples can be extremely fast. The 
objective is to ensure that the analyzed sample is representative as much as possible of the 
metabolome before collection, i.e. is as close as possible to the freshly collected sample. 
Validation of methods for sample collection/handling of human biofluids is essential. As samples 
are generally not collected in the confines of well-regulated academic laboratories for research 
purposes but typically in clinics or even in a domestic environment (urine) where organization and 
priorities are not those of future possible non-standard analytical approaches like metabolomics, 
time and temperature  from collection through processing should be carefully recorded.  
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Urine and whole blood result to be “living fluids” even after collection from the patient: presence of 
cells and residual enzymatic activities bring about significant changes in the specimen from the 
point of collection through the time of analysis.  
In order to quench bacterial/enzymatic activity in urine a mild pre-centrifugation combined with 
filtration results to be the safest way to avoid contamination of the metabolome with soluble 
molecules derived from cellular components. This is particularly important when urine samples 
need to be stored in biorepositories at -80 °C; storage in liquid nitrogen would be preferred but may 
become too expensive in a biobanking environment, if it has to be applied for a the long-term 
storage of large collections of urine samples. Urine did not result to be sensitive to the presence of 
oxygen, but a number of enzymatic reactions occur in this biofluid. Addition of  inhibitors is able to 
quench/slow-down such activities but invariably alters the metabolic profile as it introduces in the 
spectra signals of the added molecules, whose presence may also induce changes in pH, ionic 
strength, further altering the whole spectral properties. In this sense, keeping the sample at the 
lowest possible temperature from collection throughout the analysis is extremely important. 
Whole blood is generally collected in vacutainers that protect it from oxygen. The effect of time and 
temperature from blood collection through processing are revealed by the alterations in the relative 
concentration of three very important metabolites i.e. glucose, lactate and pyruvate, which are 
attributable to erythrocyte activity. These metabolites often play a key role in determining the 
signature of a disease in metabolomics studies (Warburg 1956, Garber 2004, Shaw 2006, 
Sreekumar et al. 2009), for example low glucose and enhanced lactate in cancer are indicators of the 
enhanced glycolysis expected on the basis of the Warburg effect (Qiu et al. 2009). The variability of 
these metabolites thus represents a real pitfall in metabolomic studies, as blood is usually collected 
in clinics and then transferred to analytical departments where it is processed: samples from 
different patients are collected the same day at different times and then delivered all together to the 
processing. It is also important that samples are all kept at a controlled temperature.  
For serum, the processing time has to be reduced to a minimum (after the canonical 30’ at room 
temperature needed for clotting) and must never to be longer than 2 hours; storage for any time after 
clotting and before processing should be at 4 °C. The same holds for plasma. 
After blood processing, glucose, lactate and pyruvate concentrations remain stable over time, but 
the presence of oxygen causes changes in a number of other metabolites (albumin, triglycerides, 
LDL/VLDL, proline, citrate and histidine). Processing and sample handling under inert atmosphere 
and storage and analysis under inert atmosphere would be advisable.  
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Captions to the figures 
Fig. 1 Experimental design for: (A) the evaluation of the impact of pre-centrifugation speed on the 
NMR metabolomic fingerprint, (B) the evaluation of the effect of the use of pre-centrifugation as a 
function of the temperature used for sample storage, C) the comparison of the efficiency of pre-
centrifugation, filtration and addition of sodium azide in reducing bacterial content 
Fig. 2 Effect of the pre-centrifugation speed on the NMR spectra obtained with the experimental 
design of Fig. 1A. The absolute value of the difference in the first component of the PLS-CA 
analysis for spectra of samples pre-centrifuged (PC) at different speeds and that of the non pre-
centrifuged sample (NPC) is plotted as a function of the centrifugation speed. Diamonds and circles 
are used to indicate urine samples from two different individuals, the former containing a larger 
number of cells. The comparison of the two plots shows the importance of the pre-centrifugation 
step in samples with high cellular components. 
Fig. 3 Experimental design for: (A) the evaluation of the effect of the time between blood collection 
and processing on serum and plasma NMR spectra; (B) the evaluation of the effect of the time 
between processing and freezing on the quality of NMR spectra of plasma and serum 
Fig. 4 PLS-CA clustering as a function of the time delay between blood collection and processing 
for plasma at (A) 4 °C and (B) 25 °C and serum at (D) 4 °C and (E) 25 °C. Dots colour coding is: 
red = 0 h; yellow = 1 h; green = 2 h; blue = 3 h; purple = 4 h. Change of the average value of the 
first PLS-CA component as a function of time at 4 °C (blue line) and 25 °C (red line) for plasma 
(C) and serum (F). PLS-CA clustering as a function of time delay between processing and analysis 
on plasma (G) and serum (H). Dots color coding is red = 0 h; yellow = 6 h; green = 12 h; blue = 18 
h; purple = 24 h. (I) Change of the average value of the first component as a function of time for 
plasma (green line) and serum (blue line)  
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Fig. S1 (A) pH-dependence of the 1H chemical shift of the Hε1 resonance of N-methylhistidine (Npi 
•, Nτ •) and histidine (•) in urine samples. Above pH 7.5 the resonance of Nτ could not be followed 
due to signal overlap. (B) Chemical shift values of the Hε1 of Nτ-methylhistidine for the non pre-
centrifuged and pre-centrifuged fresh urine (■) reported on the calibration curve of panel (A). (C) 
Chemical shift variations of the Hε1 of Npi-methylhistidine (▲) observed in pre-centrifuged urine 
over time (24 h) reported on the calibration curve obtained for Npi-methylhistidine of panel (A)  
  
Fig. S2 PLS clustering according to donor identity of differently treated urine samples. Different 
aliquots have been produced from each of the four donors: eight different pre-centrifugation speeds 
(NPC, 600, 800, 1000, 1400, 1800, 2000, 2500 RCF) have been tested in combination with different 
storage conditions (fresh; one week in liq. N2). In this plot, the same color has been used for 
aliquots from the same donor. A clear clustering of samples from the same individual is apparent 
  
Fig. S3 Average variation in the concentration of some metabolites (glutamate in A and B; 
succinate in C and D, lactate in E and F, acetate in G and H, urea in I and J) as a function of time 
(0-24 h) in differently treated urine samples that have been analyzed either fresh (A, C, E, G, I) or 
after one week of storage at -80 °C (B, D, F, H, J). Signal intensities have been normalized with 
respect to that of the invariant CH3 alanine resonance. Blue = pre-centrifuged; red = non-pre-
centrifuged; green = pre-centrifuged and treated with NaN3; purple = pre-centrifuged and filtered. 
The pre-centrifugation speed was 1000 RCF 
  
 
 
Fig. S4 Average variation in the concentration of glucose (green), lactate (red) and pyruvate (blue) 
as a function of time between blood collection and processing for samples kept at 25 °C (continous 
line) and 4 °C (dotted line) in plasma (A) and in serum (B) 
 
  
 
Fig. S5 Average variation in the concentration of proline in serum (blue) and plasma (green) as a 
function of time (0-24 hours) 
 
  
 
Fig. S6 Spectral variations observed for the signals of citrate in serum (A) and plasma (B) as a 
function of time. Color coding: (A) black  t = 0 h, blue t = 6 h, green t = 12 h, brown t= 18 h, grey t 
= 24 h; (B) black  t = 0 h, green t = 6 h, blue t = 12 h, brown t= 24 h 
  
 
Table S1 Results of the urine culture tests performed on differently treated aliquots of a sample of 
Subject 1: C (pre-centrifuged at 1000 RCF), CF (pre-centrifuged and filtered). Urine culture tests 
were performed at time zero and after 2, 4, 6 and 24 hours, starting either from fresh urine (first 
value in the cell) or from urine samples stored for a week at -80 °C (second value in the cell). 
Notice that in the non filtered aliquots analysed after 24 hours the growth of coliforms visible in 
fresh aliquot is stopped by the storage at -80 °C. 
  
Table S2 Results of the urine culture tests performed on differently treated aliquots of a sample of 
Subject 2: C (pre-centrifuged at 1000 RCF), CF (pre-centrifuged and filtered), CNA (pre-
centrifuged and treated with sodium azide), NC (not pre-centrifuged), NCF (filtered), NCNA 
(treated with sodium azide). Urine culture tests were performed at time zero and after 2, 4, 6 and 24 
hours, starting either from fresh urine (first value in the cell) or from urine samples stored for a 
week at -80 °C (second value in the cell). 
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